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Summary of thesis 
 
Congestive heart failure (CHF) is the most commonly diagnosed and treated condition in 
veterinary cardiology as it is the sequela of a multitude of cardiovascular diseases. 
Development of this syndrome marks the beginning of the end, with many losing the battle 
against the collapse in circulatory function and excessive fluid retention within a year and a 
half of diagnosis. Medical therapy plays the vital role of providing relief of symptoms, a good 
quality of life, and time. In this thesis, current practices in CHF therapeutics within veterinary 
medicine are reviewed, and novel approaches to medical therapy of CHF are explored. 
The work begins by examining the existing literature surrounding the topic in 
Chapter 1. Common aetiologies and pathophysiology of CHF in dogs and cats are discussed. 
Common practices in veterinary medicine are scrutinised in light of existing scientific 
evidence, and areas requiring further research support are highlighted. Throughout the 
chapter, references to human literature are made to underline inter-species differences and 
contemplate alternative treatment methods. Finally, the aims of this thesis are presented. 
The following three chapters (Chapters 2, 3, and 4) extend upon the knowledge basis 
supporting current CHF therapeutics in veterinary patients and present insights for 
improvements to treatment regimen. Chapters 2 and 3 examine the pharmacokinetics and 
pharmacodynamics of pimobendan in dogs and cats, respectively. Major findings include the 
discovery of greater metabolism of pimobendan and cardiovascular effects in dogs 
compared to cats; in addition, echocardiography is proven to be an effective method of 
monitoring treatment effects in the former but not the latter. Thus, the importance of further 
investigations on use of pimobendan in cats is stressed. The focus moves on from 
pimobendan to the realm of multi-drug therapy of CHF in dogs with myxomatous mitral valve 
disease (MMVD) in Chapter 4. This is a descriptive chapter detailing the disease course in 
eleven dogs from the time of first diagnosis of CHF till death or the conclusion of the study. 
The use of pimobendan, frusemide, benazepril, and spironolactone resulted in a median 
survival time of 419 days, with recurrence of CHF being the most common cause of death or 
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euthanasia in this cohort of dogs. In the absence of published studies evaluating the benefit 
of such combination therapy, this work serves to present objective survival data in a small, 
yet relevant, group of individuals for veterinary practitioners. 
In the final two chapters of the body (Chapters 5 and 6), the natriuretic peptide 
system is evaluated as a novel therapeutic target in dogs with CHF. Due to existing 
concerns regarding cross-reactivity between active and inactive components of the system 
when immunoassays are employed, a specific method of detecting active brain natriuretic 
peptide (BNP1-32) in canine plasma utilising mass spectrometry is investigated in Chapter 5. 
Concurrently, a method of stimulating endogenous brain natriuretic peptide production 
through administration of high-volume intravenous fluids is tested, with the aim of using the 
aforementioned assay to characterise the response of this system in healthy dogs. 
Subsequently, the effect of augmenting this system in dogs with CHF due to MMVD through 
administration of synthetic canine BNP1-32 is examined in Chapter 6. The results suggest a 
peripheral natriuretic peptide resistance and raise interesting questions regarding the 
pathophysiology of, and potential future therapeutics of, CHF in these dogs.  
The ensuing discussion brings together the findings of these five studies and 
highlights their significance within the context of current and future veterinary practices. The 
limitations of each study are considered, and suggestions for future endeavours to elucidate 
answers to remaining questions are made. Ultimately, the conclusions drawn from this work 
are hoped to contribute small pieces in the knowledge of CHF therapeutics that will help 
guide ongoing investigations into its pathophysiology and optimal treatments. 
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Chapter 1: 
Introduction, literature review, and aims of this thesis 
1
1.1) Introduction to canine and feline congestive heart failure 
Early descriptions of the cardiovascular system date back to as far as 300 – 400 years BC 
(Buchanan, 2013). Yet the foundation of modern day cardiology is most accepted to have 
been laid in the 1600's, when William Harvey conducted a series of experiments to explain 
basic cardiovascular physiology (Buchanan, 2013). Since then, large advancements in 
medical technology have led to increasing knowledge regarding various cardiovascular 
diseases affecting both humans and animals. Although descriptions of affected individuals 
existed prior to the 1900's, it was not until the early 1900's that heart disease in dogs was 
first characterised (Detweiler & Patterson, 1965). Publications describing feline 
cardiovascular diseases also emerged in the mid 1900’s (Buchanan, 2013). Fast-forward 
some 60-odd years to today, and numerous congenital and acquired heart diseases, as well 
as their natural course of pathology and pathophysiology, have been discovered and 
described in our veterinary patients.  
Despite the myriad of shades that colour the spectrum of cardiovascular diseases in 
dogs and cats, many share a common sequela known as congestive heart failure (CHF). 
CHF is a syndrome that is characterised by the presence of cardiovascular disease, fluid 
retention, and ensuing oedema. This manifests most commonly in cats and dogs as 
pulmonary oedema, pleural or peritoneal effusions, or both. The effect of CHF on the 
lifespan of affected populations has been characterised by the wealth of literature supporting 
estimated median survival times (MST) of around a year and a half or less (De Madron et al., 
2011; Ettinger et al., 1998; Ferasin et al., 2003; Finn et al., 2010; Fox et al., 2014; Fox et al., 
2018; Häggström et al., 2008; Hambrook & Bennett, 2012; Harvey et al., 2005; Jung et al., 
2016; Petric et al., 2002; Rush et al., 2002; Slupe et al., 2008; S. A. Smith et al., 2003; The 
BENCH Study Group, 1999; Tidholm et al., 1997; Vollmar, 2000); recurrent hospitalisation, 
the need for constant monitoring, and daily medical therapy pose a burden, not only for the 
patients, but also their owners, who must be “fearfully vigilant, at the mercy of the disease 
and its treatments, while worrying about that which remained unspoken” (Bursch, 2012). 
Such is the context in which numerous research efforts into the pathophysiology and 
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treatment of CHF were born, and to which this thesis aims to contribute towards as a small 
cog in the ever-revolving wheel of medical advancements.  
In this literature review, an overview of canine and feline CHF and existing 
therapeutics will be provided, and key knowledge gaps will be identified. It will start with a 
description of the leading aetiologies of CHF in dogs, cats, and people, followed by a 
discussion of the pathophysiology of CHF in individuals with specific heart disease. The 
existing therapeutic approaches in both veterinary and human cardiology will be analysed in 
light of these processes. Specific areas warranting further investigation in veterinary CHF 
therapeutics will be identified, and the aims of this thesis will be outlined. 
1.2) Aetiology of CHF 
It is well accepted in both the veterinary and medical professions that cardiovascular 
diseases leading to CHF most commonly affect older individuals.  A variety of pathological 
processes can occur to affect virtually all parts of the cardiovascular anatomy, but primary 
valvulopathies and cardiomyopathies predominate in canine and feline acquired heart 
diseases. In humans, cardiomyopathies secondary to diabetes, systemic hypertension, and 
coronary artery disease also form an important class of cardiovascular disease. 
1.2.1) Aetiology of canine CHF 
Myxomatous mitral valve disease (MMVD) is the leading acquired cause of CHF in dogs. Its 
high prevalence was noted as early as 1965, when an epidemiological study of 4831 dogs 
identified chronic valvular disease in around 75% of cases diagnosed with an acquired 
cardiovascular disease (Detweiler & Patterson, 1965). There is a known association with age, 
with higher prevalence in older animals (Detweiler & Patterson, 1965; Olsen et al., 1999; 
Thrusfield et al., 1985). Breeds most commonly affected by MMVD include small to medium 
breed dogs, with a particular predisposition towards the disease in the Miniature Poodle, 
Cocker Spaniel, Chihuahua, Cavalier King Charles Spaniel, Dachshund, and Boston Terrier, 
amongst others  (Beardow & Buchanan, 1993; Häggström et al., 1992; O'Leary & Wilkie, 
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2009; Olsen et al., 1999; D. Pedersen et al., 1999; Thrusfield et al., 1985). In the Cavalier 
King Charles Spaniel, Dachshund, Whippet, and Bull Terrier, this disease is suspected to be 
heritable, with a polygenic mode of inheritance (Madsen et al., 2011; Meurs et al., 2018; 
O'Leary & Wilkie, 2009; Olsen et al., 1999; Stern et al., 2015; Swenson et al., 1996). 
Several characteristic gross and histological abnormalities occur in the cardiac 
structures of dogs affected by MMVD. The affected valves, which most commonly include 
the mitral and tricuspid valves, grossly show elongation, thickening, haemorrhage, distortion, 
and grey-white nodular changes (Fox, 2012; Kittleson & Kienle, 1998; Whitney, 1974). At a 
cellular level, the disease involves alterations to the valvular cell population that resemble 
inflammatory and ageing changes. Valvular interstitial cells become activated, the net 
number of valvular interstitial and endothelial cells reduce, and macrophages and mast cells 
infiltrate the tissue; this, in turn, causes an increase in glycosaminoglycans and 
proteoglycans in the extracellular matrix (Aupperle et al., 2009; Connell et al., 2012; Han et 
al., 2010; Han et al., 2008; Han et al., 2013). The increase in proteoglycans and net loss of 
collagen and elastin results in obliteration of the definition between the spongiosa and 
fibrosa layers of the valve (Aupperle et al., 2009; Fox, 2012; Hadian et al., 2007; Han et al., 
2010; Kittleson & Kienle, 1998). Valvular integrity is lost, leading to elongation or rupture of 
chordae tendinae. Valvular insufficiency also contributes towards development of atrial jet 
lesions, endomyocardial splitting, atrial enlargement, eccentric ventricular hypertrophy, and 
annular dilatation (Fox, 2012; Kittleson & Kienle, 1998; Ware, 2011).  
Other causes of CHF in dogs include pericardial diseases such as idiopathic 
pericarditis; primary cardiomyopathies such as dilated cardiomyopathy (DCM); conduction 
disorders leading to severe tachyarrhythmias or bradyarrhythmias; cardiac neoplasia; 
myocarditis; valvular endocarditis; and congenital diseases including patent ductus 
arteriosus, aortic and pulmonic stenosis, septal defects, and anomalous vessels (Sisson, 
2010).  
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1.2.2) Aetiology of feline CHF 
Cats, unlike dogs, suffer predominantly from cardiomyopathies (Fox et al., 2018). Of 408 
cats presenting over a seven-year period at one referral clinic, 287 were diagnosed with a 
primary cardiomyopathy (Riesen et al., 2007). Hypertrophic cardiomyopathy (HCM) or 
hypertrophic obstructive cardiomyopathy (HOCM) occurs most frequently, comprising 
around 58 – 68% of cardiomyopathies in cats (Ferasin et al., 2003; Riesen et al., 2007). 
Males appear to be affected more commonly than females, and a breed predilection exists 
for the domestic shorthair, Persian, Maine Coon, British Blue, Ragdoll, Birman, Sphinx, 
Scottish Fold, Siamese, and American and British shorthairs, amongst others (Ferasin et al., 
2003; Granström et al., 2011; Riesen et al., 2007). Two different single point mutations in the 
gene encoding myosin binding protein C have been identified in the Maine Coon and 
Ragdoll (Meurs et al., 2007; Meurs et al., 2005), and heritability of the disease has also been 
documented in these and the Norwegian Forest, Sphinx, and a family of mixed-breed cats 
(Borgeat, Casamian-Sorrosal, et al., 2014; Kittleson et al., 1999; Kraus et al., 1999; März et 
al., 2015; Silverman et al., 2012).  
Grossly, HCM is characterised by variable degrees of left ventricular concentric and 
papillary muscle hypertrophy (Fox, 2003a). Histologically, the normally parallel distribution of 
myofibrils becomes disrupted, resulting in a disorganised array of fibres displaying 
perpendicular and oblique orientations (Fox, 2003a). Additional features include myocyte 
hypertrophy, extracellular fibrosis, arteriosclerosis, and abnormal proliferation of intramural 
coronary arteries (Fox, 2003a). These contribute towards myocardial ischemia and 
functional abnormalities predominantly consisting of impaired ventricular relaxation and 
compliance (Abbott, 2010). In those with HOCM, a dynamic left ventricular outflow tract 
(LVOT) obstruction caused by systolic anterior motion (SAM) of the mitral valve apparatus 
accompanies and compounds these hypertrophic changes. Factors that are thought to 
contribute towards the development of this dynamic obstruction include the development of 
an intraventricular pressure gradient due to the Venturi effect, the presence of anatomical 
variants such as anterior displacement of the papillary muscle, and the effect of drag forces 
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which draw the anterior mitral leaflet into the LVOT; more recently, the Venturi effect theory 
has fallen somewhat out of favour based on observations of SAM at lower LVOT velocities in 
people with HOCM (Abbott, 2010; Sherrid, 2006; Sherrid et al., 2000).  
In addition to primary HCM and HOCM, reversible ventricular hypertrophy secondary 
to systemic hypertension and hyperthyroidism can occur in cats (Fox, 2003a; Riesen et al., 
2007). Other cardiomyopathies which may result in CHF include restrictive cardiomyopathy 
(RCM), DCM, unclassified cardiomyopathy (UCM), and arrhythmogenic right ventricular 
cardiomyopathy (ARVC); more recently, transient myocardial thickening has been identified, 
particularly in younger cats (Novo Matos et al., 2018).  Myocarditis, valvular endocarditis, 
pericardial diseases, and congenital diseases such as septal defects and valvular dysplasia 
are other causes of CHF in cats (Riesen et al., 2007). 
 
1.2.3) Aetiology of CHF in humans 
There are several primary valvular and myocardial diseases in people that mimic those 
which occur in veterinary patients. Idiopathic DCM, for example, shares similar histological 
characteristics, functional abnormalities, and familiar inheritance as in dogs (Dec  & Fuster 
1994). HCM and HOCM also share similarities with the diseases seen in cats; however, the 
genetic basis of these have been better characterised in people, and sudden death due to 
arrhythmias comprises a major concern with HCM and HOCM in people (Maron, 2002). In 
the class of valvulopathies, mitral valve prolapse is one of the most commonly encountered 
diseases, with myxomatous degeneration being the leading cause of significant mitral 
regurgitation (Guy & Hill, 2012; Hayek et al., 2005). Histological and gross characteristics 
are akin to those observed in dogs with MMVD (Delling & Vasan, 2014). 
Yet by far, the most common conditions associated with CHF in people include 
systemic hypertension and coronary artery disease. These are present in up to 85-90% of 
people with CHF (Ho et al., 1993). Both are primary vascular diseases, but they induce 
gross and functional cardiac pathology that can mimic primary cardiomyopathies and lead to 
development of CHF. For example, the high afterload created by systemic hypertension 
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leads to concentric myocardial hypertrophy and diastolic dysfunction as seen with HCM 
(Levy et al., 1996; Viau et al., 2015); the increase in myocardial stress can also contribute 
towards ischemia in latter stages of this type of secondary cardiomyopathy. In contrast, a 
DCM-like phenotype can result with myocardial ischemia caused by coronary artery disease 
(Gheorghiade & Bonow, 1998). These conditions are associated closely with the metabolic 
syndrome, which arises from a combination of hypertension, obesity, dyslipidaemia, insulin 
resistance, and hyperglycaemia (Alberti et al., 2005). Despite genetic predisposition towards 
this syndrome in some individuals, environmental factors consisting of diet and lifestyle 
choices are thought to play a major role in its development (Kaur, 2014). These preventable, 
secondary cardiomyopathies are not prevalent in veterinary patients but form important 
causes of CHF in people.  
 
1.3) Introduction to the pathophysiology of CHF 
Irrespective of the underlying heart disease, there are common mechanisms involved in the 
development of chronic CHF. The process almost always begins with a slight reduction in 
cardiac output (CO) and blood pressure (BP) caused by the primary abnormality (Sisson, 
2010). This may be the result of valvular regurgitation; intrinsic or relative myocardial systolic 
dysfunction; reduced ventricular filling due to diastolic dysfunction or an inflow obstruction; 
the presence of an outflow tract obstruction; or inappropriate shunting (Sisson, 2010). In 
response, the renin-angiotensin-aldosterone system (RAAS), sympathetic nervous system 
(SNS), and a variety of local vascular and tissue processes are activated to cause sodium 
and water retention, arteriolar and venoconstriction, and positive inotropic, lusitropic, and 
chronotropic effects (Sisson, 2010). The resultant increase in preload, afterload, venous 
pressures, and cardiac contractility causes normalisation of BP and CO. Early in the course 
of disease, these processes are appropriately antagonised by feedback mechanisms and 
counter-regulatory systems once normality is established. However, chronic activation and 
pathological anomalies to these systems, together with progression of the underlying 
structural disease, result in excessive preload, afterload, and inefficient myocardial 
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remodelling (Sisson, 2010). The ability to maintain cardiovascular homeostasis becomes 
compromised, ultimately leading to CHF.  
An important characteristic of CHF is the presence of congestion caused by 
excessive sodium and water retention and exacerbated by excessive vasoconstriction. The 
RAAS and its counter-regulatory system, the natriuretic peptide system (NPS), are of 
particular importance here. Excessive RAAS activation is thought to occur due to the chronic 
reduction in forward output caused by the structural or functional heart disease. Indeed, 
enhanced RAAS activity, reflected by elevation in plasma renin, angiotensin II, and 
aldosterone concentrations, has been noted in CHF in many experimental and clinical 
studies (H. H. Chen & Burnett Jr, 2000; Francis et al., 1990; Häggström et al., 2014; 
Knowlen et al., 1983; Watkins Jr et al., 1976; Weber, 2001; Weber & Villarreal, 1993).  
More recently, evidence to support the activation of local or tissue RAAS, even in the lack of 
circulatory RAAS activation, has emerged (Carey & Siragy, 2003; Dzau et al., 2002; Fujii et 
al., 2007; Paul et al., 2006). Angiotensin II and aldosterone are the final products of both 
circulating and tissue RAAS. These bind to angiotensin type 1 receptor and 
mineralocorticoid receptors, respectively, resulting in vasoconstriction, renal sodium and 
water reabsorption, platelet activation and aggregation, stimulation of the SNS, and 
promotion of inflammatory and reparative processes through cytokine production, 
chemotaxis, macrophage activation, and stimulation of pro-fibrotic mechanisms – all of which 
propagate the syndrome of CHF (Reid, 1992; Weber, 2001).   
The effects of the RAAS are countered by the NPS, which is triggered in response to 
RAAS activation to promote diuresis, natriuresis, vasodilation, and RAAS antagonism (Potter 
et al., 2009). In the context of CHF, the NPS can thus be considered a “protective” 
mechanism. Despite high circulating concentrations of immunoreactive natriuretic peptides 
(NP), a decline in NP responsiveness, resulting in vasoconstriction and reduced natriuresis, 
has been demonstrated in those with CHF (Cody et al., 1986; Eiskjær et al., 1991; Jensen et 
al., 1999; Moesgaard et al., 2011; Nakamura et al., 1998; Schmitt et al., 2004). Although 
there is some evidence to support suppression of NPS due to excess RAAS activity (Abassi 
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et al., 1990; H. H. Chen & Burnett Jr, 2000; Margulies et al., 1991; Villarreal & Freeman, 
1991; Weber & Villarreal, 1993), a relative state of NP resistance or altered NP metabolism 
may also contribute towards the development of CHF.  
Indeed, this concept of a “NP paradox” contributing towards development of CHF has 
received much attention in human cardiology over the past 10 – 15 years (Baerts et al., 
2012). Several mechanisms have been proposed to explain this paradox, including 
alterations to the synthesis, activity, and degradation of NP as well as limitations to available 
methods of NP detection. 
Of the natriuretic peptides, atrial and brain NP (ANP, BNP), play a significant role in 
cardiovascular physiology. Both originate as inactive pro-forms, with proANP1-126 being 
stored in atrial granules while proBNP1-108 is produced mainly by ventricular myocytes 
upon demand (Potter et al., 2009). Activation of ANP and BNP is triggered through detection 
of hypervolemia via atrial and ventricular stretch and involves enzymatic cleavage of the pro-
forms mediated by transmembrane serine proteases, corin and furin (Ichiki et al., 2013). The 
products of this cleavage consist of a biologically inactive N-terminal portion  
(NT-proANP and NT-proBNP) and a biologically active c-terminal portion (ANP1-28 and 
BNP1-32, or cANP and cBNP), both of which are released into circulation. These active 
molecules bind to the natriuretic peptide receptor-A (NPR-A) and produce a cascade of 
intracellular signalling effects mediated by cyclic guanosine monophosphate (cGMP) to 
produce biological effects (Potter et al., 2009). Breakdown of the active molecules involves 
either internalisation and degradation following binding to NPR-A; degradation via the 
clearance receptor, natriuretic peptide receptor-C (NPR-C); or extracellular fragmentation to 
less active or biologically inactive fragments via circulating enzymes such as neprilysin, 
meprin, dipeptidyl peptidase IV, and insulin degrading enzyme (Ichiki et al., 2013; Potter et 
al., 2009). The circulating half-life of ANP is shorter than that of BNP, measuring around two 
minutes and twenty minutes, respectively (Potter et al., 2009). Though ANP is normally 
present in higher concentrations in circulation, a shift towards greater BNP production occurs 
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with progressive CHF, and as such, the latter has received more attention in this context 
(Langenickel et al., 2000; Luchner et al., 1998). 
In states of CHF, there is some evidence to support alterations to NP synthesis, 
degradation, and activity. Plasma and tissue concentrations of corin were reduced in animals 
(Tripathi et al., 2016) and humans (Barth et al., 2006; Dong et al., 2010; Ibebuogu et al., 
2011; Shrestha et al., 2010) with CHF. However, the relationship between concentrations of 
corin and its activity in CHF appears to be ill-defined, with some studies observing the lack of 
a clear relationship between measured corin and NP concentrations (S. Chen et al., 2010; 
Miller et al., 2011; Shrestha et al., 2010; Zhou et al., 2016). This may have been due, at 
least in part, to the complex nature of corin activation, which relies on a particular 
conformation and sequence of the extracellular component of the molecule (J. Jiang et al., 
2011; Knappe et al., 2004; W. Wang et al., 2008; Yue Zhang et al., 2014), glycosylation (X. 
Liao et al., 2007; H. Wang et al., 2015), and presence of activating substances (S. Chen et 
al., 2015; J. Jiang et al., 2011). There has also been evidence to support enhanced 
degradation of NPs, with high neprilysin activity being suggested in an experimental model 
of CHF (Margulies et al., 1995) and increased density of NPR-C being reported in platelets 
and myocardial samples from people with CHF (Andreassi et al., 2001; Kuhn et al., 2004). 
Furthermore, high circulating concentrations of neprilysin were detected in people with CHF, 
and this was associated with increased CHF-related mortality and morbidity (Bayés-Genís et 
al., 2015). Enhanced degradation of active peptides could result in diminished effects of NPs, 
but reduced numbers of, or productive interactions with, NPR-A could also attenuate their 
activity (Schiffrin, 1988; Tsunoda et al., 1988; Tsutamoto et al., 1993). 
The theory of enhanced degradation and stunted production of ANP1-28 and  
BNP1-32 in the face of CHF are also supported through advancements in assay techniques 
to measure circulating concentrations of these peptides. Immunoassays have traditionally 
been used for the detection of these peptides; yet because these rely on antibody-antigen 
interaction between specific fragments of these proteins, an inherent limitation of this 
technique is the inability to differentiate between active peptides and inactive proforms or 
10
 
 
fragments. Indeed, a handful of studies have demonstrated cross-activity between  
ProBNP1-108 and BNP1-32 (Liang et al., 2007; Nishikimi et al., 2010), ProBNP1-108 and 
NT-proBNP (Heublein et al., 2007; Liang et al., 2007), as well as BNP1-32 and its less-active 
fragments (Heublein et al., 2007; Rawlins et al., 2005) in commercially available 
immunoassays. The predominance of high-molecular weight BNP (consistent with  
ProBNP1-108) over the low-molecular form (consistent with BNP1-32) in the plasma of 
people with CHF has been identified through high-performance liquid chromatography and 
western blotting techniques (Giuliani et al., 2006; Liang et al., 2007; Yandle et al., 1993). 
When mass spectrometry was utilised to differentiate BNP1-32 from its less active fragments, 
a significantly lower concentration of specific BNP1-32 compared to the immunoassay-
derived “BNP-32” has been demonstrated in people with varying degrees of CHF 
(Hawkridge et al., 2005; Miller et al., 2011; Niederkofler et al., 2008). Thus, it appears that 
people with CHF may, in fact, have a lower concentration of biologically active NP despite 
the detection of high concentrations of NP using commercial immunoassays. Although these 
studies have as limitations their small size and lack of a control group for comparison in 
some cases, they raise the possibility of altered NP metabolism in states of CHF which may 
be masked by the inherent limitations of existing commercial immunoassays. 
In addition to the RAAS and aberrant NPS, vasopressin, or anti-diuretic hormone, is 
another contributor towards the fluid retentive and vasoconstrictive states observed in CHF. 
Vasopressin causes free water reabsorption at the level of the collecting ducts in addition to 
arteriolar vasoconstriction. Increased plasma concentrations of vasopressin and 
hyponatremia have been observed in some, but not all, patients with CHF, and these are 
recognised negative prognostic indicators linked to reduced survival and increased 
frequency of hospitalisation (De Luca et al., 2005; Lanfear et al., 2013; Sica, 2005). Although 
the overall reduction in forward blood flow and increased angiotensin-II activity are thought 
to play a role, the exact mechanisms contributing towards inappropriate vasopressin 
production in some individuals with CHF remains unclear (Gassanov et al., 2011; Imamura 
et al., 2014).  
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Another arm of the pathophysiology of CHF involves stimulation of the SNS, which 
contributes towards vasoconstriction, increased heart rate, and reduced cardiac contractility. 
SNS stimulation may occur directly via baroreceptor-mediated pathways or through 
circulating and tissue RAAS-mediated pathways (Cox et al., 1999; Lal et al., 2004; Lewis & 
Reit, 1965; Luoh & Chan, 1998; Ma et al., 1999; Reid, 1992). In human and veterinary 
patients with CHF, heightened SNS activity is evidenced by high circulating concentrations 
of its major neurotransmitter and hormone, noradrenaline (Francis et al., 1990; O'Sullivan et 
al., 2007; Santos et al., 2006; Triposkiadis et al., 2009; Ware et al., 1990). Chronic SNS 
activation results in desensitisation and malfunction of β1 adrenoreceptors, which are its 
major effect-producing receptors in the heart (Böhm et al., 1995; Triposkiadis et al., 2009). 
High levels of catecholamines are directly cardiotoxic, causing interstitial fibrosis, myocyte 
apoptosis, and oxidative damage (Behonick et al., 2001; Bindoli et al., 1992; Goldspink et al., 
2004; Liaudet et al., 2014; Singal et al., 1982; Triposkiadis et al., 2009). In humans, several 
mutations to genes encoding ɑ- and β- receptors have also been associated with heart 
failure (Triposkiadis et al., 2009). Finally, diminished baroreceptor sensitivity and 
suppression of the parasympathetic pathways in CHF further amplify these detrimental 
effects of SNS activation (Eckberg et al., 1971; Grassi et al., 1995; Higgins et al., 1972; 
Sabbah, 2012; Triposkiadis et al., 2009).  
At the vascular level, disruptions in function and production of its most potent locally-
derived vasoconstrictor, endothelin-1, and vasodilator, nitric oxide, have also been 
documented in CHF. In naturally occurring and experimentally induced chronic CHF, 
endothelin-1 concentrations are increased, seemingly due to enhanced production and 
reduced clearance (Giaid  et al., 1993; Picard et al., 1998; Sakai et al., 1996; Zolk et al., 
1999). Impaired nitrous oxide responsiveness occurs in humans with CHF, despite some 
evidence to support increased levels of nitric oxide (Bauersachs et al., 1999; Kubo et al., 
1991; Winlaw et al., 1994). In veterinary medicine, high levels of circulating endothelin-1 has 
been described in dogs (O'Sullivan et al., 2007; Prošek et al., 2004b; Tessier-Vetzel et al., 
2006) and cats with CHF (Prošek et al., 2004a). Endothelial dysfunction, as measured 
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through impairment of flow-mediated vasodilation and reactive hyperaemia, has also been 
demonstrated in Cavalier King Charles Spaniels with MMVD (Moesgaard et al., 2012) and 
dogs with CHF (S. M. Cunningham et al., 2012). Aside from contributing towards an increase 
in afterload, this elevation in endothelin-1, reduced nitric oxide synthase, and overall 
endothelial dysfunction can cause development of complications in the form of 
disproportionate pulmonary hypertension secondary to left-sided CHF (Cooper et al., 1998; 
Giaid  et al., 1993; Porter et al., 1993; Sakai et al., 1996). Thus, such imbalances at the 
vascular level not only propagate the syndrome of CHF but also trigger the development of 
further comorbidities.  
There is also evidence to support pathological alterations to the mechanisms 
involved in the contractile function of the myocardium in states of CHF due to 
cardiomyopathies. Abnormal cardiomyocyte calcium cycling occurs in the sarcoplasmic 
reticulum due to altered functions of its components such as the L-type calcium channels, 
ryanodine receptors, SERCA, and Phospholamban (Hasenfuss & Pieske, 2002; Luo & 
Anderson, 2013). The net effects are a reduction in available calcium to facilitate actin-
myosin cross-bridge formation, contributing towards systolic dysfunction; reduced 
sarcoplasmic reticulum sequestration of calcium, resulting in diastolic dysfunction; and 
prolongation of the cardiac action potential, which increases the arrhythmogenic potential 
(Luo & Anderson, 2013). Abnormal expression of, and structural anomalies to, myosin, actin, 
and associated proteins including troponins and tropomyosin are also thought to contribute 
towards altered cardiac function, leading to CHF (Yin et al., 2015).  
Other cellular mechanisms which appear to be involved in development and 
propagation of CHF include alterations to cardiovascular and renal functions due to reduced 
intracellular signal transduction via enhanced expression and function of 
phosphodiesterases (Ding et al., 2005; Pokreisz et al., 2009; Takimoto et al., 2005) and 
enhanced cardiac and valvular remodelling mediated by transforming growth factor beta and 
various matrix metalloproteinases (Aupperle & Disatian, 2012; Dobaczewski et al., 2011; 
Khan & Sheppard, 2006; Moesgaard et al., 2014; Orton et al., 2012). Finally, enhancement 
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of inflammatory pathways has also been identified as a contributor in some studies (Anker & 
von Haehling, 2004; Cesari et al., 2003; Mann & Young, 1994; Reimann et al., 2016; Zois et 
al., 2012). 
 
1.4) Comparative pathophysiology of CHF 
Despite the many shared mechanisms between various aetiologies that lead to CHF, there 
are also differences in pathophysiology between these aetiologies which are particularly 
important to consider in the context of therapeutics. For example, systolic dysfunction is an 
important contributor towards CHF in certain aetiologies such as DCM; in contrast, diastolic 
dysfunction predominates in others such as HCM and RCM. CHF resulting primarily from 
systolic dysfunction is characterised by reduced myocardial contractility. Governed by the 
Frank-Starling mechanism, the ventricles undergo eccentric hypertrophy to accommodate for 
the increase in volume required to maintain CO. Maximising CO in this context relies on 
reducing afterload, improving myocardial contractility, and preventing excessively high 
preload (Zile & Brutsaert, 2002). On the other hand, CHF resulting primarily from diastolic 
dysfunction is characterised by impaired myocardial relaxation and an increase in filling 
pressure. Due to the reduced capacity for passive ventricular filling, increasing atrial function 
and reducing heart rate to allow for prolonged filling time become more important in 
maintaining CO in this context (Zile & Brutsaert, 2002). Although both systolic and diastolic 
dysfunction can be present in many conditions that result in CHF, identifying the 
predominant form of myocardial dysfunction can therefore guide optimal therapeutic 
approaches.   
There are also a number of associated abnormalities which are specific to certain 
aetiologies or species that can accelerate the onset of CHF or contribute towards refractory 
disease. Atrial fibrillation, supraventricular tachyarrhythmias, and ventricular 
tachyarrhythmias have been described in dogs with DCM (M. W. S. Martin et al., 2009; 
Monnet et al., 1995; Wess et al., 2010), ARVC (Meurs et al., 2014; Palermo et al., 2011), 
and MMVD (Crosara et al., 2010). Acute chordal rupture occurs in around 16% of dogs with 
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MMVD (Serres, Chetboul, Tissier, et al., 2007), and tearing of the atrial septum or caudal 
wall may also develop with this disease (Buchanan & Kelly, 1964; Peddle & Buchanan, 
2010; Reineke et al., 2008); however, chordal rupture and atrial tears have not been 
reported in the literature for common canine or feline cardiomyopathies. Disproportionate 
pulmonary hypertension is also a relatively common complication of MMVD that is seen in 
up to 40% of affected dogs, and it is thought to occur as a result of increased pulmonary 
venous pressures, combined with various neuroendocrine pathways and endothelial 
dysfunction as previously described (Borgarelli et al., 2015; Kellihan & Stepien, 2012). 
Cardiomyopathies or myocarditis are less commonly associated with secondary pulmonary 
hypertension in dogs (Johnson et al., 1999; Serres, Chetboul, Gouni, et al., 2007). Although 
some clinicians have speculated upon the possibility of severe left atrial dysfunction and 
subsequent pulmonary hypertension contributing towards pleural effusion in cats with CHF 
(Johns et al., 2012), the significance and prevalence of pulmonary hypertension in feline 
cardiomyopathies have not yet been characterised. Finally, thromboembolic disease is a 
unique feature of feline, but not canine, cardiomyopathies, with caudal aortic 
thromboembolism (ATE) being the most common location and a well-recognised component 
of HCM (Fox et al., 2018; Rush et al., 2002; Trehiou-Sechi et al., 2012) and other 
cardiomyopathies (S. A. Smith et al., 2003). These comorbidities cause an increase in 
preload, increase in afterload, reduced myocardial contractility, or a combination of these, 
and thus, negatively impact both individuals with CHF and those at risk of developing it. 
 
1.5) Classifications of CHF 
There are various methods of defining and describing severity of CHF, with some differences 
existing between aetiologies and species. These definitions and methods of categorising 
severity of symptoms play an important role in guiding diagnosis and treatment 
recommendations. 
In humans, several established methods of CHF classifications exist. The most 
commonly utilised classification scheme to describe various functional stages of CHF in 
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people is the New York Heart Association (NYHA) classification scheme (Table 1.5a). More 
recently, the American College of Cardiology/American Heart Association (ACC/AHA) 
created guidelines for staging disease severity which also include presence or absence of 
structural abnormalities (Table 1.5b). Treatment guidelines for CHF are also governed by 
the presence or absence of a reduction in ejection fraction (EF). Those with CHF with an EF 
of ≥ 50% are said to have heart failure with preserved ejection fraction (HFpEF), whereas 
those with an EF of < 40% are said to have heart failure with reduced ejection fraction 
(HFrEF); those with an EF between 40 – 49% fall in between these categories and are said 
to have heart failure with mid-range ejection fraction (HFmrEF) (Ponikowski et al., 2016). It is 
important to note that EF is used as a measure of ventricular function and does not refer to 
specific aetiologies or types of myocardial dysfunction. However, in general, HFpEF tends to 
accompany disorders resulting in either a normal or concentric hypertrophy of the left 
ventricle, with or without left atrial enlargement; therefore, it may occur more commonly in 
diseases resulting in primary diastolic dysfunction (Ponikowski et al., 2016). In contrast, 
HFrEF often reflects the predominance of systolic dysfunction. 
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Table 1.5a: New York Heart Association (NYHA) classification of heart failure based 
on severity of symptoms in people [adapted from Web Table 3.2, (Ponikowski et al., 
2016)]. 
NYHA Class Description 
Class I No limitation of physical activity. Ordinary physical activity does 
not cause undue breathlessness, fatigue, or palpitations. 
Class II Slight limitation of physical activity. Comfortable at rest, but 
ordinary physical activity results in undue breathlessness, 
fatigue, or palpitations. 
Class III Marked limitation of physical activity. Comfortable at rest, but 
less than ordinary physical activity results in undue 
breathlessness, fatigue, or palpitations. 
Class IV Unable to carry on any physical activity without discomfort. 
Symptoms at rest can be present. If any physical activity is 
undertaken, discomfort is increased. 
 
Table 1.5b: American College of Cardiology/American Heart Association (ACC/AHA) 
classification of heart failure based on symptoms and structural diseases [adapted 
from Web Table 3.3, (Ponikowski et al., 2016)]. 
ACC/AHA Stage Description 
A At high risk for heart failure but without structural heart disease or 
symptoms of heart failure. 
B Structural heart disease but without signs or symptoms of heart 
failure. 
C Structural disease with prior or current symptoms of heart failure. 
D Refractory heart failure requiring specialised interventions. 
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In the world of veterinary cardiology, CHF classifications and guidelines for diagnosis 
are somewhat less structured and varies based on the aetiology and species. In dogs, the 
two largest classification schemes utilised include the American College of Veterinary 
Internal Medicine (ACVIM) classification scheme for MMVD (Table 1.5c) and the 
International Small Animal Cardiac Health Council (ISACHC) scheme (Table 1.5d). 
Importantly, the definition of presence or absence of CHF differs between the two, with the 
ACVIM scheme necessitating radiographic evidence of pulmonary oedema in order to 
differentiate between CHF and primary respiratory causes of such symptoms (Atkins et al., 
2009; International Small Animal Cardiac Health Council (ISACHC), 1999). As such, it is 
considered a more stringent classification scheme than the ISACHC scheme. These 
classification systems are not commonly utilised in dogs with diseases other than MMVD or 
for cats. Dogs with DCM, for example, are typically classified into occult or symptomatic 
DCM based on the presence or absence of symptoms and a point-based system of 
diagnostic testing (Dukes-McEwan et al., 2003). In cats with HCM, there are no formal 
definitions of disease severity; mild, moderate, and severe disease is defined based on an 
individual clinician’s preference regarding left ventricular thickness and left atrial size 
(MacDonald, 2010). CHF is defined as the point at which pulmonary oedema or body cavity 
effusions become appreciable in the presence of left ventricular and atrial enlargements. 
Contrary to the situation in humans, where EF is used for treatment and prognostic purposes, 
EF is uncommonly used in veterinary cardiology. 
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Table 1.5c: The American College of Veterinary Internal Medicine (ACVIM) 
classification scheme for congestive heart failure (CHF) due to myxomatous mitral 
valve disease (MMVD) in dogs [adapted from (Atkins et al., 2009)). 
ACVIM Stage Description 
A Patients at risk for developing heart disease with no current 
structural abnormalities. 
B Patients with structural heart disease but without clinical signs of 
CHF. 
Substage B1 Asymptomatic patients without radiographic or echocardiographic 
evidence of cardiac remodelling in response to MMVD. 
Substage B2 Asymptomatic patients with radiographic or echocardiographic 
evidence of left heart enlargement (atrial and ventricular) in 
response to MMVD. 
C Patients with past or current clinical signs of CHF associated with 
structural heart disease. Radiographic evidence of CHF. 
D Patients with end-stage disease with clinical signs of CHF due to 
MMVD that are refractory to standard therapy and that require 
advanced or specialised treatments to maintain comfort. 
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Table 1.5d: The International Small Animal Cardiac Health Council (ISACHC) 
classification scheme for congestive heart failure (CHF) in dogs [adapted from 
(International Small Animal Cardiac Health Council (ISACHC), 1999)]. 
ISACHC Class Description 
IA Patients with heart disease without clinical signs or cardiac 
remodelling. 
IB Patients with heart disease without clinical signs but with 
radiographic or echocardiographic evidence of cardiac 
remodelling (e.g. left ventricular or atrial enlargement) 
II Patients with mild to moderate CHF. Clinical signs (such as 
exercise intolerance, cough, tachypnoea, mild respiratory 
distress, and ascites) present at rest or mild exercise but without 
significant effect on the quality of life. 
No evidence of hypo-perfusion at rest. 
IIIA Patients with advanced CHF in which home treatment is 
possible. Clinical signs (such as dyspnoea, marked ascites, 
profound exercise intolerance, hypo-perfusion at rest, 
cardiogenic shock) are obvious. Death or severe debilitation is 
likely without treatment. 
IIIB Patients with advanced CHF which require hospitalisation for 
treatment. Clinical signs (such as dyspnoea, marked ascites, 
profound exercise intolerance, hypo-perfusion at rest, 
cardiogenic shock) are obvious. Death or severe debilitation is 
likely without treatment. 
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These differences in definition and grading schemes of CHF across aetiologies and 
between species make it difficult to extrapolate and compare findings of various studies. For 
example, a human study evaluating treatment effects in people with HFpEF may include a 
large number of people with systemic hypertension; thus, the assumption that these study 
results could be applied to dogs with MMVD or cats with primary HCM should not be made. 
Treatment recommendations in people with mitral valve prolapse may not align with those 
recommended in dogs with MMVD due to the different cut-off points used in people (e.g. use 
of NYHA class, EF) compared to dogs (e.g. use of ACVIM staging). Careful inspection of the 
inclusion criteria, including disease aetiology and description of disease severity, is essential 
when attempting such extrapolations. 
 
1.6) Treatment of CHF 
The underlying disease process and various pathways involved in the development of CHF 
provide potential therapeutic targets for this syndrome. Some of these have been 
investigated more rigorously than others, but the evidence provided by existing research 
efforts, as well as cross-species extrapolation of these concepts, have led to a multi-modal 
approach to treatment of CHF in veterinary patients. With MMVD and HCM/HOCM being the 
most common forms of heart disease leading to CHF in dogs and cats, respectively, the 
proceeding discussion will focus on treatment of CHF resulting from these. For comparative 
purposes, and to present avenues for future investigation, treatment approaches in human 
medicine have also been reviewed.  
 
1.6.1) Medical therapy of canine CHF due to MMVD 
The therapeutic approach to CHF in canine patients with MMVD has been reasonably well-
described, with a moderate to large supply of evidence to support clinical practices. These 
have formed the basis of guidelines for the treatment of this condition, which were published 
by the ACVIM (Atkins et al., 2009). Essential components of treatment include the use of 
loop diuretics to reduce preload, RAAS modulation through angiotensin converting enzyme 
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(ACE) inhibition with or without a mineralocorticoid receptor antagonist (MRA), and an 
inodilator to provide positive inotropic and vasodilatory support. Yet certain knowledge gaps 
still exist, as highlighted below. 
 
1.6.1.1) Loop diuretics 
Loop diuretics form the cornerstone of CHF therapeutics, and in human medicine, a meta-
analysis of a few small, randomised, controlled trials supported the role of loop and thiazide 
diuretics in reducing CHF-related morbidity and mortality (Faris et al., 2002). In contrast, 
controlled clinical studies in veterinary patients with CHF do not exist. This is an important 
consideration as the use of loop diuretics is not entirely benign. Frusemide is the most widely 
used diuretic within this class, though increasing use of torsemide has emerged in recent 
years (Chetboul et al., 2017). Frusemide acts through inhibition of sodium reabsorption via 
the sodium-potassium-chloride cotransporter in the ascending limb of the loop of Henle, and 
as such, its use can result in side effects including hypokalaemia and hypochloraemic 
metabolic alkalosis (Plumb, 2015a). It can also unmask or exacerbate renal disease in those 
with suboptimal kidney function. In humans with chronic CHF, initiation of frusemide caused 
detrimental short-term hemodynamic effects such as a rise in ventricular filling pressure, 
increase in SVR, and increase in heart rate accompanied by activation of both RAAS and 
SNS (Francis et al., 1985). High doses of frusemide were also associated with increased 
mortality in several clinical trials (Hasselblad et al., 2007; Peacock et al., 2009). This last 
statement is confounded by the fact that greater disease severity may have necessitated use 
of higher doses of frusemide; nevertheless, the range of deleterious side effects associated 
with the use of loop diuretics should not be ignored. 
One method of reducing the negative impact of diuretics may be through therapeutic 
monitoring and goal-oriented approaches to diuretic therapy. A clinical measure that may be 
useful in guiding treatment with diuretics in dogs is the sleeping or resting respiratory rate. 
Indeed, there is data identifying the upper limit of normal respiratory rates in dogs with 
subclinical and medically controlled CHF (Ohad et al., 2013; Porciello et al., 2016; Schober 
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et al., 2011); however, the benefits of using respiratory rates to guide the amount of long-
term diuretic use in these patients has not yet been formally evaluated.  
 
1.6.1.2) RAAS antagonism 
The use of ACE inhibitors (ACE-I) in chronic management of CHF due to MMVD has been 
established through several prospective, controlled clinical studies in dogs with MMVD and 
DCM which observed haemodynamic, clinical, and survival benefits of treatment (Ettinger et 
al., 1998; Sisson, 1995; The BENCH Study Group, 1999; Woodfield, 1995). This evidence, 
together with the wealth of information supporting its benefits in the treatment of CHF in 
humans (Ponikowski et al., 2016; Yancy et al., 2017) and its theoretical role in 
neuroendocrine modulation led to its inclusion in the routine therapy of CHF due to MMVD in 
dogs. Yet it is interesting to note that there are no published studies in the veterinary 
literature which have reported successful attenuation of angiotensin II, aldosterone, or their 
effects in dogs with naturally occurring CHF treated with ACE-I. In fact, a recent study in the 
target population observed no effects of short-term benazepril therapy on these endocrine or 
cardiovascular variables (Häggström, Lord, et al., 2013). Other studies in normal dogs 
demonstrated that ACE-I therapy did not attenuate diuretic-induced activation of RAAS (M. K. 
Ames et al., 2015; Lantis, Ames, Werre, et al., 2015), thereby raising concerns about their 
effectiveness for this purpose in dogs with CHF. These findings are in contrast to the clinical 
benefits observed in the aforementioned larger trials examining the use of ACE-I in dogs 
with CHF and bring to question the true role of ACE-I therapy.  
This is an interesting point to contemplate, as there are reasons why ACE-I may not 
provide adequate RAAS suppression in dogs with CHF. ACE-independent pathways for 
angiotensin conversion exist, with tissue chymase-driven conversion being the dominant 
alternate pathway in several species including the dog (Dell'Italia et al., 1995; Paul et al., 
2006). In addition, loss of ACE-I activity through the aldosterone escape mechanism has 
been observed with chronic ACE-I therapy in humans (Struthers, 2004). In normal dogs 
undergoing frusemide or amlodipine-induced RAAS activation, a more immediate form of 
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aldosterone breakthrough has been reported (M. K.  Ames et al., 2016; Lantis, Ames, Atkins, 
et al., 2015), and aldosterone breakthrough has been demonstrated in around 30% of dogs 
with and without CHF being treated with an ACE-I over a longer period (M. K. Ames et al., 
2017). The small numbers of dogs included in the study; the variable length, doses, and 
types of ACE-I therapy; and lack of strict definitions for aldosterone breakthrough in 
veterinary medicine are some of the limitations associated with this latter study, but these 
findings nevertheless raise questions regarding the efficacy of ACE-I in dogs with CHF. 
These concerns regarding ACE-I led to the investigation of MRA as an additional 
method of overcoming RAAS effects in people with CHF. In humans with HFrEF, several 
large, double-blinded, randomised controlled trials have been conducted in which the 
addition of MRA to standard therapy resulted in prolonged survival and reduced morbidity 
(Pitt et al., 2003; Pitt et al., 1999; Zannad et al., 2011). The reason for these benefits 
appears to be related to its anti-fibrotic effects (Deswal et al., 2011; Zannad et al., 2000). 
However, similar survival benefits have yet to be proven in dogs with CHF due to MMVD. In 
one double-blinded, randomised controlled trial of dogs with MMVD and varying degrees of 
CHF, ~ 55% reduction in risk to combined cardiac death, euthanasia, or severe progression 
of disease was observed in the spironolactone treated group compared to placebo (Bernay 
et al., 2010). Unfortunately, only 18% of dogs in this study reached this endpoint. In another 
smaller study of dogs with MMVD and DCM, addition of spironolactone to standard therapy 
reduced the risk of progression of disease but did not result in improved survival, circulating 
endocrine markers, or hemodynamic measures over the six month duration of treatment 
(Schuller et al., 2011). However, this study was limited by the short follow-up duration and 
very small numbers of dogs. Currently, there is also a lack of information to support 
successful attenuation of cardiac remodelling in dogs with CHF due to MMVD treated with 
MRA. Thus, despite the growing popularity of MRA as a potassium-sparing adjunctive 
diuretic and RAAS-modulating drug, whether they offer a true benefit in canine CHF remains 
ambiguous. 
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The presence of conflicting evidence surrounding ACE-I and MRA in dogs with CHF 
due to MMVD raises questions regarding the role of the RAAS in the development and 
propagation of CHF in these dogs. Indeed, RAAS activation here is relatively ill-defined 
compared to the situation in dogs and people with cardiomyopathies resulting in significant 
systolic dysfunction (Dzau et al., 1981; Koch et al., 1995; Tidholm et al., 2001). In 
asymptomatic dogs with MMVD, the RAAS may (H. D. Pedersen et al., 1995) or may not 
(Häggström et al., 1997) be activated, and valvular insufficiency may cause differential 
activation of circulating and tissue RAAS (Fujii et al., 2007). Additionally, RAAS activation 
may be pulsatile, increasing only around times of rapid ventricular remodelling (Hezzell, 
Boswood, Chang, Moonarmart, & Elliott, 2012). In contrast to findings of one retrospective 
study in Doberman Pinschers with DCM (O'Grady et al., 2009), where benefits of ACE-I in 
delaying the onset of CHF were suggested, ACE-I have not been proven to attenuate the 
progression to CHF in neither humans with valvular diseases nor in dogs with MMVD, and 
are therefore not routinely recommended for use in preclinical disease (Atkins et al., 2007; 
Baumgartner et al., 2017; Kvart et al., 2002). One retrospective study observed longer 
survival in dogs treated with benazepril in the pre-clinical stage of MMVD compared with 
those who were not, but this difference was less likely to be related to cardiac benefits of 
ACE-I as the causes of death were mainly non-cardiac in nature, and there was no 
difference in time to CHF or cardiac-related deaths between the groups (Pouchelon et al., 
2008). Interestingly, there is also the possibility that some of the aforementioned studies 
presenting haemodynamic and survival benefits of ACE-I in dogs with CHF may have been 
influenced significantly by the inclusion of a large portion of dogs with DCM (Sisson, 1995; 
Woodfield, 1995). Compared to dogs with MMVD, those with DCM treated with ACE-I were 
observed to have greater improvements in overall clinical evaluation (Sisson, 1995) and 
improvements in a larger number of haemodynamic and clinical variables evaluated 
(Woodfield, 1995). Despite this, fewer dogs with MMVD experienced progressive disease on 
benazepril treatment in one large, multi-centre, double-blinded, randomised controlled study 
(The BENCH Study Group, 1999), and this finding was supported by the prolonged time to 
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treatment failure in MMVD dogs on enlaparil in another long-term study (Ettinger et al., 1998) 
Ultimately, these existing studies evaluating the role of RAAS in the development and 
propagation of CHF due to MMVD are few in number and limited by small sample sizes in 
some cases; as such, it is impossible to reach compelling conclusions regarding this matter.  
As can be appreciated, the history behind ACE-I and MRA in the treatment of CHF 
due to MMVD is rather convoluted. The role of the RAAS, as well as ACE-I therapy and any 
alternate or additional methods targeting the RAAS, in the development and treatment of 
CHF due to MMVD, is an area requiring further investigation. 
 
1.6.1.3) Inodilators 
Much like with diuretics and ACE-I, inodilators were initially used in people prior to their rise 
in veterinary medicine. Yet in contrast to the success of ACE-I, inodilators experienced a 
spectacular course of demise in human medicine.  
Pimobendan is a benzimidazole-pyridazinone derivative that produces both positive 
inotropic and vasodilatory effects via selective phosphodiesterase III inhibition and calcium 
sensitisation (Brunkhorst et al., 1989; C. H. Chen et al., 1997; Fujimoto, 1994; Fujimoto & 
Matsuda, 1990; Fujino et al., 1988b; Rüegg et al., 1984; Solaro et al., 1989). Following 
administration, it is metabolized to an active metabolite (UD-CG 212 CL) via oxidative 
demethylation (O-demethylation) in the liver (Hagemeijer, 1993; Pahernik et al., 1995). In 
humans with HFrEF, pimobendan caused an acute increase in EF, cardiac index and output, 
stroke volume (SV) and SV index, and rate of rise in maximal left ventricular pressure 
(LVmax dP/dt); in addition, a decrease in right atrial and pulmonary pressures, systemic 
vascular resistance (SVR), peripheral vascular resistance, systemic blood pressure (BP), 
and end systolic and diastolic volumes were also observed (Baumann et al., 1989; 
Hagemeijer, Brand, & Roth, 1989; Hagemeijer, Brand, & Van Mechelen, 1989; Hasenfuss et 
al., 1989; Katz et al., 1992; Permanetter et al., 1989; Pouleur et al., 1989; Remme et al., 
1989; Renard et al., 1988; Walter et al., 1988). Despite this, it failed to demonstrate any 
significant longer-term benefits in haemodynamic, quality of life, or survival measures across 
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three major randomised, double-blinded, and placebo-controlled and clinical trials (Kubo et 
al., 1992; Lubsen et al., 1996; The EPOCH Study Group, 2002). This, along with the 
unfortunate discovery of adverse effects associated with other positive inotropes which were 
being investigated at the time, led to it disappearing from all but a small Asian market of 
cardiovascular pharmaceuticals across the world. 
Yet in the early 2000’s, when pimobendan was introduced to the world of veterinary 
cardiology, convincing evidence in favour of its use emerged. The largest and most 
compelling study examining its use in dogs with CHF due to MMVD was the “QUEST” study 
– a multi-centre, single-blinded, randomised study in 260 dogs (Häggström et al., 2008). In 
contrast to the long-term outcome in humans, a definitive benefit of pimobendan over 
benazepril was highlighted in the significantly longer time to reach the combined endpoint of 
cardiovascular death/euthanasia or treatment failure in pimobendan-treated dogs (median 
267 days for pimobendan vs 140 days for benazepril). Two smaller studies examining long-
term effects of pimobendan compared with an ACE-I in dogs with CHF due to MMVD also 
reported similar benefits. Conclusions from both studies favoured treatment with 
pimobendan, with one study showing a 25% reduction in likelihood of an adverse outcome 
due to CHF in the pimobendan group (P. J. Smith et al., 2005) while the other observed a 
significantly longer MST (430 days, compared with 228 days in those treated with an ACE-I) 
in dogs treated with pimobendan (Lombard et al., 2006). 
The positive outcomes observed in clinical trials were supported by findings of 
beneficial haemodynamic changes induced by pimobendan in dogs with experimental or 
naturally occurring mitral valve insufficiency. Kanno et al., (2007) identified significant 
reductions in left ventricular internal diameter in systole (LVIDs), left ventricular internal 
diameter in diastole (LVIDd), left ventricular end systolic volume (ESV), left ventricular end 
diastolic volume (EDV), and regurgitant stroke volume in four dogs with experimentally 
induced mitral valve insufficiency over a four-week period of time. Using another 
experimental model of mitral regurgitation, Suzuki et al. (2011) also observed a reduction in 
left atrial pressure and mitral regurgitation indices after seven days of pimobendan treatment. 
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An increase in fractional shortening (FS) was also found after the same period of treatment 
in another study on 20 dogs with MMVD (Caro et al., 2009). In dogs with MMVD and 
pulmonary hypertension, a chronic reduction in LVIDs and increase in left ventricular 
shortening area were also documented (Atkinson et al., 2009). These studies confirmed a 
lack of significant changes to heart rate (HR) and BP in dogs treated with pimobendan. 
Together, these experimental and clinical studies highlighted the benefits of 
pimobendan in dogs with CHF due to MMVD. Moreover, the larger clinical studies 
specifically demonstrated the superiority of pimobendan over use of an ACE-I. To add to this 
pool of evidence, a recent multi-centre, placebo-controlled, double-blinded, randomised 
clinical trial of 360 dogs with advanced pre-clinical MMVD demonstrated a significant delay 
in the onset of either CHF or cardiac-related death/euthanasia when treated with 
pimobendan (Boswood et al., 2016). This study, known as the “EPIC” study, therefore raised 
the possibility that pimobendan may modulate the pathophysiology leading to CHF in dogs 
with MMVD. This is in contrast to the situation with ACE-I, where a clear benefit of treatment 
in the preclinical phase could not be demonstrated. It is interesting to note that despite this 
pool of evidence to support the advantages of pimobendan over ACE-I, both drugs are 
recommended in the gold standard of treatment in dogs with MMVD. Although a large, 
single-blinded, randomised study investigating the benefits of adding an ACE-I to 
pimobendan and frusemide was commenced in 2005, results have not yet been published 
(Wess, 2017); as such, it is not yet known whether such combination therapy would offer 
additional advantages. 
Pimobendan has also been used in clinical practice at a higher frequency (three 
times daily at 0.2 – 0.3 mg/kg) than the labelled twice daily dosing regimen. This practice is 
typically reserved for dogs with refractory CHF (Atkins et al., 2009) but may also be utilised 
in cases of concurrent renal insufficiency (to optimise haemodynamics in the face of diuretic 
intolerance) or severe airway disease (to reduce compression of mainstem bronchi). The 
reported pharmacokinetic properties of this drug include rapid absorption and elimination, 
with achievement of maximal plasma concentrations at two and three hours following oral 
28
 
 
dosing, and elimination half-life of 0.5 and two hours, for pimobendan and its active 
metabolite, respectively (Plumb, 2015b). Its duration of action also appears to be long, with 
LVmax dP/dt remaining elevated for over eight hours following oral dosing at 0.5 mg/kg (Van 
Meel & Diederen, 1989). Based on this information, it would appear that the off-label dosage 
regimen may provide effective, or potentially better, inodilation. However, information 
regarding effectiveness of this regimen is lacking.   
 
1.6.2) Medical therapy of feline CHF 
In contrast to the situation in canine medicine, where a body of evidence exists to support 
practices undertaken in the therapy of CHF, there is a distinct lack of research into feline 
CHF therapeutics. This is likely due to their small body size and blood volume, tendency to 
display resistance towards training and unsolicited handling, and the historically small size of 
the feline market (Downes et al., 2009; Slater et al., 2008; Toribio et al., 2009). Nevertheless, 
current practices in feline medicine have been guided by the few published literature, expert 
opinions, personal experience, and theoretical benefits (Rishniw & Pion, 2011). Key 
components here include the use of loop diuretics to reduce volume overload, RAAS 
modulation through ACE inhibition, and an antiplatelet agent to reduce the risk of 
thromboembolic disease. Most recently, the use of inodilators in this population has been 
debated.  
 
1.6.2.1) Loop diuretics 
Much like the situation in dogs, diuretics form an integral component of CHF therapeutics in 
cats despite the lack of randomised, controlled trials to support survival and quality of life 
benefits. In cats, there is, perhaps, an even greater need for more robust guidelines on 
frusemide use as there is a widespread belief amongst clinicians that cats have a tendency 
to be more “sensitive” to the diuretic effects of frusemide. This is partially, but not entirely, 
supported by an experimental study in which a difference in diuretic and natriuretic effects of 
frusemide between dogs and cats was suggested (Klatt et al., 1975); in addition, cats suffer 
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from concomitant chronic kidney disease more commonly than dogs, and they appear to be 
more particular in their feeding and drinking habits – thus making them prone to dehydration. 
As such, lower doses of diuretics are recommended for use in this species (Barrett, 2010; 
Plumb, 2015a); however, a goal-oriented approach would, of course, be ideal. Sleeping or 
resting respiratory rates may be a useful tool, but further evaluation of its use in this setting 
is required (Ljungvall et al., 2014; Porciello et al., 2016). 
 
1.6.2.2) ACE inhibitors 
The lack of prospective clinical trials to investigate the use of frusemide in cats with CHF is 
not surprising. What is surprising, however, is the similar lack of prospective clinical trials 
investigating the use of ACE-I in this context. One retrospective study described small 
reductions in left ventricular wall thickness and left atrial sizes when enalapril was used with 
or without other medications in 19 cats with clinical and subclinical HCM; however, the effect 
of treatment on survival or long-term outcome measures could not be identified due to the 
variable treatment regimen utilised in each case and the lack of a control group (Rush et al., 
1998). Three small prospective studies evaluated the use of ACE-I in cats with HCM with 
and without CHF, with no obvious benefit of ACE-I therapy compared to an active control or 
placebo (MacDonald et al., 2006; Taillefer & Di Fruscia, 2006) except for a small reduction in 
left ventricular free wall thickness in one study (Amberger et al., 1999). Preliminary results of 
one study evaluating long-term outcomes of ACE-I in cats with CHF due to HCM, HOCM, 
UCM, or RCM suggested a shorter period of time to hospitalisation for recurrent CHF in cats 
treated with ACE-I and frusemide when compared with frusemide alone, and addition of an 
ACE-I did not affect overall mortality rates (Fox, 2003b). Unfortunately, this study was never 
published, and as such, effects of ACE-I on survival or long-term outcomes remain ill-defined. 
Despite this, its use in cats with CHF has been advocated by experts based on 
extrapolations from human and canine literature and as an attempt to attenuate RAAS 
activation secondary to frusemide therapy (Gordon & Côté, 2015). 
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1.6.2.3) Antithrombotic agents 
Depending on the population studied, roughly 4 – 17% of cats with HCM may present with 
ATE (Fox et al., 2018; Rush et al., 2002; Trehiou-Sechi et al., 2012). This is thought to occur 
in part, but not entirely, due to the presence of hypercoagulability (Stokol et al., 2008). 
Although ATE can occur in the absence of CHF, it is a significant cause of death or 
euthanasia, with reported MST in those surviving the acute period of hospitalisation ranging 
from 94 to around 345 days (Borgeat, Wright, et al., 2014; Hogan et al., 2015; Laste & 
Harpster, 1995; Schoeman, 1999; S. A. Smith et al., 2003). Recurrent thrombosis is 
common in those surviving the initial insult, and a handful of studies have evaluated the 
effects of aspirin and clopidogrel as a means of reducing recurrence or prolonging the time 
to recurrence of ATE (Hogan et al., 2015; Schoeman, 1999; S. A. Smith et al., 2003). To 
date, the most compelling evidence exists for clopidogrel, which was shown to reduce the 
recurrence of ATE and double the time to recurrence of ATE in a randomised, multi-centre, 
double-blinded clinical trial utilising aspirin as an active control (Hogan et al., 2015). Yet 
there is no solid evidence to guide the criteria for initiation of antithrombotic medications prior 
to the development of a thromboembolic episode. Due to the high morbidity and mortality 
associated with this disease, many clinicians advocate the use of antithrombotic medications 
in the presence of severe left atrial enlargement, spontaneous echocardiographic contrast, 
or an intra-atrial thrombus (Ferasin, 2009; Hogan, 2017). 
 
1.6.2.4) Inodilators 
The strong evidence to support pimobendan use in dogs with CHF led to investigations into 
its off-label use in cats with CHF. To date, there have been no prospective studies 
evaluating the use of pimobendan in this population; however, a number of retrospective 
studies have been conducted (Gordon et al., 2012; Hambrook & Bennett, 2012; MacGregor 
et al., 2011; Reina-Doreste et al., 2014). Pimobendan appears to be well-tolerated, with only 
a single report of significant adverse effects being reported in a cat with mitral valve 
dysplasia, systolic anterior motion, and a ventral septal defect (Gordon et al., 2012). The 
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majority of these studies examined its use in cats with systolic dysfunction, with one case-
control study reporting around a four-fold increase in MST in cats with CHF due to DCM 
treated with pimobendan compared to a group of controls receiving either digoxin or no 
positive inotropes (49 days with pimobendan versus 12 days in the controls) (Hambrook & 
Bennett, 2012). This difference just reached significance (p = 0.048), but pimobendan 
treatment was not identified as a significant prognostic indicator. Another recent case-control 
study also observed a longer MST in cats with CHF due to HCM and HOCM without systolic 
dysfunction when pimobendan was used in addition to standard therapy (626 days with 
pimobendan versus 103 days in the controls, p = 0.024) (Reina-Doreste et al., 2014). 
Despite suggestions that pimobendan may offer survival benefits in cats with CHF, these 
findings were clouded by the relatively small sample size, changes in medical practices 
during the ~ 10 year period from which the data were collected, and the lack of control over 
various aspects of medical management due to the retrospective design.  
Thus, prospective studies are still required to elucidate the role of pimobendan in 
feline CHF and to identify the population that truly benefits from treatment. For example, its 
effect in cats with HOCM remains controversial. In theory, presence of an outflow tract 
obstruction is a contraindication for treatment with inodilators; although some studies have 
commented on successful use of pimobendan in cats with HOCM (MacGregor et al., 2011; 
Reina-Doreste et al., 2014), negative effects have been observed in cats with outflow tract 
obstructions (Gordon et al., 2012), and the small numbers of cats in the existing studies 
prohibits any conclusions to be drawn. In addition, the two aforementioned case-control 
studies observed a relatively high drop-out rate of ~ 30 – 40% in both cases and controls in 
the first part of the survival curve (equivalent to ~ 25 days in the study by Hambrook and 
Bennett (2012)). Thus, any benefit of pimobendan treatment may only be in individuals who 
survive this initial period of disease. There may also be a portion of “non-responders” who 
experience an early demise. In the Hambrook and Bennett (2012) study, more cats treated 
with pimobendan died of sudden death (n = 7) compared to controls (n = 4). The incidence 
of sudden death was not clarified in the study by Reina-Doreste et al. (2014). With some 
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evidence to suggest inter-species differences in pharmacokinetics of the drug between dogs 
and cats (Hanzlicek et al., 2012), further evaluation of optimal dosing regimen and potential 
differences in cardiovascular effects between species is warranted.  
 
1.7) Medical therapy of CHF in humans 
Human medicine has influenced aspects of veterinary medicine throughout history, and the 
treatment of CHF has not been an exception. As such, a review of current medical practices 
is essential to provide additional evidence for or against current practices in veterinary 
medicine. In addition, these may provide inspiration for prospective novel therapeutics in 
veterinary patients.  
The prevalence of CHF amongst people world-wide is estimated to be around  
1 – 2% (Ponikowski et al., 2016). The often poor prognosis associated with it is well-
recognised amongst medical professionals, with a one year mortality rate for those requiring 
hospitalisation reaching around 17% (Ponikowski et al., 2016). Those suffering from HFrEF 
due to dilated and ischemic cardiomyopathies have a worse prognosis than those with 
HFpEF, and this has driven numerous investigations into novel approaches to the medical 
management of CHF arising from these aetiologies. Thus, it is interesting to note that even 
in humans, there is little evidence to support medical therapy of CHF in those with diseases 
encountered in our veterinary patients such as mitral valve disease and HCM; in fact, even 
the use of treatments such as ACE-I and diuretics for CHF secondary to these diseases is 
not well-supported, with the level of evidence comprising primarily of expert opinions and 
extrapolations from studies in people with dilated and ischemic cardiomyopathies 
(Baumgartner et al., 2017; Elliott et al., 2014). Due to the superiority of surgery in most 
situations, medical therapy consisting of ACE-I with or without beta-blockers and MRA is 
only recommended in people with symptomatic mitral valve disease with an EF of < 30%, 
and there are no recommendations on the use of positive inotropes (Baumgartner et al., 
2017). The diastolic dysfunction and the arrhythmogenic tendencies associated with HCM 
and HOCM in people have led to beta blockers, calcium channel blockers, and anti-
33
 
 
arrhythmics forming the cornerstone of therapy (Elliott et al., 2014; Gersh et al., 2011).  
ACE-I are only recommended in people with symptomatic HCM if the ejection fraction is 
< 50%; interestingly, the use of diuretics and ACE-I in people with HOCM appears 
controversial, with recommendations to avoid these or to use with caution due to potential 
exacerbation of the obstructive pathology (Elliott et al., 2014; Gersh et al., 2011). Here, the 
use of positive inotropes is absolutely contraindicated, even in the presence of hypotension 
and pulmonary oedema (Elliott et al., 2014; Gersh et al., 2011). 
The cornerstone of medical therapy in people with symptomatic HFrEF involves the 
use of an ACE-I, beta-blocker, and a MRA (Ponikowski et al., 2016; Yancy et al., 2017).  
A significant body of evidence in the form of large randomised, controlled, clinical trials exist 
to support their survival and quality of life benefits in people with HFrEF. Some of these also 
advocate the use of combination therapy. For example, a reduced risk of sudden death and 
death due to CHF was observed when beta-blockers and MRAs were used with ACE-I 
(Packer et al., 2001; Pitt et al., 1999; The MERIT-HF Study Group, 1999; Zannad et al., 
2011). Other treatments that are recommended for use in certain people include diuretics in 
those who require this to control symptoms, along with angiotensin receptor type-I 
antagonists in those suffering from side effects of ACE-I therapy.  
Most recently, the combined angiotensin receptor neprilysin inhibitor (ARNI) has 
been added to these guidelines as a replacement for ACE-I (Ponikowski et al., 2016; Yancy 
et al., 2017). This class of medication combines an angiotensin receptor type-I antagonist 
with a neprilysin inhibitor. Neprilysin is a metalloproteinase that is involved in the breakdown 
of numerous peptides in the body, including those involved in cardiovascular homeostasis 
such as natriuretic peptides and adrenomedullin (McMurray et al., 2014). This combination 
of drugs therefore results in RAAS antagonism and enhancement of the NPS. In a double-
blinded, randomised, controlled clinical trial of 8442 people with HFrEF, treatment with ARNI 
resulted in ~20% reduction in risk of reaching the combined primary outcome of 
cardiovascular death and rehospitalisation due to CHF compared to ACE-I therapy 
(McMurray et al., 2014). ARNI was also associated with a lower rate of all-cause mortality 
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and increased functional capacity. The benefits of neprilysin inhibitors on cardiovascular and 
renal systems have also been documented in pacing-induced models of CHF in dogs, with 
the effect of combined neprilysin and RAAS inhibition providing superior increase in CO and 
SV, reduction in mean BP (MBP) and SVR, and renal function (H. H. Chen et al., 1999; 
Margulies et al., 1991; F. L. Martin et al., 2005; Seymour et al., 1993). In addition, ARNI 
reduced myocardial cell hypertrophy and fibrosis in rats with myocardial infarction (von 
Lueder et al., 2014). This approach of combined NPS augmentation and RAAS inhibition 
therefore appears to provide superior treatment of CHF than with RAAS inhibition alone and 
highlights the significance of the NPS in the pathophysiology of CHF in those with systolic 
dysfunction. 
The success of ARNI in people with HFrEF supports the theory of relative NP 
deficiency in states of CHF, which was previously discussed in section 1.3. Yet interestingly, 
NPS augmentation via administration of exogenous NP was not effective in people with CHF. 
Much like the situation with pimobendan, exogenous NP resulted in acute benefits such as a 
reduction in pulmonary capillary wedge pressure, right atrial pressure, systemic vascular 
resistance, systolic and pulmonary blood pressures, left ventricular volume indices, and 
symptoms such as dyspnoea and fatigue, in people with symptomatic CHF participating in 
double-blinded, randomised, controlled trials (H. H. Chen et al., 2012; Colucci et al., 2000; 
Publication Committee for the VMAC Investigators, 2002). This resulted in the registration of 
Nesiritide, a recombinant BNP1-32 product, for use in people with acute CHF. However, a 
subsequent trial examining the effect of this product on 30-day rehospitalisation and 
mortality rates showed no clear benefits over standard therapy; furthermore, Nesiritide 
resulted in greater incidences of hypotension (O'Connor et al., 2011). This led to Nesiritide 
falling out of favour in human cardiology. This contrast between Nesiritide and ARNI may 
suggest a greater role of enhanced NP degradation in CHF; alternatively, neprilysin inhibition 
could be producing beneficial effects outside of the NPS.  
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1.8) Knowledge gaps and aims of the thesis 
As can be appreciated, many knowledge gaps exist in the pathophysiology and treatment of 
CHF in both veterinary and human medicine. Considering the timeline, physical capacity, 
and financial capacity in the context of this project, the following areas were selected for 
further investigation. 
Despite the established use of pimobendan in dogs with CHF due to MMVD, there 
has been little evidence to support off-label practices such as the higher frequency of dosing 
in dogs with latter stages of disease (Atkins et al., 2009). Of particular importance here is the 
lack of published pharmacodynamic studies investigating the effects of pimobendan 
following single, oral administration of labelled doses. This makes it difficult to predict the 
effect of these treatment regimens. In addition, therapeutic monitoring is not employed; as 
such, benefits of altering treatment regimen at an individual level are currently unknown.  
There are also concerns related to treatment compliance. It is well-known that 
treatment compliance reduces in people with increased frequency and number of dosing 
(Claxton et al., 2001; Eisen et al., 1990). In veterinary medicine, an additional concern is the 
willingness of pets to receive medications, with solid dose forms proving troublesome for 
many. Pimobendan is particularly challenging to work with as its dosing recommendations 
call for administration without food. Finally, the life-long nature of treatment adds up to a 
considerable expense – thus necessitating evidence of benefit in order to maintain owner 
compliance.  
The second chapter of this thesis will aim to address these concerns through 
investigation of pharmacokinetic and pharmacodynamic properties of a non-aqueous, liquid 
formulation of pimobendan in healthy dogs. In addition to assessing the suitability of this 
formulation as an alternative to existing solid dose forms, this study will explore the utility of 
echocardiography as a non-invasive method of monitoring drug effects and provide a 
rationale for alternative treatment regimen.  
The debate surrounding the use of pimobendan in cats exists due, at least in part, to 
the questions regarding its pharmacokinetics and pharmacodynamics which have yet to be 
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answered. The in-vivo disposition of pimobendan appears to differ in cats compared to dogs, 
with one published study raising a hypothesis that it may not undergo significant metabolism 
in this species (Hanzlicek et al., 2012); however, this has not been proven, and the 
relationship between the parent drug and its active metabolite remains unknown. This is 
important to clarify as there is data to suggest that pimobendan produces greater positive 
inotropic and vasodilatory effects than its metabolite at physiological concentrations (Böhm 
et al., 1991; Endoh et al., 1991; Fujimoto, 1994; Verdouw et al., 1987). There are two 
existing studies that have investigated the acute effects of pimobendan in cats, but these did 
not comment on the magnitude, duration, or range of its effects (Kent, 2011; Von Meel, 
1985). Thus, further pharmacological studies are required to guide optimal treatment 
strategies and further investigations into the benefit, if any, of pimobendan in cats with CHF. 
In the third chapter of this thesis, the dose-effect relationship of pimobendan will be 
investigated in healthy cats through evaluating its pharmacokinetics and pharmacodynamics. 
The ability to detect treatment effects using echocardiography will also be tested, and by 
employing a similar study design to that of the preceding chapter, the suitability of this 
method to monitor treatment effects across species will be evaluated. Inter-species 
differences in drug disposition, particularly regarding its metabolism, will be considered. 
The conflicting information regarding the role of the RAAS in CHF in dogs with 
MMVD, together with the proven benefits of pimobendan over ACE-I in the treatment of this 
condition, raise the need for further evaluations regarding optimal medical therapy for this 
condition. This is an important consideration in veterinary medicine, where cost and 
compliance form major determinants of viable treatment options. Although a large 
prospective study investigating potential benefits of combination therapy compared to 
treatment with pimobendan and frusemide alone has been performed, results have not yet 
been published (Wess, 2017). With some evidence to suggest the presence of aldosterone 
escape and ACE-independent pathways in dogs, another unanswered question relates to 
whether concomitant use of MRBs and ACE-I to provide a more comprehensive approach to 
RAAS antagonism might positively alter the course of this disease. 
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Interestingly, even the natural course of disease on these combination therapies 
utilising pimobendan and RAAS inhibition is minimally documented in the existing literature. 
Aside from the major studies evaluating survival outcomes in dogs with MMVD being treated 
with an ACE-I or pimobendan (Ettinger et al., 1998; Häggström et al., 2008; Lombard et al., 
2006; The BENCH Study Group, 1999), several other longitudinal studies evaluating survival 
and risk factors for negative outcomes in dogs with CHF due to MMVD exist (Beaumier et al., 
2018; Borgarelli et al., 2008; De Madron et al., 2011; Häggström, Boswood, et al., 2013; 
Hezzell, Boswood, Chang, Moonarmart, Souttar, et al., 2012; Hezzell, Boswood, 
Moonarmart, et al., 2012; M. Mizuno et al., 2017; Serres, Chetboul, Tissier, et al., 2007; 
Serres et al., 2008; Slupe et al., 2008; Wolf et al., 2012). However, the treatments used were 
highly variable, and pimobendan and RAAS inhibition were often not administered 
concurrently. In addition, some studies focused more on prognostic clinical variables without 
evaluating the role of varying treatment regimen. Finally, many of these studies failed to 
enrol dogs at the first onset of CHF. As such, the expected course of disease on 
combination therapy utilising pimobendan and RAAS inhibition remains ill-defined.  
The fourth chapter of this thesis will consist of a prospective study evaluating the 
natural course of disease in dogs with newly diagnosed CHF due to MMVD undergoing 
treatment with frusemide, pimobendan, benazepril, and spironolactone. This study will aim to 
add to existing survival data in dogs with CHF due to MMVD by describing the evolution of 
disease when pimobendan and comprehensive RAAS inhibition are included in the 
treatment strategy. 
In humans, aspects of the NPS have been investigated for their role in the 
pathophysiology of CHF, and this has resulted in the development of ARNI as a novel 
therapeutic agent. Although a pilot study examining the short-term use of ARNI in dogs with 
subclinical MMVD has very recently been published (Newhard et al., 2018), the various 
components of the NPS have not been thoroughly investigated in the context of MMVD in 
dogs. Thus, it remains a mystery as to whether reduced production of, accelerated 
degradation of, or peripheral resistance to, the active BNP1-32 and ANP1-28 may be 
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present in those that develop CHF. Aside from the aforementioned pilot study and one other, 
in which synthetic BNP1-32 was administered to healthy dogs and those with subclinical 
MMVD (Oyama et al., 2017), the NPS has not been examined as a therapeutic target in 
veterinary medicine.  
The fifth chapter of this thesis will examine methods of evaluating the BNP system in 
healthy dogs as a starting point to its investigation in dogs with MMVD. A primary aim will be 
to develop an assay utilising mass spectrometry to identify active BNP1-32 in canine plasma. 
A secondary aim will be to examine the BNP system in healthy dogs undergoing an increase 
in preload induced through high-volume fluid therapy.  
Finally, the effect of augmenting the BNP system in dogs with CHF due to MMVD will 
be examined in the sixth chapter. This study will document the efficacy of synthetic BNP1-32 
administered subcutaneously to dogs with compensated CHF due to MMVD and aim to 
provide support for further investigations into its use in this population.  
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Pimobendan is an inodilator used in the treatment of canine congestive heart fail-
ure (CHF). The aim of this study was to investigate the pharmacokinetics and car-
diovascular effects of a nonaqueous oral solution of pimobendan using a single-
dose, operator-blinded, parallel-dose study design. Eight healthy dogs were divided
into two treatment groups consisting of water (negative control) and pimobendan
solution. Plasma samples and noninvasive measures of cardiovascular function
were obtained over a 24-h period following dosing. Pimobendan and its active
metabolite were quantified using an ultra-high-performance liquid chromatogra-
phy–mass spectrometer (UHPLC-MS) assay. The oral pimobendan solution was
rapidly absorbed [time taken to reach maximum concentration (Tmax) 1.1 h] and
readily converted to the active metabolite (metabolite Tmax 1.3 h). The elimination
half-life was short for both pimobendan and its active metabolite (0.9 and 1.6 h,
respectively). Maximal cardiovascular effects occurred at 2–4 h after a single oral
dose, with measurable effects occurring primarily in echocardiographic indices of
systolic function. Significant effects persisted for <8 h. The pimobendan nonaqu-
eous oral solution was well tolerated by study dogs.
(Paper received 18 February 2015; accepted for publication 30 April 2015)
Niek Jozef Beijerink, University Veterinary Teaching Hospital, Faculty of
Veterinary Science, University of Sydney, NSW 2006, Australia.
E-mail: niek.beijerink@sydney.edu.au
INTRODUCTION
Pimobendan is a benzimidazole-pyridazinone derivative that is
widely used in veterinary medicine for treatment of canine
congestive heart failure (CHF). Its mechanism of action is via
calcium sensitization and inhibition of phosphodiesterase III;
vasodilation and an increase in myocardial contractility with-
out a disproportionate increase in myocardial oxygen con-
sumption result (Boyle & Leech, 2012). In the latest published
guidelines for treatment of canine CHF, the American College
of Veterinary Internal Medicine (ACVIM) recommends pimob-
endan as one of three essential drugs for the treatment of
symptomatic CHF (ACVIM heart disease stage C and D) (Atkins
et al., 2009). This recommendation is supported by a number
of prospective, randomized, controlled trials that have reported
improvements in survival and time to treatment failure in dogs
with CHF due to myxomatous mitral valve disease (MMVD)
treated with pimobendan when compared to those treated with
an angiotensin converting enzyme inhibitor (ACE-I) (Smith
et al., 2005; Lombard et al., 2006; H€aggstr€om et al., 2008).
Currently, several registered oral formulations of pimoben-
dan are commercially available. These formulations consist of
solid dosage forms (flavoured and chewable tablets and cap-
sules). Some limitations of these pimobendan formulations
include difficulties in accurately dosing small patients, making
dose adjustments and administering the substance to non-
tractable patients. Successful medical treatment of veterinary
patients relies on acceptable owner and patient compliance.
The availability of a range of effective pharmaceutical prepa-
rations of a medication will aid in achieving this aim and will
be particularly beneficial when long-term therapy is required
as in the case of CHF. This study was designed to evaluate
the pharmacokinetics and cardiovascular effects of pimoben-
dan and its active metabolite after administration of a novel
nonaqueous oral pimobendan solution which may serve as an
alternative to currently existing registered formulations of this
drug.
MATERIALS AND METHODS
Animals
Eight healthy, adult dogs (Beagles; four male, four female;
weight 13.6–23.8 kg; age 4–6 years old) were recruited for
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the study. Ethics approval for the study was obtained from the
Wongaburra Research Centre Animal Care and Ethics Commit-
tee and University of Sydney Animal Ethics Committee prior to
the study.
Study design
A randomized, operator-blinded, single-dose, parallel-dose study
design was used. Dogs were block-randomized into the two
treatment groups (four dogs per group). Randomization was
also stratified by dog weight and sex to give an even male to
female ratio and distribution of body weights between groups.
Investigators involved in pharmacokinetic analysis and mea-
surement of pharmacodynamic parameters were blinded to the
treatment allocation until plasma concentrations of the drug
and metabolite were quantified and all cardiovascular measure-
ments were assessed.
Schedule of events
The study was conducted over 2 weeks in February 2014. All
animals underwent a full physical examination on the first day
of the study and were deemed to be fit and healthy. Recorded
body weight from this day was used to calculate treatment
dose given to each dog.
On the day prior to dosing, all dogs underwent a second
physical examination. Blood pressure measurements and echo-
cardiography (details below) were performed twice to familiar-
ize dogs with the procedures and to ensure normal cardiac
anatomy and function. Following these procedures, dogs were
sedated lightly with butorphanol (Zoetis Australia, Rhodes,
NSW, Australia). A jugular catheter (B. Braun Certofix Duo or
B. Braun Cavafix Certo with Splittocan; B. Braun Australia Pty
Ltd, Bella Vista, NSW, Australia) was placed aseptically in the
right jugular vein under local anaesthesia (lignocaine; Troy
Laboratories Australia Pty Ltd., Glendenning, NSW, Australia).
Dogs were fed in the evening to provide a minimum fasting
time of 10 h prior to dosing. Water was available ad libitum
overnight.
On the day of dosing, dogs were treated with a single oral
dose of treatment according to their allocated treatment
groups. Negative control dogs received 10 mL water, and the
pimobendan solution dogs received a nonaqueous oral pimob-
endan solution (3.5 mg/mL pimobendan supplied by Luoda
Pharma, Caringbah NSW, Australia) at 0.27 mg/kg (range:
0.26–0.28 mg/kg). Each dose was followed by 5–10 mL of
water administered orally to ensure the dose was swallowed.
Echocardiography, blood pressure and heart rate (HR) monitor-
ing were performed 30 min prior to dosing, immediately prior
to dosing, then at 15, 30 min, 1, 1.5, 2, 3, 4, 8, 12 and 24 h
postdosing. Five millilitres of blood were acquired via the
jugular catheter prior to dosing and at 5, 10, 15, 30, 45 min,
1, 1.5, 2, 3, 4, 8, 12, and 24 h following oral dose
administration.
Throughout the sampling period, water was available ad
libitum. Dogs were fed after obtaining the 4 h sample.
Blood sample processing and storage
Blood samples were collected in lithium heparin-coated blood
tubes and centrifuged for 5 min within 2 h of collection to
harvest plasma. Plasma samples were stored frozen at 30 °C
until the time of analysis.
Analytical method
The analytical method was developed and validated at a com-
mercial laboratory (PIA PHARMA Pty Ltd., Gladesville, NSW,
Australia). Identification of plasma concentrations of pimoben-
dan and its O-demethylated metabolite (ODMP), i.e. UD CG
212 Cl, was performed using ultra high-performance liquid
chromatography (UHPLC) (Eksigent ekspert ultra LC100; AB
Sciex, Redwood City, CA, USA) coupled with a mass spectrom-
eter (MS) (AB Sciex API3200, AB Sciex, Framingham, MA,
USA). Quantification, analysis and generation of the calibration
curve were performed with AB Sciex Multiquant software
(version 2.1; Foster City, CA, USA). Analytical grade racemic
pimobendan (Toronto Research Chemicals, Toronto, Ontario,
Canada) and ODMP (BDG Synthesis Ltd., Wellington, New
Zealand) were utilized as reference standards for the analysis.
Analytical grade fenbendazole (Sigma-Aldrich Pty Ltd., Castle
Hill, NSW, Australia) was utilized as the internal standard for
all analysis. All reagents utilized throughout analysis were of
analytical grade.
Procedure. Each plasma sample was thawed at room
temperature on the day of analysis. Fenbendazole internal
standard (50 lL containing 2.5 ng Fenbendazole) was added
to plasma (250 lL) and mixed gently. Deproteinization was
performed by adding acetonitrile (450 lL). The mixture was
vortex mixed and centrifuged prior to addition of water
(250 lL) to improve peak shape. The sample was centrifuged
again, and the supernatant was removed and passed through
a 0.45-lm Hydraflon filter into a collection plate for analysis.
Quantification method. For identification of pimobendan and
ODMP, 10 lL of the extract was injected into the ultra-
high-performance liquid chromatography–mass spectrometer
(UHPLC-MS) system. Reverse-phase chromatography utilizing a
Supelco Discovery column (C18, 50 9 2.1 mm, 5 lm; Sigma-
Aldrich Pty Ltd.) maintained at 40 °C was performed. A mobile
phase consisting of 1–99% water and acetonitrile was used for
gradient elution at a flow rate of 0.8 mL/min.
Both compounds were detected using mass spectrometry
with a triple quadrupole mass analyser. Ionization was per-
formed with positive electrospray ionization at 5500 V. The
desolvation temperature was set to 500 °C. Multiple reaction
monitoring (MRM) was utilized to obtain transitions for identi-
fication of each compound. The transitions for ODMP, pimob-
endan and fenbendazole were 321.3 ? 305.2, 335.2 ?
319.1 and 300.2 ? 159.2, respectively. The retention times
for ODMP, pimobendan and fenbendazole were 1.55, 1.66 and
1.89 min, respectively.
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Quantification of pimobendan and ODMP was performed
using a calibration curve derived from a series of matrix-
matched calibration controls (MMC) created on each day of
analysis. Each MMC was prepared using blank plasma and
contained pimobendan and ODMP added at incremental con-
centrations ranging between 0.5 and 20 ng/mL. Each curve
was generated from area ratios between the analyte and fen-
bendazole utilizing a minimum of six MMCs. Linear regression
analysis using a 1/x weighting system to maximize accuracy
and reduce the coefficient of variation (CV) at the lower end of
the curve was performed. The coefficient of determination (R2)
was >0.99 for all calibration curves.
Analytical validation and stability. Validation of the assay
followed standard operating procedures for the laboratory and
consisted of analyte identification, selectivity, determination of
carryover, acceptable identification of the limits of
quantification, accuracy and precision.
Analyte identification was assessed through visual observa-
tion of chromatograms. Adequate selectivity of the assay and
lack of carry-over between analyses were assessed through
sequential testing of samples containing the analyte. The per-
centage area ratio was <20% of the lower limit of quantifica-
tion (LLOQ) for pimobendan and ODMP and <5% of the peak
for fenbendazole in all samples.
Intraday accuracy and precision were determined using six
replicates of fortified samples at concentrations ranging
between 0.22 and 13.23 ng/mL for pimobendan and
0.32–19.13 ng/mL for ODMP and were represented as the
ratio between the measured and nominal concentrations. The
mean percentage of accuracy ranged between 97.2–108.6%
and 89.8–103.8% for pimobendan and ODMP, respectively.
Precision was represented as %CV, and ranged between 2.7–
9.7% for pimobendan and 4.0–13.6% for ODMP. At fortified
concentrations of 0.55 ng/mL (pimobendan) and 0.32 ng/mL
(ODMP), the mean percentage of accuracy was 96.4% (pimob-
endan) and 97.2% (ODMP), and the %CV was 9.7% (pimoben-
dan) and 7.9% (ODMP). The LLOQ for pimobendan and ODMP
was identified at 0.5 ng/mL.
Interday assay performance was assessed using quality con-
trol samples for accuracy and precision. A total of 10% of the
samples run on each day of analysis consisted of fortified
quality control samples (minimum of four concentrations,
assayed in duplicate between 0.54–16.28 ng/mL for pimoben-
dan and 0.64–19.13 ng/mL for ODMP) prepared on the day
of the analysis. The mean percentage of accuracy
(n = 3 days) was 94.8–102.6% for pimobendan at 0.54 ng/mL
and 90.1–119.9% at all other concentrations. The mean
percentage of accuracy (n = 3 days) was 94.7–99.8% for
ODMP at 0.64 ng/mL and 92.3–119.4% at all other concen-
trations.
Stability testing on fortified samples was also performed to
determine whether storage and freeze–thaw cycles contributed
toward degeneration of the analyte. Analysis of samples stored
frozen for 2 months (n = 6) showed >90% recovery. Following
three freeze–thaw cycles (n = 6), recovery was >85%.
Pharmacokinetic analysis
The area under the plasma concentration–time curve to the
final measured concentration value (AUC0-t) was determined
using the trapezoidal rule. The elimination rate constant (kel)
was calculated using the log-linear slope of the terminal por-
tion of the concentration–time profile.
The kel was used to calculate the area under the plasma con-
centration–time curve extrapolated to infinity (AUC0-∞). The
median dose administered to the pimobendan solution group
was 5 mg. The AUC0-∞ for pimobendan was adjusted to this
dose using the following equation:
Adjusted AUC01 ¼ AUC01  Dose=5
The elimination half-life (t1/2) was calculated as ln2/kel.
For pimobendan, the apparent clearance (CL/F) and appar-
ent volume of distribution (V/F) were also determined using
the equations:
CL/F ¼ Dose=AUC01
V/F ¼ ðCL/FÞ=kel
Results of pharmacokinetic analyses were reported as the med-
ian and range.
Echocardiography and blood pressure measurements
Dogs were trained to lie in lateral recumbency for the proce-
dures prior to the study, and no chemical restraint was utilized
at any point during the sampling period. Echocardiography
was performed by a single investigator (NB) throughout the
course of the study. A commercially available high-frame-rate
ultrasound system equipped with a 3.5–8.0 MHz sector trans-
ducer and simultaneous electrocardiography (Vivid I; General
Electric Healthcare, Silverwater, NSW, Australia) was used. All
images were recorded and analysed at a later time.
The aortic root diameter (Ao), left atrial diameter (LA),
systolic and diastolic measurements of interventricular septal
thickness (IVSs, IVSd), left ventricular internal diameter
(LVIDs, LVIDd) and left ventricular posterior wall thickness
(LVPWs, LVPWd) were measured using 2D and M-mode func-
tions from standard right parasternal short-axis views as previ-
ously described (Chetboul et al., 2004). The fractional
shortening (FS) was calculated using the following equation:
FS = (LVIDd  LVIDs)/LVIDd.
The maximal aortic velocity (Ao vel), pre-ejection period
(PEP) and left ventricular ejection time (LVET) were obtained
via ECG-gated pulsed-wave Doppler measurements of aortic
outflow derived from the subcostal view (Dukes-McEwan et al.,
2002; Abbott & Maclean, 2003; Rajabioun et al., 2008). Addi-
tionally, the HR was taken from recorded ECG-gated M-mode
images obtained during echocardiography. For each parameter
measured at each time point, three separate cardiac cycles
were measured and averaged.
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Blood pressure was measured indirectly using an oscillomet-
ric device (VetHDO monitor; Memo Diagnostic, Darmstadt,
Germany) coupled with an inflatable cuff, measuring 36–50%
of the tail diameter, placed at the tail base (Egner, 2006; Meyer
et al., 2010; Mitchell et al., 2010). The systolic (SBP), diastolic
(DBP) and mean (MBP) blood pressures were also measured
three times at each time point and averaged.
Observer variability in echocardiography
The CV for each of the echocardiographic parameters for the
investigator performing echocardiography (NB) was established
prior to the study. Echocardiography was performed on a total of
six healthy adult dogs (three male, three female) over the course
of 6 h in 1 day (11 am to 5 pm). Dogs were examined five times
in succession in the same order throughout the examination per-
iod. Images were recorded and analysed at a later time. For each
parameter measured in each time period, six cardiac cycles were
measured. The overall CV (mean  standard deviation) was
<10% for Ao (5.8%  0.6%), LA (6.9%  2.5%), Ao vel
(8.7%  2.4%), IVSs (8.7%  2.0%), LVIDd (4.4%  1.4%),
LVIDs (5.3%  0.9%), LVPWd (8.6%  3.1%), LVPWs
(6.8%  2.6%) and LVET (6.1%  2.2%). This value was
slightly higher for IVSd (10.2%  2.6%) and PEP
(12.8%  3.0%).
The potential effect of time on the CV (e.g. increase in varia-
tion due to operator fatigue) was also examined using a simple
linear regression model. Non-normally distributed data were
log-transformed prior to analysis. Other assumptions were eval-
uated post hoc via inspection of residual plots. The results
showed no significant effect of time (P > 0.05) on CV for any
of the measured parameters.
Pharmacodynamic and statistical analysis
Descriptive analysis of the cardiovascular effects was performed
through visual observation of graphs representing the effect
plotted against time for each parameter. Because the size of
dog has been previously identified as an influencing factor for
IVSs, IVSd, LVIDs, LVIDd, LVPWs, LVPWd, LA and Ao, these
were normalized to body weight (Cornell et al., 2004).
The effects of treatment and time on the measured pharma-
codynamic parameters were assessed via linear mixed model-
ling with restricted maximal likelihood estimation using a
commercially available software program (Genstat 16th Edi-
tion; VSN International Ltd., Hemel Hempstead, UK). The time
point following dosing (time) and treatment group (treatment)
were specified as fixed effects, with individual dogs comprising
the random effects in this model. The interaction between time
and treatment was included in the model to enable assessment
of differences arising between treatment groups at each time
point, as well as differences from the baseline value within a
treatment group. Significance was set at an alpha of 0.05.
Parameters that were not normally distributed were log or
power transformed to resemble a normal distribution prior to
analysis. Fulfilment of assumptions for the model was checked
via visual inspection of residual plots.
Results of pharmacodynamic analysis are reported as the
mean and standard deviation.
RESULTS
Drug dosing
Dosing was tolerated well in all dogs receiving the pimobendan
solution. Potential adverse effects of treatment manifested as
minor transient hypersalivation in one dog in the treated
group.
Pharmacokinetics
Individual plasma concentration–time profiles of pimobendan
and ODMP following treatment with the oral liquid pimoben-
dan formulation are presented in Fig. 1. Plasma concentrations
were below LLOQ from 8 h onwards for pimobendan and from
12 h onwards for ODMP.
The pharmacokinetic parameters for pimobendan and ODMP
for dogs receiving pimobendan are summarized in Table 1. The
pimobendan nonaqueous oral solution was rapidly absorbed
(median time taken to reach maximum concentration (Tmax)
1.1 h, range: 0.5–2.0 h). There was a large range in V/F
(median 15.5 L/kg, range: 5.9–22.3 L/kg) and CL/F (median
176.5 mL/min/kg, range: 105.0–301.0 mL/min/kg).
The concentration–time profile of ODMP lagged slightly
behind that of pimobendan. Conversion of pimobendan to
ODMP appeared to occur rapidly, with only a minor delay in
Tmax for ODMP (median 1.3 h, range: 0.8–2.0 h). The AUC for
ODMP tended to be higher than for pimobendan (median
AUC0-∞ ODMP to AUC0-∞ pimobendan ratio 1.6, range:
1.2–1.7).
Both pimobendan and ODMP displayed first-order elimina-
tion at the dose administered (Fig. 1), and the t1/2 of both
compounds following a single dose of the nonaqueous solution
was short (median 0.9 h, range: 0.7–1.1 h for pimobendan
and median 1.6 h, range: 1.3–1.9 h for ODMP).
Pharmacodynamics
Baseline cardiovascular values were not significantly different
between treatment groups (Table 2).
Significant differences (P < 0.05) from the baseline value
over time were observed in dogs treated with pimobendan for
the following echocardiographic parameters: Ao Vel (1–4 h),
FS (2–4 h), LVIDd (2–4 h), LVIDs (1.5–4 h), LVPWs (1.5–4 h)
and PEP (1, 2, 3 h) (Fig. 2). Ao Vel, FS and LVPWs increased
from baseline, whereas LVIDd, LVIDs and PEP decreased. Maxi-
mal effects were observed between 2 and 4 h following treat-
ment, and significant effects were lost within 8 h of dosing. Of
these, a significant difference (P < 0.05) was also observed
between pimobendan treated and control groups from 1.5 to
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4 h for Ao Vel, at 3 h for FS and LVPWs, from 3 to 4 h for
LVIDs and from 2 to 3 h for PEP.
No significant effect over time was observed in dogs in the
treated group for Ao, LA, HR, IVSs, IVSd, LVET, LVPWd, DBP,
MBP and SBP. Values from dogs in this group were not signifi-
cantly different to those of control dogs for these parameters.
DISCUSSION
In this study, the pharmacokinetics and acute cardiovascular
effects of an oral, nonaqueous solution of pimobendan were
investigated in order to evaluate its potential as an alternative
to the currently existing solid preparations of this medication.
These evaluations play an important role in the establishment
of a drug’s efficacy and safety profile.
The oral nonaqueous pimobendan solution was absorbed
quickly, with maximal average plasma concentrations detected
at around 1 h following dosing. Pimobendan solution showed
a large V/F and this, in addition to the known lipophilic nature
of the drug, suggests that it is readily distributed into tissues.
Pimobendan was rapidly converted to ODMP, with maximal
average plasma concentrations occurring at 1.3 h following
dosing. The systemic exposure was larger for ODMP than for
pimobendan. Inspection of the graph and comparison of t1/2
and kel for pimobendan and ODMP in treated individuals sug-
gest an elimination rate-limited disposition of the metabolite.
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Fig. 1. Individual concentration–time plots of total pimobendan and O-demethylated metabolite (ODMP) for dogs (n = 4) treated with a single dose
of nonaqueous oral pimobendan solution. Conc, concentration. Concentrations fell below the lower limit of quantification (LLOQ) by 8 and 12 h for
pimobendan and ODMP, respectively.
Table 1. Summary of pimobendan and O-demethylated metabolite
(ODMP) pharmacokinetic parameters (median, range) for dogs treated
with a single dose of nonaqueous pimobendan oral solution
Parameter (units)
Pimobendan oral solution (n = 4)
Pimobendan ODMP
Tmax (h) 1.1 (0.5–2.0) 1.3 (0.8–2.0)
Cmax (ng/mL) 18.6 (6.1–25.3) 16.2 (6.0–22.3)
AUC0-∞ (ng/mLh) 27.1 (15.2–44.2) 42.1 (25.1–52.7)
AUC0-∞ (ng/mLh)* 31.9 (12.7–42.1) –
t1/2 (h) 0.9 (0.7–1.1) 1.6 (1.3–1.9)
CL/F (mL/min/kg) 176.5 (105.0–301.0) –
V/F (L/kg) 15.5 (5.9–22.3) –
Tmax, time taken to reach maximum concentration; Cmax, maximum
concentration; AUC0-∞, area under the plasma concentration–time
curve extrapolated to infinity; t1/2, elimination half-life; CL/F, apparent
clearance; V/F, apparent volume of distribution.
*AUC0-∞ normalised to a dose of 5 mg pimobendan
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Therefore, the greater AUC0-∞ for ODMP appears largely attrib-
utable to prolonged duration of time spent in the body by this
compound as a result of slower elimination rather than as a
result of slower formation.
In terms of tolerability, the pimobendan solution was well
tolerated by the study dogs, with no major adverse effects
observed during the study.
In this study, noninvasive methods of monitoring cardiovas-
cular changes were employed. This is the first study to evalu-
ate the acute effects of pimobendan in this fashion. Both
echocardiography and oscillometric blood pressure monitoring
are established modes of monitoring hemodynamic changes
and utilized commonly in veterinary practice. Aside from posi-
tive animal welfare implications of using a noninvasive mode
of evaluation, an additional benefit to utilizing these methods
include the potential for identifying practical methods of evalu-
ating therapeutic effects which may be used in routine clinical
practice. They do not require general anaesthesia or sedation,
and as such, may also be a more accurate method of detecting
true drug effects.
Pimobendan solution caused a significant rise in Ao Vel, FS,
and LVPWs and a reduction in LVIDs and PEP from around
1–2 h after dosing. Maximal effects, which were significantly
different to values from dogs in the control group, were
observed between 3 and 4 h following treatment. These
parameters relate to enhanced left ventricular systolic function
and are consistent with findings of prior studies in dogs in
which invasive monitoring methods were used (Von Meel,
1985; Pouleur et al., 1988, 1989; Van Meel & Diederen,
1989; Ohte et al., 1997; FDA-CVM, 2007).
The maximal effects observed in this study occurred slightly
later (3–4 h) than in prior invasive studies evaluating systolic
function after oral doses (1.5–2 h) (Von Meel, 1985; Van Meel
& Diederen, 1989). This is most likely attributable to the use of
higher dosages (0.5–1 mg/kg) in prior studies as a shorter time
to maximal effect for higher dosages has been previously
reported in dogs (FDA-CVM, 2007) and in humans (Walter
et al., 1988). The duration of significant effects observed in this
study (<8 h) was also shorter than what has been previously
reported (Von Meel, 1985; Van Meel & Diederen, 1989; FDA-
CVM, 2007). This may be attributable to the fact that the sig-
nificance of the effect in relation to the baseline or an
untreated animal was not evaluated in prior studies or that
the small number of dogs in our study resulted in failure to
detect significant differences at later time points.
Pimobendan has been reported to reduce blood pressure in
prior studies conducted on anesthetized dogs (Kitzen et al., 1988;
Lynch et al., 1989; Van Meel & Diederen, 1989; Pagel et al.,
1996). In the present study, a significant effect on blood pressure
was not observed. This may be due to the use of an indirect
method of measurement. In addition, >10% variability in the
triplicate blood pressure readings was present at times and may
have contributed toward reduced accuracy of blood pressure
assessment. It is also possible that the effect on blood pressure is
not readily measurable in conscious dogs, and findings of one
study on conscious instrumented dogs (Von Meel, 1985) and a
handful of others evaluating the effect of chronic pimobendan
treatment (Chetboul et al., 2007; Ouellet et al., 2009; Suzuki
et al., 2011) suggest that this is a plausible theory.
The findings from this study would suggest that the plasma
concentration of pimobendan and ODMP is unlikely to accu-
mulate at the dosage regimen currently recommended for this
drug (0.4–0.6 mg/kg/day divided twice daily). Although the
cardiovascular response to pimobendan may be different in
dogs with heart disease, it appears that to achieve a narrower
range of daily effects, an increase in dosing frequency would
be required. Interestingly, there are currently no data available
regarding the optimal magnitude and duration of effects associ-
ated with outcome variables such as survival, morbidity, and
development of adverse effects. It is known that the current
dosage regimen leads to a favourable increase in longevity of
dogs with CHF (Smith et al., 2005; Lombard et al., 2006;
H€aggstr€om et al., 2008). It is not known, however, if it is
advantageous or disadvantageous to increase the daily pimob-
endan dose. Thus, it could very well be possible that enhancing
the systolic function continuously could be detrimental to the
animal in the long term. Further evaluation of pimobendan
pharmacokinetic–pharmacodynamic relationship and charac-
terization of the long-term effects in dogs with heart disease is
required to clarify the role of pimobendan in managing canine
Table 2. Table of baseline cardiovascular measurements (prior to dos-
ing, i.e. time zero) in dogs dosed with water only (Control; n = 4) or a
nonaqueous oral pimobendan solution (pimobendan; n = 4)
Parameter (units) Control Pimobendan
Ao Vel (m/s) 1.5 (0.2) 1.7 (0.2)
Ao* (cm) 0.9 (0.1) 0.9 (0.1)
FS (%) 34.3 (8.2) 33.3 (6.9)
HR (bpm) 117.0 (18.2) 108.3 (21.6)
IVSd* (cm) 0.5 (0.1) 0.5 (0.1)
IVSs* (cm) 0.7 (0.1) 0.6 (0.1)
LA* (cm) 1.2 (0.1) 1.2 (0.1)
LVET (ms) 185.8 (20.9) 182.3 (25.1)
LVIDd* (cm) 1.5 (0.1) 1.6 (0.1)
LVIDs* (cm) 0.9 (0.1) 1.0 (0.1)
LVPWd* (cm) 0.5 (0.0) 0.5 (0.1)
LVPWs* (cm) 0.7 (0.1) 0.7 (0.1)
PEP (ms) 49.3 (5.5) 50.1 (6.9)
MBP (mmHg) 102.8 (8.2) 99.3 (9.4)
DBP (mmHg) 71.0 (6.5) 66.1 (5.5)
SBP (mmHg) 162.0 (23.8) 161.6 (20.8)
Ao Vel, aortic velocity; Ao, aortic diameter; FS, fractional shortening;
HR, heart rate; IVSd, interventricular septum (diastole); IVSs, interven-
tricular septum (systole); LA, left atrium; LVET, left ventricular ejection
time; LVIDd, left ventricular internal diameter (diastole); LVIDs, left
ventricular internal diameter (systole); LVPWd, left ventricular poster-
ior wall (diastole); LVPWs, left ventricular posterior wall (systole); PEP,
pre-ejection period; MBP, mean blood pressure; DBP, diastolic blood
pressure; SBP, systolic blood pressure.
No values were significantly different between treatment groups
(P > 0.05).
Values expressed as mean (standard deviation).
*Indexed to body weight (Cornell et al., 2004).
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heart disease. Such information could also be utilized to indi-
vidualize treatments to achieve better outcomes.
A number of limitations were present in this study. At the
time of planning this study, a registered intravenous formula-
tion of pimobendan was not available. As such, absolute bio-
availability could not be elucidated. The health status of the
dogs included in this study was determined with physical
examination, evaluation of history and cardiovascular testing.
Because clinical pathology was not performed to ascertain spe-
cific organ function, this may be considered a weakness in the
inclusion criteria. In addition, the study utilized a small
number of dogs. This is not an uncommon occurrence when
0 5
0.0
0.5
1.0
1.5
2.0
2.5
10 15 20 25
Aortic velocity
Time (h)
M
ax
 A
o 
V
el
 (m
/s
ec
)
*
**
*
*
† † † † †
Tx P 0.016
Time P 0.006
Tx*Time P <0.001
0 5
1.2
1.4
1.6
1.8
10 15 20 25
Left ventricular internal diameter (diastole)
Time (h)
LV
ID
d 
(c
m
, w
t n
or
m
)
*
*
*
Tx P 0.838
Time P 0.001
Tx*Time P 0.004
0 5
0
20
40
60
10 15 20 25
Fractional shortening
Time (h)
FS
 (%
)
*
*
*
†
Tx P 0.308
Time P 0.047
Tx*Time
Tx
Time
Tx*Time
Tx
Time
Tx*Time
P <0.001
0 5
0.0
0.5
1.0
1.5
10 15 20 25
Left ventricular internal diameter (systole)
Time (h)
LV
ID
s 
(c
m
, w
t n
or
m
)
*
***
† †
Tx P 0.488
Time P <0.001
Tx*Time P <0.001
0
5
0.5
0.6
0.7
0.8
0.9
1.0
1.1
10 15 20 25
Left ventricular posterior wall (systole)
Time (h)
LV
P
W
s 
(c
m
, w
t n
or
m
) ****
†
P 0.276
P 0.017
P <0.001
0 5
0
20
40
60
80
10 15 20 25
Pre-ejection period
Time (h)
P
E
P
 (m
s)
***
†
†
P 0.074
P 0.021
P 0.014
Fig. 2. Graphical representation of change in select cardiovascular effects over time for dogs treated with pimobendan oral solution (pimobendan group;
n = 4) and those treated with water (control group; n = 4). Solid line represents control group; dashed line represents pimobendan group. Ao Vel, aortic
velocity; FS, fractional shortening, LVIDs, left ventricular internal diameter (systole); PEP, pre-ejection period; LVIDd, left ventricular internal diameter
(diastole); LVPWs, left ventricular posterior wall (systole); cm, wt norm, weight-normalized centimeters (indexed to body weight, as per Cornell et al.,
2004). *Significant difference (P < 0.05) from baseline (time 0) within the pimobendan group at indicated time. There were no significant differences
from baseline in the control group. †Significant difference (P < 0.05) between control and pimobendan groups at indicated time. Group mean and
standard deviation are represented by point and bars, respectively. P-values associated with fixed (Tx = treatment; Time = time) and interaction
(Tx*Time = treatment*time) terms in the model are displayed on each graph.
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companion animal models are utilized in pharmacokinetic
studies; however, this raises the possibility of both type I and II
errors in our findings, with the latter being more likely.
Although the observed haemodynamic trends in systolic func-
tion are convincing, we were unable to clarify the exact dura-
tion of effect due to reduced sampling points at later time
points. The inclusion of repeated baseline measurements on
the day of sampling to further characterize the resting cardio-
vascular status would also have been ideal. Finally, the cardio-
vascular parameters measured during this study were not
adjusted for the preceding R-R interval. It is well known that a
longer R-R interval would result in higher end-diastolic vol-
ume. The Frank-Starling mechanism dictates that this would
increase the contractile energy and left ventricular systolic
function. Therefore, the possibility exists that part of the total
variability observed in our data set may have been attributable
to the effect of HR, and adjusting for this effect may result in
better assessment of systolic function.
CONCLUSION
The nonaqueous oral solution of pimobendan was absorbed,
metabolized and excreted rapidly. Following a single oral dose,
pimobendan treatment produced positive inotropic effects
which were able to be measured utilizing echocardiography.
Maximal aortic velocity and left ventricular internal diameter
in systole were particularly useful for this evaluation. Depend-
ing on the measured variable, maximal effects appeared to
occur around 2–4 h following a dose and were maintained at
a significant level for <8 h. This may be useful in detecting an
individual’s response to dosing.
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over time using linear mixed modelling.
Results: Pimobendan was rapidly absorbed and converted to ODMP with the pimo-
bendan AUC0eN greater than ODMP AUC0eN (ODMP:pimobendan AUC0eN ratio 0.6
[LD] and 0.5 [HD]) despite a longer elimination half-life of ODMP (pimobendan t1/
2 0.8 h vs. ODMP t1/2 1.6 h [LD]; pimobendan t1/2 0.7 h vs. ODMP t1/2 1.3 h [HD]).
Averaged across all time points, pimobendan increased several measures of systolic
function; however, its effect could not be further characterised. Although treat-
ment was well-tolerated, two cats vomited following HD and another had a ventri-
cular premature beat recorded following LD.
Conclusions: The lower ODMP:pimobendan AUC0eN ratio compared to that ob-
served previously in dogs suggests reduced metabolism in cats. Treatment effects
were observed in measures of systolic function; however, the duration of action
and differences in effects between the two pimobendan doses could not be charac-
terised. Further studies are required to evaluate pimobendan in feline cardiovascu-
lar medicine.
ª 2016 Elsevier B.V. All rights reserved.ity
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of distributionIntroduction
Pimobendan is utilised in the treatment of canine
congestive heart failure. It primarily produces
positive inotropic and vasodilatory effects via
phosphodiesterase III inhibition and calcium54sensitisation [1e6]. Additional effects such as
positive lusitropy, improvements in myocardial
compliance, regional increases in coronary blood
flow, and positive effects on myocardial oxygen
consumption have also been reported [6e13].
Following administration, it is metabolised to an
f Vetmedin 1.25-mg chewable tablets, Boehringer Ingelheim,
North Ryde, NSW, Australia.
312 M. Yata et al.active metabolite, O-desmethylpimobendan
(ODMP, or UD-CG 212 CL), which induces similar
inodilatory effects, primarily through phospho-
diesterase III inhibition [14e16].
In the past decade, the off-label use of pimo-
bendan in cats with congestive heart failure has
received increasing attention. A number of retro-
spective studies evaluating pimobendan use in cats
with heart failure due to a variety of aetiologies
suggested that the drug was tolerated well and did
not negatively impact morbidity and mortality
[17e20]. Despite this, published literature on the
cardiovascular effects of treatment in this species
remains sparse.
To date, only one study has reported the direct
haemodynamic effect of pimobendan in cats [21].
This study utilised anaesthetised cats and cumu-
lative dosing methods. Pimobendan produced a
dose-dependent increase in ventricular con-
tractility and heart rate and reduction in diastolic
blood pressure. The interpretation of these find-
ings, however, is complicated by the influences of
anaesthesia, and the duration of drug effects
were not evaluated. More recently, the effect of
multiple doses of pimobendan on left atrial func-
tion and size in healthy cats was evaluated indi-
rectly via echocardiography [22]. Although
pimobendan treatment reduced maximal left
atrial diameter and volume, the left atrial func-
tion did not change significantly. The cats utilised
in this study were sedated for echocardiography,
and the duration of effect was not evaluated. Two
of the aforementioned retrospective studies also
evaluated haemodynamic effects after a period of
treatment with multimodal therapy which inclu-
ded pimobendan [17,18]. Limitations to the data
from these studies include a wide range of time to
follow-up evaluation, lack of information regard-
ing the temporal relationship of measured effects
to time of dosing, inability to differentiate the
effect of pimobendan from that of other medi-
cations which were administered concurrently,
and low numbers of animals for which follow-up
data were available. Thus, the dose-response
relationship of pimobendan in cats remains poorly
understood.
In 2012, Hanzlicek et al. prospectively eval-
uated the pharmacokinetics of oral pimobendan
administered to healthy cats at a dose similar to
that used in dogs (0.25e0.30 mg/kg administered
orally twice daily) [23]. A major finding from this
study was that the peak plasma concentration of
pimobendan was approximately ten times higher
than that previously described in dogs given similar
doses [24], and the elimination half-life of pimo-
bendan in cats was also longer. Unfortunately, the55active metabolite was not measured; as such, the
total body exposure to all of the active moieties
related to pimobendan could not be clarified. It is
possible that the presence of higher pimobendan
concentrations may, for example, be due to a
relative lack of conversion of this compound to
ODMP. This pimobendan metabolite is more potent
but less effective, than pimobendan in vitro
[15,16]. Thus, inter-species differences in drug
disposition may contribute towards a difference in
cardiovascular response. In particular, reduced
metabolism of pimobendan may result in greater
cardiovascular effects in cats. The importance of
clarifying the response to drug administration
(pharmacodynamics) and need for further evalua-
tion of pharmacokinetics in this species was
highlighted.
The aim of the present study was to address this
knowledge gap by investigating the pharmacoki-
netics and cardiovascular effects of two single
doses of pimobendan administered orally to
healthy cats. We hypothesized that conversion of
pimobendan to the active metabolite may be low
in cats and that treatment with pimobendan would
cause measurable effects in echocardiographic
parameters representing systolic function.Animals, materials and methods
Animals
Eight healthy adult cats (two entire males, five
neutered males, and one spayed female; weight
3.7e4.8 kg; age 1e4 years) that were amenable to
handling were utilised in this study. The cats were
sourced from a contract research facility. Each cat
underwent a full physical examination, echo-
cardiography, electrocardiography, and blood
pressure evaluation to ensure that no significant
physical or cardiovascular abnormalities were
present. The methods utilised in this study were
approved by the University of Sydney Animal Ethics
Committee (Project 678).
Study design
A randomised, single-blinded, cross-over design
was used to investigate the pharmacokinetics and
cardiovascular effects of two single doses of
pimobendanf in these cats. Three treatment con-
ditions consisting of low-dose pimobendan (LD e
Pimobendan PK/PD in cats 3130.625-mg pimobendan PO; equivalent to a median
dose of 0.14 mg/kg with range 0.13e0.17 mg/kg),
high-dose pimobendan (HD e 1.25-mg pimobendan
PO; equivalent to a median dose of 0.28 mg/kg
with range 0.27e0.32 mg/kg), and water as a
control (3-mL water PO) were tested in each cat.
Before the study, each cat was assigned to receive
one of three treatment sequences (water, LD, HD;
HD, water, LD; and LD, HD, water) via a random
draw by an assistant. All investigators involved in
sampling procedures remained blinded to the
order of treatments until measurements were
completed.g Eksigent ekspert ultra LC100; AB Sciex, Redwood City, CA,
USA.
h AB Sciex API3200, AB Sciex, Framingham, MA, USA.
iSchedule of events
The study was conducted over a two-month period
(JanuaryeMarch, 2015) at the University Veteri-
nary Teaching Hospital, Sydney. Following arrival
at the clinic, cats were acclimatised for a mini-
mum of three days before receiving the first dose
of treatment. During this time, cats were also
familiarised with echocardiography and blood
pressure techniques. Cats were fasted overnight
for a minimum of 10 h before administration of
each dose.
On the first day of dosing, cats were treated
with the first assigned treatment by an assistant
who did not perform any of the sampling proce-
dures or recording of measurements. The inves-
tigators were not present in the room at the time
of dosing. Oral tablet dosing was followed by
administration of water (3 mL) to encourage
oesophageal transit. Blood samples (3 mL) were
collected via jugular or cephalic venipuncture at
20 min, 1, 2, 4, and 6 h following dosing. Echo-
cardiography, heart rate (HR), and blood pressure
measurements were obtained before dosing, then
20, 40 min, 1, 2, 4, 6, 8, 10, and 12 h following
dosing. Cats were fed 2 h following dosing. These
procedures were repeated for each subsequent
dose, which was administered 1 week apart to give
a seven-day wash-out period between doses. This
was deemed to be adequate for recovery from
study procedures and was greater than five times
the elimination half-life of pimobendan (w1.3 h)
as described in a previous study [23].
Deviations from this protocol occurred on sev-
eral occasions. Cat 7 received a dose of treatment
(HD) 2 h before the scheduled time on the first day
of treatment. The cat was fed immediately
thereafter in an attempt to reduce absorption of
the drug, and no cardiovascular measurements
were taken on this day. This cat was allocated a
different treatment order, and the cat received56the newly allocated treatment (water) 48 h later.
Because cardiovascular measurements were not
taken on this day, and based on the previously
reported elimination half-life of pimobendan in
cats [23], the 48 h wash-out period was deemed to
be adequate.
On another occasion, one dose of treatment (HD)
thought to have been given to cat 8 was found intact
in the cage 3.5 h following dosing. It was suspected
that this tablet was most likely regurgitated shortly
following administration. In order to maintain
blinding, the investigator performing echocardiog-
raphy (N.J. Beijerink)was not advised of this finding.
The data collected on this day was categorised as
being under the water treatment, and the cat was
treated the subsequent week with HD pimobendan
instead of the scheduled water treatment. Blood
was not collected from one cat (cat 8) that did not
tolerate venipuncture, andone other cat (cat 1) only
had blood collected twice after treatment with LD
due to development of strong aversion towards this
procedure at this occasion.
Analytical method
Blood samples were collected in plastic tubes
coated with lithium heparin, placed on ice, and
centrifuged at 15,800 RPM for 150 s within 20 min
of collection. Plasma was separated and placed on
ice for up to 1 h before freezing. Plasma was
stored at or below 20 C for four to six months
before analysis. Greater than 90% recovery of
pimobendan from frozen canine plasma samples
stored for two months has been reported [25], but
the stability of pimobendan in frozen feline plasma
is unknown.
Plasma concentrations of pimobendan and
ODMP were determined by ultra-high-performance
liquid chromatographyg coupled with a mass
spectrometerh (UHPLC-MS) at a commercial ana-
lytical laboratoryi.
A previously validated assay with minor adjust-
ments was employed [25]. Briefly, 40 mL of
pimobendan-d3 (internal standard) and 350 mL of
acetonitrile were added to 200 mL of plasma after
thawing at room temperature. The mixture was
vortexed and centrifuged. Subsequently, 200 mL of
water was added to improve the chromatography
and centrifuged again. The supernatant was
passed through a 0.45-mm Hydraflon filter, and
5 mL of this solution were injected into the system.PIA PHARMA Pty Ltd, Gladesville, NSW, Australia.
314 M. Yata et al.Reverse-phase chromatography with a Dionex
Acclaim Polar Advantage II column (2.1  150 mm,
3 mm)j maintained at 40 C was performed. The
mobile phase consisted of formic acid (0.1% in
water) and acetonitrile in gradient mode at
0.5 mL/min, and the total run time was 3 min for
each sample. Tandem mass spectrometry was uti-
lised for identification of the compounds, and
calibration curves (R2 > 0.99) spanning 0.2e60 ng/
mL (pimobendan) and 0.4e25 ng/mL (ODMP) gen-
erated from matrix matched calibration standards
were utilised for quantitation of each compound.
The lower limit of quantitation was 0.2 ng/mL for
pimobendan and 0.4 ng/mL for ODMP. All samples
were analysed on a single day. For concentrations
above the lower limit of quantitation, the mean
accuracy and precision (% CV) for pimobendan
ranged between 99.9e116% and 0.9e7.4% respec-
tively and the accuracy and precision (% CV) for
ODMP ranged between 105.7e116.9% and
1.8e8.0% respectively.
Echocardiography and blood pressure
measurements
Cats were manually restrained in right and left
lateral recumbency without sedation. Echo-
cardiography was performed by a veterinary car-
diologist certified by the European College of
Veterinary Internal Medicine (N.J. Beijerink) using
a commercially available ultrasound system
equipped with a 3.5e8 MHz sector transducer and
simultaneous electrocardiographyk. 2D evaluation
in the right parasternal short axis view was utilised
to obtain the thickness of the interventricular
septum in systole and diastole (IVSs, IVSd), left
ventricular internal diameter in systole and dia-
stole (LVIDs, LVIDd), and thickness of the left
ventricular posterior wall in systole and diastole
(LVPWs, LVPWd). This method of evaluation of the
left ventricular indices was selected as end-
systolic cavity obliteration, which produced inter-
ference caused by papillary muscles entering the
sampling beam on M-mode, was present at times
during the study. The fractional shortening (FS)
was calculated as (LVIDd e LVIDs)/LVIDd * 100. The
left apical five chamber view was utilised to
measure the peak aortic velocity (Ao Vel). The HR
was calculated using the ReR interval between
four to five consecutive beats captured during Ao
Vel interrogation.j Thermo Fisher Scientific, Scoresby, VIC, Australia.
k Vivid I; General Electric Healthcare, Silverwater, NSW,
Australia.
l VetHDO monitor; Memo Diagnostic, Darmstadt, Germany.
57An oscillometric blood pressure devicel coupled
with an appropriately-sized inflatable cuff
(40e50% of the circumference of the limb) placed
on the tail base or the right foreleg was utilised to
obtain the systolic (SBP), mean (MBP), and dia-
stolic (DBP) blood pressures. The cats were placed
in sternal recumbency for tail measurements or
restrained in a sitting position with the limb held
up at the level of the chest for forelimb meas-
urements. Measurements were taken repeatedly
until three consecutive or near-consecutive read-
ings with good-quality pressure curves and little
variability were obtained.
For each cat at each time point, echocardio-
gram, HR, and blood pressure measurements were
obtained in triplicates and averaged. Consecutive
beats were utilised for the majority of
measurements.
Observer variation
On the day after arrival at the clinic, six of the
eight cats underwent echocardiography at 9 AM, 11
AM, 1 PM, 3 PM, and 5 PM. Echocardiography was
performed by a single investigator (N.J. Beijerink),
and six cardiac cycles from each time point were
utilised to obtain the coefficient of variation for
the investigator. The overall coefficient of varia-
tion (mean  standard deviation) was 7  3% for
IVSd; 10  5% for IVSs; 4  2% for LVIDd; 8  5% for
LVIDs; 9  3% for LVPWd; 10  4% for LVPWs; and
3  2% for Ao Vel. The effect of time on the
coefficient of variation for each parameter was
assessed using linear mixed modellingm. The time
was set as a fixed effect, and the cat ID was set as
a random effect. There were no significant effects
of time on the coefficient of variation (p>0.05).
Inter-day and inter-cat variations were not
assessed.
Data analysis
Pharmacokinetic analysis was performed using
non-compartmental analysis on the plasma
concentration-time data using a Microsoft Excel
plug-in software program (PK Solver) [26]. The
linear trapezoidal method was utilised for calcu-
lation of the area under the curve to the last
observed concentration. The slope of the terminal
portion of the concentration-time plot (kel) was
utilised to extrapolate this to infinity (AUC0eN).
The elimination half-life was calculated as ln2/kel.
The apparent clearance (CL/F ¼ dose/AUC0eN)
m GenStat 16th Edition, VSN International Ltd, Hemel Hemp-
stead, UK.
Pimobendan PK/PD in cats 315and the apparent volume of distribution (CL/F/kel)
were also calculated for pimobendan. The phar-
macokinetic data were reported as median and
range unless otherwise specified.
The effect of each treatment over time was
depicted graphically for descriptive analysis.
Statistical analysis was performed using GenStatm.
Evaluation of the QeQ plot for normality was
performed on the haemodynamic data collected.
Where the data were not normally distributed, log
(Ao Vel, IVSd, LVIDs, LVPWs) or power (FS) trans-
formations were applied to approximate normal-
ity. A linear mixed model with restricted maximal
likelihood estimation was performed to identify
the effect of treatment and time on the car-
diovascular parameters. The assumptions of this
model were assessed through visual inspection of
residual plots. The model used to evaluate the
effect of treatment and time on each of the car-
diovascular parameters was as follows:
bYðcardiovascular parameterÞ ¼ Treatment
þ Timeþ Treatment  Time
þCat IDðrandom effectÞ þ ε
Where the Treatment*Time interaction was not
significant (p>0.05), the term was dropped from
the model. For all significant effects (p<0.05),
subsequent evaluation of pairwise comparisons
was performed using least square differences
of the means with a nominated significance level
of 5%.Results
Drug dosing and adverse effects
None of the cats voluntarily ate the treatments
offered; however, treatment was tolerated well in
all cats during the study.
Possible minor adverse effects were observed
during the study. One cat (cat 6) developed self-
limiting vomiting within 10 min of treatment with
HD. Another cat (cat 5) developed self-limiting
vomiting and diarrhoea around 24 h following
treatment with HD. A third cat (cat 3) had a single
ventricular premature beat recorded on the ECG
during echocardiography 1 h following treatment
with LD. No other arrhythmias were observed in
any of the cats (including this cat at subsequent
treatments) during the remainder of the study
period. No serious adverse effects were encoun-
tered at any point in time during or after the study.58Pharmacokinetics
Blood samples were collected from seven cats
following HD treatment (cats 1e7), six cats fol-
lowing LD treatment (cats 2e7), and seven cats
following water treatment (cats 1e7). One cat (cat
6) vomited a small amount of liquid within 10 min
of the HD treatment. Although the tablet could not
be identified in the vomitus, the measured plasma
concentrations were not higher than those
obtained following LD treatment in this cat. In
another cat (cat 7), the measured plasma con-
centrations were much lower than the concen-
trations observed in other cats at both the HD and
LD treatments. There was no discernible reason
(e.g. vomiting, diarrhoea, hypersalivation, incom-
plete dosing, physical exam abnormalities, or
other abnormalities in assessment of clinical well-
being) throughout the course of the study for this.
The data for these two cats (cats 6 and 7) were
reported separately.
Pimobendan treatment resulted in detectable
concentrations of pimobendan and ODMP from the
time of first sampling in the majority of cats
(Fig. 1). As expected, HD tended to produce higher
plasma concentrations of both compounds com-
pared to LD. In the majority of cats, the maximal
plasma concentration of pimobendan occurred at
the first sampling point (20 min); as such, the
ascending phase of plasma drug concentrations for
pimobendan could not be captured for these cats.
However, the elimination phase was adequately
captured (percentage extrapolation for AUC0eN
was <7% for pimobendan and <14% for ODMP for
all cats, including cats 6 and 7).
A summary of pharmacokinetic parameters is
presented in Table 1. Pimobendan and ODMP
pharmacokinetics in dogs treated with
0.26e0.28 mg/kg of oral pimobendan solution [25]
has also been included in this table for comparison.
Both the HD and LD treatments resulted in rapid
absorption of pimobendan and conversion into
ODMP (median pimobendan Tmax 40 min [LD] and
20 min [HD] and ODMP Tmax 1 h [LD and HD]). For
both doses, the AUC0eN for pimobendan appeared
to be higher than for ODMP. Inspection of the ratios
of AUC0eN of ODMP to pimobendan showed a
median AUC0eN ODMP:pimobendan of 0.6 (range
0.5e0.8) for LD treatment and 0.5 (range 0.4e0.7)
for HD treatment.
A summary of pharmacokinetic parameters for
cats 6 and 7 are presented in Table 2.
No active compounds were detected in samples
from all seven cats in which plasma samples were
obtained following water treatment.
Figure 1 Individual concentration-time plots for plasma concentrations of pimobendan (A) and O-desmethylpi-
mobendan (ODMP) (B) following single oral administration of low-dose (0.625 mg; n ¼ 4) and high-dose (1.25 mg;
n ¼ 5) pimobendan. Concentration-time plots of pimobendan and ODMP in cats 6 (C and D) and 7 (E and F) are
presented separately. Dashed line ¼ low-dose pimobendan; solid line ¼ high-dose pimobendan.
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60Cardiovascular effects
Data from 6 cats (cats 1e5 and cat 8) were
included in the cardiovascular analysis. The
data from cats 6 and 7 were excluded for
aforementioned reasons pertaining to the
pharmacokinetics. Although cat 8 did not have
blood samples taken (and therefore, did not
undergo all of the same procedures as the
other seven cats in the study), this was con-
sistent across all three treatments. The data
from cat 1, who did not complete the full
extent of blood collection after LD treatment,
were also included as this cat largely under-
went the same conditions for all three
treatments.
The baseline haemodynamic values were
similar for all treatments (Table 3). However,
the MBP and DBP at baseline for HD treatment
were significantly lower than for water treat-
ment (p<0.05). The MBP for HD was also sig-
nificantly lower than for LD treatment
(p<0.05).
The effect of each treatment over time is
demonstrated in Fig. 2. On visual inspection of
the graphs, pimobendan treatment appeared
to increase Ao Vel, FS, IVSs, IVSd, and LVPWd
within the first few hours of treatment. LVIDs
and LVIDd appeared to decrease. However,
similar trends were observed following water
treatment for many of these parameters. In
addition, a high degree of variability was
observed for all of these parameters.
Statistical analysis revealed that there
were no significant differences between
water and pimobendan treatments at specific
time points following dosing. This was evi-
denced by the non-significant interaction
term for all cardiovascular parameters other
than DBP. Within this parameter, the
significant between- and within-treatment
interactions occurred sporadically and with
no discernible pattern to indicate a true bio-
logical effect of treatment (Fig. 2). Thus, for
all parameters other than DBP, the model was
reduced to:
bYðcardiovascular parameterÞ ¼ Treatment
þ TimeþCat IDðrandom effectÞ þ ε
Using this model, the effect of treatment
averaged across the entire sampling period
(0e12 h) was evaluated. The relevant group
means are presented in Table 4. Averaged
across all time points, both HD and LD treat-
ments were associated with a significantly
Table 2 Pharmacokinetic parameters following non-compartmental analysis of plasma concentrations of pimo-
bendan (Pimo) and its metabolite (ODMP) in cats 6 and 7 dosed with single oral treatments of low-dose (0.625 mg)
and high-dose (1.25 mg) pimobendan.
Pimo
0.625 mga
ODMP
0.625 mg
Pimo
1.25 mgb
ODMP
1.25 mg
Cat 6 Cmax (ng/ml) 23.9 8.9 24.0 8.2
Tmax (h) 0.3 1.0 0.3 0.3
AUC0eN (ng/ml*h) 32.3 20.4 30.0 22.5
Vz/F (L/kg) 3.6 e 7.0 e
CL/F (ml/min/kg) 74.1 e 159.1 e
t1/2 (h) 0.6 1.2 0.5 1.4
AUC0eN ODMP:Pimo 0.6 0.8
Cat 7 Cmax (ng/ml) 12.4 5.5 8.3 5.4
Tmax (h) 0.3 0.3 2.0 2.0
AUC0eN (ng/ml*h) 16.4 13.9 20.4 16.1
Vz/F (L/kg) 9.8 e 17.1 e
CL/F (ml/min/kg) 169.1 e 272.3 e
t1/2 (h) 0.7 1.2 0.7 1.3
AUC0eN ODMP:Pimo 0.8 0.8
Cmax ¼ maximal plasma concentration; Tmax ¼ time of maximal plasma concentration; AUC0eN ¼ area under the concentration-
time plot extrapolated to infinity; Vz/F ¼ apparent volume of distribution; CL/F ¼ apparent clearance; t1/2 ¼ elimination half-
life.
a Equates to 0.14 mg/kg (cat 6) and 0.17 mg/kg (cat 7).
b Equates to 0.29 mg/kg (cat 6) and 0.33 mg/kg (cat 7).
Table 3 Baseline values (mean, SD) of car-
diovascular parameters for water (3-mL water), low-
dose pimobendan (0.625 mg), and high-dose pimo-
bendan (1.25 mg) treatments in six cats.
Parameter
(units)
Water Low dose High dose
Ao Vel (m/s) 1.0 (0.1) 1.0 (0.1) 1.1 (0.1)
HR (bpm) 178.4 (32.1) 176.7 (28.2) 172.1 (17.5)
IVSd (mm) 3.9 (0.2) 3.8 (0.4) 3.8 (0.4)
IVSs (mm) 6.5 (0.8) 6.6 (0.9) 6.4 (0.7)
LVIDd (mm) 16.1 (1.8) 16.2 (1.4) 16.2 (1.7)
LVIDs (mm) 9.0 (1.8) 8.5 (1.9) 9.0 (2.1)
LVPWd (mm) 4.4 (0.8) 4.5 (0.4) 4.5 (0.7)
LVPWs (mm) 6.4 (0.8) 6.4 (0.7) 6.7 (0.8)
FS (%) 44.3 (10.0) 46.9 (13.1) 44.8 (11.1)
DBP (mmHg) 82.6 (4.0) 77.7 (7.0) 72.1 (5.4)a
MBP (mmHg) 104.4 (6.7) 102.4 (9.6) 93.6 (10.5)a,b
SBP (mmHg) 144.2 (16.9) 147.7 (20.8) 132.7 (22.2)
Key: Ao Vel ¼ aortic velocity; HR ¼ heart rate; IVSd/
s ¼ interventricular septum thickness in diastole/systole;
LVIDd/s ¼ left ventricular internal diameter in diastole/
systole; LVPWd/s ¼ left ventricular posterior wall thickness
in diastole/systole; FS ¼ fractional shortening;
DBP ¼ diastolic blood pressure; MBP ¼ mean blood pressure;
SBP ¼ systolic blood pressure; SD, standard deviation.
Model: Y^ (cardiovascular parameter) ¼ Treatment þ Cat ID
(random effect) þ Ɛ
a Denotes significant differences (p<0.05) from water.
b Denotes significant differences (p<0.05) from low dose.
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61higher Ao Vel, IVSs, IVSd, and significantly lower
LVIDs, than water treatment (p<0.05). HD treat-
ment was also associated with a significantly
higher FS than water treatment (p<0.05). The SBP
was higher with LD treatment than with HD or
water (p<0.05). The HR was lower with HD treat-
ment than with LD or water (p<0.05). The LVPWs
was also higher for HD treatment than for LD
treatment (p<0.05).Discussion
In this study, the pharmacokinetics and pharma-
codynamics of two single doses of pimobendan
were evaluated in healthy, conscious cats. The
pharmacokinetic relationship between pimo-
bendan and ODMP was identified and the haemo-
dynamic responses following pimobendan
treatment were described.
The pimobendan pharmacokinetics from this
study were generally in agreement with those
previously reported in the cat [23]. There were
some differences in the magnitude of parameters
that may be attributable to differences in sampling
schedule, analytical method, and method of
pharmacokinetic evaluation. In both studies,
pimobendan was absorbed rapidly after oral
Figure 2 Graphical representation of cardiovascular parameters over time following water (3-mL water), low-dose
(0.625-mg pimobendan), and high-dose (1.25-mg pimobendan) treatments in six cats. The mean and standard devi-
ation have been plotted. Abbreviations: Ao Vel ¼ aortic velocity; DBP ¼ diastolic blood pressure; FS ¼ fractional
shortening; HR ¼ heart rate; IVSd/s ¼ interventricular septum thickness in diastole/systole; LVIDd/s ¼ left ventricular
internal diameter in diastole/systole; LVPWd/s ¼ left ventricular posterior wall thickness in diastole/systole;
MBP ¼ mean blood pressure; SBP ¼ systolic blood pressure. Solid lines represent water (3 mL water) treatment.
Dotted lines represent low-dose (0.625-mg pimobendan) treatment. Dashed lines represent high-dose (1.25-mg
pimobendan) treatment. a and b denote significant deviations from time zero (p<0.05) at the specified time for the
high-dose (1.25-mg pimobendan) and water (3-ml water) treatments respectively. X and Y indicate significant dif-
ferences (p<0.05) between the high-dose and water treatments and low-dose and water treatments respectively at
the specified time.
Pimobendan PK/PD in cats 319
62
Fig. 2 (continued)
320 M. Yata et al.administration, displayed a high apparent volume
of distribution, and was eliminated readily from
the plasma. High plasma concentrations of pimo-
bendan were observed, with the Cmax and AUC0eN
being higher than previously reported values from
studies evaluating pimobendan pharmacokinetics63in dogs given similar mg/kg doses [24,25]. Poten-
tial reasons for these findings include a higher
bioavailability or a lower clearance
(i.e. conversion to ODMP or elimination via faecal/
urinary excretion) in the cat.
Table 4 Treatment means averaged across time
(0e12 h post treatment) for select cardiovascular
parameters following water (3-mL water), low-dose
(0.625-mg pimobendan), and high-dose (1.25-mg
pimobendan) treatments in six cats.
Parameter (units) Water Low dose High dose
Ao Vel (m/s) 1.18 1.23a 1.27a
HR (bpm) 203.5 202.6 195.9a,b
IVSd (mm) 3.80 4.07a 4.01a
IVSs (mm) 6.78 7.16a 7.03a
LVIDs (mm) 7.83 7.38a 7.16a
LVPWs (mm) 6.46 6.34 6.62b
FS (%) 52.09 53.44 54.78a
SBP (mmHg) 143.1 148.7a 142.9b
Key: Ao Vel ¼ aortic velocity; HR ¼ heart rate; IVSd/
s ¼ interventricular septum thickness in diastole/systole
respectively; LVIDs ¼ left ventricular internal diameter in
systole; LVPWs ¼ left ventricular posterior wall thickness in
systole; FS ¼ fractional shortening; SBP ¼ systolic blood
pressure.
Model: Y^ (cardiovascular parameter) ¼ Treatment þ Time þ
Cat ID (random effect) þ Ɛ
a Denotes significant differences (p<0.05) from water.
b Denotes significant differences (p<0.05) from low dose.
Pimobendan PK/PD in cats 321Intravenous administration of pimobendan and
ODMP was not performed in our study. As such, the
absolute bioavailability could not be determined.
Clearance and volume of distribution reported
here are also estimated values corrected for an
unknown bioavailability. This is a limitation of the
study that prohibits between-species evaluations
of these parameters. However, an important fac-
tor that can be explored through our data is the
potential for inter-species differences in the
metabolism of this drug.
Comparisons of our data with published data in
dogs show that the elimination half-life of pimo-
bendan and ODMP were similar between cats and
dogs (Table 1). Interestingly, the AUC0eN of
pimobendan appeared higher than the AUC0eN of
ODMP in cats, which is in contrast to what has
been reported in dogs (Table 1). This resulted in
the ratio of AUC0eN ODMP:pimobendan being
lower in cats than in dogs (median 0.5, range
0.4e0.7 in cats for HD vs. median 1.6, range
1.2e1.7 in dogs). This reduced AUC0eN ratio in
the face of similar elimination profiles in dogs and
cats suggests a relatively reduced conversion of
pimobendan to ODMP in cats. Pimobendan con-
version to ODMP involves specific cytochrome P-
450 isoenzymes in humans [27]. In addition, both
pimobendan and ODMP are ultimately glucur-
onidated and excreted [28]. Because differences
in the activity of cytochrome P-450 isoforms and64ability to glucuronidate compounds have been
identified between dogs and cats [29e34], these
pathways could be contributing towards the dif-
ference in metabolism of pimobendan in these
two species.
A difference in pharmacokinetics between spe-
cies may result in inter-species variation in
response to treatment. Thus, two doses of pimo-
bendan were utilised in our study to investigate
the potential effect of dose. A non-invasive study
design which we have previously employed for the
detection of pimobendan effects in dogs [25] was
chosen to avoid the impacts of general anaesthesia
and instrumentation whilst providing the addi-
tional benefit of being clinically applicable.
Averaged across the sampling period, HD and LD
treatments were associated with significant dif-
ferences from water in some echocardiographic
parameters representing systolic function
(increased Ao Vel and FS and decreased LVIDs for
HD; increased Ao Vel and decreased LVIDs for LD).
These changes reflect the positive inotropic
effects of pimobendan. In general, HD was sig-
nificantly different to water in a greater number of
parameters than LD was to water.
We were unable to characterise the duration of
effects, timing of maximal effects, and any dif-
ference in effects between the two doses of
pimobendan. Major complicating factors included
the high degree of variability in the data, the small
number of cats in our study, and the presence of
similar haemodynamic trends which were observed
following the water treatment. These contributed
towards obscuring both the within- and between-
treatment effects over time as evidenced through
the non-significant interaction term in the model.
It is possible that the intensive handling, ven-
ipuncture, and greater environmental activity in
the hospital during the first few hours of sampling
may have contributed towards increased anxiety in
the cats regardless of the treatment administered.
With so many similarities in the cardiovascular
changes expected with anxiety and with pimo-
bendan treatment, and because pimobendan
treatment did not result in haemodynamic changes
that extended beyond reported reference ranges
[35] on the majority of occasions, it would be
impossible to fully separate the relative con-
tributions of anxiety and treatment in conscious
animals. Retrospectively, more extensive training
of the cats for these procedures may have been
helpful to reduce some of the anxiety experienced
during the study.
It is also possible that non-invasive methods of
monitoring may not have been sensitive enough to
322 M. Yata et al.detect consistent treatment effects in cats. On
several occasions with both HD and LD treatment,
end-systolic cavity obliteration of the left ven-
tricle was observed. This may have contributed
towards measurement errors and prohibited dif-
ferentiation of the maximal positive inotropic
effects between the two doses of pimobendan.
With the size of the heart being small in cats, small
inconsistencies in measurements between indi-
vidual cats and across time points could contribute
towards enough variability in the data to obscure
treatment effects. Variable correlations between
direct and oscillometric techniques of blood pres-
sure monitoring have also been observed pre-
viously in this species [36e39]. It is possible that
this contributed towards the wide range of blood
pressures observed.
In our study, there was a focus on measuring
ventricular systolic indices as they were commonly
measured parameters which reflect the primary
effect of pimobendan. However, diastolic dysfunc-
tion plays a large role in feline heart disease due to
the propensity of this species to develop hyper-
trophic and restrictive cardiomyopathies. In these
conditions, atrial systolic function, which was not
evaluated in the present study, becomes vital in
maintaining ventricular filling. Therefore, possible
effects of pimobendan on ventricular diastolic and
atrial systolic functions need further evaluation.
Treatment with a single oral dose of pimo-
bendan did not result in any major adverse events
in the study cats. Vomiting occurred in cat 6
shortly after HD treatment. In cat 5, vomiting
occurred around 24 h following HD treatment. The
temporal relationship between dosing and symp-
toms, as well as the nature of the symptoms
observed (productive vomiting associated with
nausea), make an adverse drug reaction possible
for cat 6 but questionable in cat 5. Minor gastro-
intestinal signs have been observed in 0e11% of
pimobendan-treated cats in prior studies
[17,19,20,23], and none of the cats in this study
developed gastrointestinal signs with LD or water
treatment. Thus, it is possible that any potential
minor gastrointestinal adverse effects may be
dose-dependent or not necessarily repeatable.
One cat (cat 3) had a single ventricular pre-
mature complex recorded around 1 h following
treatment with LD. No further arrhythmias were
noted in this cat on this occasion, and arrhythmias
were not noted following HD or water treatment in
this cat. Although further testing to evaluate other
causes of this arrhythmia were not performed, it is
possible that this cat may have had a pre-existing
arrhythmia which was not otherwise captured65during brief electrocardiography preceding and
accompanying the screening echocardiogram.
There are contrasting reports regarding the effects
of pimobendan on cardiac rhythm in other species.
Some studies suggested pro-arrhythmic effects
[40,41] while others did not document this
[42e52]. To date, no pro-arrhythmic effects of
pimobendan have been identified in cats [18,20];
however, large-scale evaluations for this effect
have not been conducted.
One cat (cat 7) had lower plasma concentrations
of pimobendan and ODMP following both LD and HD
when compared to other cats and was therefore
excluded from group analysis. However, the
AUC0eN ODMP:pimobendan ratio was similar to
that of other cats, thus suggesting a similarity in
the extent of metabolism of pimobendan to ODMP.
Although no abnormalities were identified in the
initial health assessment or during the study, it is
possible that this cat had undetected gastro-
intestinal, hepatic, or plasma protein abnormal-
ities that contributed towards lower bioavailability
or altered distribution of the drug. The inclusion of
serum biochemistry in the screening examination
or retrospective diagnostic testing of gastro-
intestinal function may have provided further
insight. Alternatively, it is possible that the data
from this cat may be representative of one end of
the spectrum of drug concentrations in the general
population of cats. A population-based pharma-
cokinetic study in a larger number of individuals
may aid in further evaluation of this anomaly.
There were a number of other limitations in this
study that may have influenced our findings. This
study utilised a reduced sampling protocol for
blood collection which resulted in depletion of
around 6% of the total blood volume each week in
the smallest cat. This protocol did not allow for
identification of the ascending phase of plasma
concentrations in the majority of cats. Thus, the
true Cmax and Tmax may not have been captured.
Although a higher number of plasma samples may
have facilitated a more accurate pharmacokinetic
analysis, this had to be balanced with the effect of
bleeding on the cardiovascular system. Ideally, the
between-day coefficient of variation for the car-
diologist should also have been assessed, and the
gender of cats and order of treatment should have
been fully balanced. The small number of animals
also precluded adjustments for these imbalances
in the statistical model.
Had the treatment effects been more readily
appreciable, the data could have also been ana-
lysed using simultaneous pharmacokinetic-
pharmacodynamic modelling to provide further
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our findings, however, it would seem that evaluat-
ing a wider range of cardiovascular parameters to
monitor treatment effects and employing further
measures to minimise anxiety in the study cats
would be advisable to obtain more reliable data for
this purpose. Pimobendan is marketed as a racemic
mixture; however, stereoselective pharmacoki-
netics and pharmacodynamics have been observed
in prior studies [6,53e56]. Thus, evaluation of
enantiomer kinetics and effects may also aid in
refining such a model to describe the dos-
eeresponse relationship in this species.
The data from this study were collected from
healthy cats; however, the effect of drug treat-
ment may be different in cats with cardiovascular
disease. In addition, this drug is typically admin-
istered chronically, thus necessitating further
evaluations in the form of multidose studies.
Ultimately, further pharmacological inves-
tigations and rigorous prospective clinical trials in
cats with cardiovascular diseases are required to
clarify the optimal dosing regimen, identify
whether cardiovascular effects are detectable in
the target animals for this drug, and whether
these effects translate to positive clinical
outcomes.Conclusions
Pimobendan treatment was well-tolerated in
fasted cats. Minor potential adverse effects con-
sisting of vomiting and documentation of a single
ventricular premature contraction were observed
in our study. The results from this study suggest a
reduced metabolism of pimobendan into the
active metabolite in cats compared to dogs.
Treatment effects with pimobendan at both
1.25 mg (HD) and 0.625 mg (LD) were observed in
measures of systolic function; however, the
duration of action and differences in effects
between the two pimobendan doses could not be
characterised. These findings can be used to
guide further investigations into the safety and
efficacy of pimobendan treatment in feline
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Introduction 
The most commonly acquired cardiovascular disease in dogs is myxomatous mitral valve 
disease (MMVD), which is characterised by progressive degeneration of affected valves. 
The accompanying effects on cardiovascular haemodynamics and activation of various 
neuroendocrine systems, though initially beneficial, become maladaptive and deleterious 
with chronicity. The natural course of disease is variable; yet typically, several years of 
asymptomatic disease precedes development of congestive heart failure (CHF) (Borgarelli & 
Buchanan, 2012). Progression to CHF depends on many factors including the age of the 
individual and the severity of disease. In a recent study, around 33 – 43% of dogs with 
evidence of cardiomegaly developed CHF within 3.5 years (Boswood et al., 2016). Once in 
CHF, both morbidity and mortality are negatively impacted.   
 Medical therapy is the primary treatment of CHF in dogs with MMVD; yet this is not 
curative. Rather, the aims of therapy are to palliate the clinical signs and to achieve the best 
quality of life for as long as possible. To this end, the benefit of a variety of medications has 
been evaluated in large-scale clinical studies over the past three decades (Amberger et al., 
2004; Bernay et al., 2010; Chetboul et al., 2017; Ettinger et al., 1998; Häggström et al., 
2008; The BENCH Study Group, 1999; Woodfield, 1995).  
Based on these findings, the American College of Veterinary Internal Medicine 
(ACVIM) produced guidelines for the treatment of dogs with CHF due to MMVD in 2009 
(Atkins et al., 2009). According to these guidelines, the gold standard therapy of chronic 
CHF due to MMVD, supported by all panel members, would consist of combination therapy 
including frusemide (a diuretic), pimobendan (an inodilator), and an angiotensin converting 
enzyme inhibitor (ACE-I). The majority of panellists also recommended the concurrent use of 
spironolactone as an aldosterone antagonist in order to provide more robust RAAS 
antagonism. These medications act through mediating the neuroendocrine pathways 
contributing towards CHF (ACE-I and aldosterone antagonists) or by overcoming their 
effects (diuretics and inodilators). Thus, combination therapy would theoretically result in 
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successful obliteration of multiple pathways contributing towards CHF, and therefore, offer 
the best outcome.  
It is interesting to note, however, that there is a relative lack of literature evaluating 
the true effects of such combination therapy. Prior to the commencement of this study, the 
long-term effects of the aforementioned combination therapy had only been evaluated in a 
single retrospective study which described the outcome of dogs treated with frusemide, 
pimobendan, an ACE-I, spironolactone, and amlodipine (De Madron et al., 2011). Dogs 
included in this study had a median survival time of 430 days from the time of diagnosis of 
CHF, with the majority of deaths being cardiac-related. These findings appear similar to, or 
possibly better than, survival outcomes reported by existing studies evaluating effects of 
various components of this combination therapy (160 days till treatment failure in the LIVE 
study (Ettinger et al., 1998); mean survival time of 428 days in the BENCH study (The 
BENCH Study Group, 1999); median time to combined cardiac death, euthanasia, and 
treatment failure of 267 days with pimobendan or 140 days with benazepril in the QUEST 
study (Häggström et al., 2008); median survival time of 430 days with pimobendan or 228 
days with benazepril in a study by Lombard et al., (2006); however, such comparisons 
between studies are speculative at best, due to the vast differences in study design, cohort 
of dogs enrolled, and classification systems for CHF. In addition, the retrospective nature of 
the study by De Madron et al., (2011) made it more susceptible to selection bias and 
confounders. 
The aim of this study was therefore to evaluate, prospectively, the natural course of 
disease in dogs with newly diagnosed CHF due to MMVD when treated with a combination 
therapy consisting of frusemide, pimobendan, an ACE-I, and spironolactone.  
 
Materials and Methods 
Animals 
Eleven client-owned dogs with ACVIM class C (chronic) CHF due to MMVD were recruited 
from first opinion or referral caseload presenting to the University Veterinary Teaching 
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Hospital, Sydney (Sydney, NSW, Australia) between February, 2015 and March, 2016. 
Ethics approval was obtained from the University of Sydney Animal Ethics Committee prior 
to commencement of the study (project approval numbers 2013/532 and 2014/727). 
 
Study design 
This study was a prospective observational study examining the natural course of disease in 
dogs with CHF due to MMVD on oral treatment with frusemide tablets or solution (APO 
Frusemide; Apotex Pty Ltd, Macquarie Park, NSW, Australia or Flusapex; Apex laboratories 
Pty Ltd, Somersby, NSW, Australia), pimobendan solution (Vetmedin 3.5 mg/ml oral 
solution; Boehringer Ingelheim Pty Ltd, North Ryde, NSW, Australia), benazepril tablets 
(Fortekor; Elanco Australasia Pty Ltd, West Ryde, NSW, Australia), and spironolactone 
tablets (Aldactone; Pfizer Australia Pty Ltd, West Ryde, NSW, Australia) from the time of first 
onset of CHF to death or the conclusion of the study period. The pimobendan was a liquid 
formulation in the process of gaining registration by the Australian Pesticides and Veterinary 
Medicines Authority at the time this study was commenced. Registration was obtained 
during the course of the study (15 September, 2016; APVMA approval no 81552/103342). 
It was a single-centre study conducted at the University Veterinary Teaching Hospital, 
Sydney between February, 2015 and June, 2017.  
 
Enrolment Criteria 
Prior to enrolment, each dog had a screening examination which consisted of a review of the 
history, physical examination, oscillometric blood pressure measurements (VetHDO monitor; 
Memo Diagnostic, Darmstadt, Germany), electrocardiogram, echocardiogram, and thoracic 
radiography. Select blood and urine tests were also performed in-house at the clinic using 
the IDEXX Catalyst One® Chemistry Analyser (IDEXX Laboratories Inc., Rydalmere, NSW, 
Australia), the Multistix 10 SG Reagent Strips (Siemens Healthcare Pty Ltd., Bayswater, VIC, 
Australia), and a refractometer. The PCV, total protein, electrolytes, urea, creatinine, 
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phosphate, calcium, alanine aminotransferase, alkaline phosphatase, urine dipstick, and 
urine specific gravity were evaluated. 
 The inclusion criteria consisted of older (greater than 5 years of age), small breed 
dogs (weight less than 20 kg) diagnosed with first onset of left-sided CHF due to MMVD 
(ACVIM Stage C) within 14 days of the screening exam. This diagnosis was confirmed 
during the screening consultation and necessitated documentation of characteristic 
radiographic changes (left atrial enlargement, pulmonary oedema, and venous congestion) 
and symptoms (such as dyspnoea, orthopnoea, tachypnoea, changes to lung sounds on 
auscultation, cyanosis/reduced oxygen saturation, cough, loud systolic left apical murmur, 
and tachycardia) of CHF at the time of original diagnosis, as well as echocardiographic 
findings consistent with severe MMVD at the screening exam (mitral valve thickening with 
valve prolapse or flail valve, presence of mitral regurgitation, and evidence of cardiomegaly 
based on left atrium to aorta ratio > 1.6 with increased left ventricular internal diameter in 
diastole (Gonçalves et al., 2002). The signs of CHF needed to be adequately controlled 
(normal respiratory rate and effort, no side effects of initial medical therapy, and resolution of 
pulmonary oedema on thoracic radiographs at screening) for a minimum of two days and 
maximum of 14 days prior to enrolment.  
 The exclusion criteria consisted of CHF due to aetiologies other than MMVD (e.g. 
cardiomyopathies, arrhythmias, endocarditis, congenital heart disease); primary right-sided 
CHF at the time of screening; haemodynamically significant arrhythmias refractory to 
treatment at the time of screening; treatment with frusemide or pimobendan prior to onset of 
initial CHF; presence of significant systemic diseases which may interfere with treatment of 
CHF (e.g. chronic gastrointestinal, hepatic, or renal diseases) at the time of screening; and 
chronic treatment with medications which may interfere with treatment of CHF (e.g. 
sucralfate, antacids). 
 Pre-set exit criteria for discharge from the study included severe adverse reactions to 
drugs used for treatment of CHF (frusemide, pimobendan, benazepril, spironolactone); 
significant lack of owner compliance to adhere to treatment regimen or prescribed follow-up 
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examinations; and development of significant unrelated diseases which may affect 
cardiovascular function or require treatment with cardiotoxic agents. The development of 
symptomatic pulmonary hypertension, right-sided CHF, arrhythmias, and other complications 
of MMVD were not criteria for discharge from the study.  
 
Schedule of visits 
Upon successful enrolment into the study, each dog was required to commence quadruple 
therapy with frusemide, benazepril, spironolactone, and pimobendan. The doses of 
medications were adjusted as required throughout the course of the study, with acceptable 
standard dosing defined as 3 – 12 mg/kg/day divided for frusemide; 0.25 – 0.5 mg/kg/day for 
benazepril; 2 – 6 mg/kg/day divided for spironolactone; and 0.4 – 0.6 mg/kg/day divided for 
pimobendan. Routine evaluations consisting of history, physical examination, blood pressure 
measurements, electrocardiogram, standard echocardiography, thoracic radiographs, and 
basic clinical pathology (as per the screening exam) were performed at one week, one 
month, then every three months following enrolment until death or the conclusion of the 
study period.  
 In addition to these routine scheduled visits, dogs were also seen for non-routine 
visits by the investigators or other clinicians if required. These visits were not controlled and 
consisted of any diagnostic and medical interventions which were deemed necessary by the 
investigators or the attending clinician at the time.  
 
Variables evaluated 
Clinical variables evaluated in the study included body weight (kg); total dose of medications 
per day; identifications of any arrhythmias present; identification of any concurrent diseases 
or medications; adherence to treatment regimen; identification of any gastrointestinal or 
behavioural abnormalities; sleeping or resting respiratory rates (SRR, RRR); murmur grade, 
heart rate (HR); body condition score (BCS); and systolic, mean, and diastolic blood 
pressure (SBP, MBP, DBP). In addition, a 32-point clinical scoring system adapted from 
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Häggström et al., (2008) consisting of exercise tolerance, demeanour, appetite, respiratory 
effort, coughing, nocturnal comfort levels, pulmonary oedema score, and ACVIM heart 
failure class was also evaluated based on history and exam findings (Table 1).  
The aforementioned blood and urine tests were also performed in-house at each visit 
where possible.  
 Standard three-view thoracic radiographs consisting of right and left lateral and 
dorsoventral views were performed. The vertebral heart score (VHS) was calculated by 
measuring the long and short axis of the cardiac silhouette on a lateral projection of the 
thorax and adding the number of vertebral bodies equivalent to these distances starting from 
the fourth thoracic vertebral body (Buchanan & Bücheler, 1995). 
 Echocardiography was performed by a board-certified specialist in cardiology (NB), a 
cardiology resident, or a veterinarian (MY) under the guidance of the cardiologist or 
cardiology resident. An ultrasound system (Vivid I; General Electric Healthcare, Silverwater, 
NSW Australia) coupled with a 3.5 – 8 mHz sector probe and simultaneous 
electrocardiography was used. Two dimensional right parasternal short axis views were 
used to measure the left atrium (LA) and aorta (Ao), and left ventricular indices were 
obtained using M-mode at the level of the chordae tendinae. The left ventricular internal 
diameter in systole and diastole were normalised for body weight (wnLVIDs, wnLVIDd) 
(Cornell et al., 2004). Fractional shortening (FS) was calculated as (LVIDd – LVIDs) / LVIDd. 
The aortic velocity was measured from the left apical five chamber view. Moderate to severe 
pulmonary hypertension was detected in animals with a tricuspid regurgitation if the velocity 
of the regurgitant jet exceeded 3.5 m/s (Borgarelli et al., 2015; Kellihan & Stepien, 2012).  
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Table 1: Clinical scoring system for evaluation (maximum 32 points) of general well-
being in dogs with congestive heart failure (CHF) due to myxomatous mitral valve 
disease (MMVD). Adapted from Häggström et al. (2008). 
 
  Exercise tolerance  
1 Very good: Dog moved around with ease, was able to fully exercise 
2 Good: Dog moved around with ease, was not able to fully exercise; ability to run was reduced 
3 Moderate: Dog was less active than normal, moved around a few times per day, avoided long 
walks 
4 Poor: Dog was inactive and would only get up to eat, drink, or urinate 
 
Demeanour  
1 Alert, responsive 
2 Mildly lethargic 
3 Moderately lethargic 
4 Minimally responsive 
 
Appetite  
1 Increased 
2 Normal 
3 Decreased (2/3 normal) 
4 Markedly decreased (< 2/3 normal) 
 
Respiratory effort 
1 Normal 
2 Mildly increased rate or effort 
3 Moderately laboured 
4 Severe respiratory distress 
 
Coughing  
1 None 
2 Occasional (a few times a week) 
3 Frequent (a few times a day) 
4 Persistent (frequently during the day) 
 
Nocturnal discomfort 
1 None 
2 Mild: Restlessness experienced <2 nights a week or need to toilet; no dyspnoea or coughing 
3 Moderate: Restlessness experienced 3-5 nights a week or frequent need to toilet; mild 
dyspnoea or coughing 
4 Severe: Restless on a nightly basis, frequent need to toilet, and presence of moderate 
dyspnoea 
 
Pulmonary oedema 
1 None 
2 Mild  
3 Moderate  
4 Severe 
 
ACVIM heart failure classification 
1 Class C (chronic) 
2 Class D (chronic) 
3 Class C (acute) 
4 Class D (acute) 
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Endpoints  
The primary endpoint of this study was death. This included both cardiovascular and non-
cardiovascular causes, as well as euthanasia. An alternate endpoint was reached at the 
conclusion of the study period (30 June, 2017) if an animal was still alive at this time. 
 
Statistical analysis 
Analysis consisted of summary statistics and visual observation of graphs depicting 
longitudinal data. The median and ranges were reported unless otherwise specified.  
A Kaplan-Meier curve was created to obtain an estimation of median survival time to all-
cause death and cardiovascular death. All animals alive at the end of the study period were 
censored in the former analysis, while animals suspected of non-cardiac death were also 
censored in the latter analysis. 
 
Results 
A total of eleven dogs were enrolled between February, 2015 and March, 2016. The median 
age was 12 years (range 6 – 16), median body weight was 5.9 kg (range 2.7 – 8.6), and 
there was even distribution of the sexes (1 entire female and 5 spayed females; 1 entire 
male and 4 neutered males). Breeds represented included the Japanese Chin (n = 1), 
Chihuahua (n = 1) or Chihuahua cross (n = 2), Shih Tzu cross (n = 1), Miniature Fox Terrier 
(n = 2), Jack Russell Terrier cross (n = 1), Maltese cross (n = 2), and Cavalier King Charles 
Spaniel (n = 1). At the time of enrolment, all dogs were receiving treatment with frusemide 
(median dose 3.7 mg/kg/day; range 2.9 – 6.3) and pimobendan (median dose  
0.5 mg/kg/day; range 0.3 – 0.8). One dog was also receiving spironolactone (2.1 mg/kg/day), 
and seven dogs were also receiving benazepril (median dose 0.2 mg/kg/day; range 0.2 –
 0.6). Dogs had been on treatment for a median of seven days (range 6 – 14 days) prior to 
screening. 
 Relevant baseline clinical information at enrolment has been listed in Table 2. Two of 
the eleven dogs were suspected to have suffered acute chordal rupture which caused them 
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to develop CHF; they had less cardiomegaly compared to other dogs in the study. Left atrial 
rupture was suspected in one dog at the time of initial diagnosis with CHF and in another 
dog around two months prior to presentation with initial onset of CHF. One dog had both 
right and left-sided CHF at the time of initial onset of CHF. Five dogs had evidence of 
moderate to severe pulmonary hypertension, two of which displayed clinical signs 
associated with this (syncope and right-sided CHF). 
Concurrent diseases at the time of enrolment included a history of seizures in two 
dogs; dynamic airway disease or suspected chronic bronchitis in four dogs; skin allergies in 
three dogs; and testicular neoplasia in one dog. One dog had mild systemic hypertension at 
the time of screening and was subsequently diagnosed with, and successfully treated for, 
hyperadrenocorticism. One dog developed evidence of kidney disease within one month of 
the screening exam. This was thought to be attributable to exacerbation of pre-existing 
subclinical kidney disease as a result of treatment with frusemide and benazepril.  
Throughout the course of the study, the five dogs with moderate to severe pulmonary 
hypertension all developed clinical signs (syncope, n = 2; right-sided CHF, n = 2; cyanosis,  
n = 1) for which treatment with sildenafil was commenced at 0.7 – 2.2 mg/kg twice daily. One 
dog developed supraventricular tachycardia which was treated with digoxin (1.7 mg/kg two 
to three times daily) and diltiazem (3.6 μg/kg twice daily); another developed atrial fibrillation 
which was treated with diltiazem at 2.3 mg/kg twice daily (18% for combined 
tachyarrhythmias). Six dogs (55%) developed at least one episode of decompensated left 
(n = 5) or right (n = 1) sided CHF prior to reaching the endpoint of death. Decompensation 
first occurred between 2 – 6.5 months prior to death. 
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Table 2: Clinical variables at enrolment in eleven dogs with congestive heart failure 
(CHF) due to myxomatous mitral valve disease (MMVD). The median and range were 
reported. Abbreviations: BCS – body condition score; SBP, MBP, DBP – systolic, 
mean, and diastolic blood pressure; LA:Ao – left atrium to aorta ratio; wnLVIDs/d – 
weight normalised left ventricular internal diameter in systole/diastole; FS – fractional 
shortening; VHS – vertebral heart score; Crea – creatinine; ALT – alanine 
aminotransferase. 
Variable Median Range 
Heart rate (bpm) 150 80 - 180 
Murmur grade (/6) 4 4 - 5 
BCS (/5) 3 1.5 - 3.5 
SBP (mmHg) 146 125 - 169 
MBP (mmHg) 97 80 - 120 
DBP (mmHg) 71 51 - 83 
LA:Ao 2.0 1.6 - 3.4 
wnLVIDs (cm) 1.0 0.8 - 1.7 
wnLVIDd (cm) 2.2 1.6 - 3.0 
FS (%) 49.4 37 - 62.2 
Aortic velocity (m/s) 1.1 0.7 - 1.5 
VHS 11 10.0 - 14.0 
Clinical Score (/32) 10 9 - 13 
Crea (μmol/L) 98 59 - 128 
Urea (mmol/L) 13.1 7.6 - 20.8 
ALT (U/L) 102 42 - 164 
 
Nine out of the eleven enrolled dogs (82%) reached the endpoint of death. The most 
common cause of death was death or euthanasia due to recurrence of decompensated CHF 
(n = 6; 55%). Other causes of death included euthanasia for suspected CHF (n = 1; 9%), 
sudden death following a seizure-like episode (n = 1; 9%), and death of unknown cause 
following development of lethargy, inappetence, and diarrhoea (n = 1; 9%). 
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The proportion of dogs alive from the day of diagnosis of CHF till the end of the study 
period is represented in Figure 1. The median survival time was 419 days to all-cause death 
(95% confidence interval 184 – 616). The two dogs that originally developed CHF following a 
suspected acute chordal rupture had lived for 481 and 773 days and were alive at the end of 
the study period. When the one dog that possibly died of extra-cardiac causes (following 
lethargy, inappetence, and diarrhoea in the other) was also censored to give the median 
survival time to cardiovascular causes of death and euthanasia, the figure did not change 
(Figure 2). 
The trends in select clinical variables measured have been depicted in  
Figures 3. The two dogs alive at the end of the study period (represented by dotted lines) 
tended to have smaller measurements of heart size (LA:Ao, wnLVIDd, wnLVIDs, VHS) and 
lower aortic velocity and FS (Figure 3). In contrast, dogs that reached the primary endpoint 
earlier tended to have larger LA:Ao, wnLVIDs, and wnLVIDd. The LA:Ao appeared to 
increase before the primary endpoint was reached.  
The clinical exam findings recorded in this study remained largely static. The SRR 
remained below 30 breaths per minute on the whole. The murmur grade was static except in 
one dog, in which this reduced noticeably over the course of the study. This dog was alive at 
the end of the study period and was one of the dogs that had chordal rupture with minimal 
cardiac remodelling.  
There were no discernible trends in each of the eight measures included in the 
clinical scoring system (exercise tolerance, demeanour, appetite, respiratory effort, coughing, 
nocturnal discomfort, pulmonary oedema score, and ACVIM heart failure class), body 
condition score, urea, creatinine, or ALT. The urea and creatinine were abnormally high in 
one dog that developed kidney disease. The ALT increased in two dogs that developed 
supraventricular tachycardia and atrial fibrillation, which necessitated addition of 
antiarrhythmic therapy (diltiazem and digoxin). Of these dogs, it is unclear as to why one 
tended to have a high ALT throughout the course of the study. 
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Overall, the treatment compliance was high throughout the study, with all owners 
reporting adherence to treatment regimen all or most of the time. In the latter case, the most 
common deviation to the treatment regimen related to the timing of administering 
pimobendan in relation to feeding. All owners were instructed to dose this medication on an 
empty stomach, one to two hours before food. Where deviations to treatment occurred, this 
was due to the need to either administer pimobendan with food or to feed pets shortly 
following treatment. In addition, the timing of medications was not always consistent, and 
minor difficulties administering solid dose forms were reported by some of the owners. This 
was usually overcome through administering medications with various food items considered 
to be treats.  
 
  
82
 
 
 
Figure 1: Kaplan-Meier curve depicting percentage of dogs alive in relation to time, 
starting from the day of diagnosis of congestive heart failure (CHF). Data from eleven 
dogs with myxomatous mitral valve disease (MMVD) have been included. Deaths were 
represented by vertical lines and included both cardiac and non-cardiac causes; the 
two dogs alive at the end of the study period were censored and are represented by 
the ticks. The median survival time was 419 days. 
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Figure 2: Kaplan-Meier curve depicting percentage of dogs alive in relation to time, 
starting from the day of diagnosis of congestive heart failure (CHF). Data from eleven 
dogs with myxomatous mitral valve disease (MMVD) have been included. Deaths were 
represented by vertical lines and represent only cardiac-related causes; the two dogs 
alive at the end of the study period and the one dog that possibly died of extra-cardiac 
causes were censored and are represented by the ticks. The median survival time was 
419 days. 
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Figure 3: Individual trends in echocardiographic and radiograph findings over time in 
eleven dogs with congestive heart failure (CHF) due to myxomatous mitral valve 
disease (MMVD). The two dogs that were alive at the conclusion of the study are 
represented by dotted lines. Abbreviations: LA:Ao – left atrium to aorta ratio; 
wnLVIDs/d – weight normalised left ventricular internal diameter in systole/diastole; 
FS – fractional shortening; VHS – vertebral heart score. 
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Discussion 
The primary aim of this study was to describe the natural course of disease in dogs with 
CHF due to MMVD receiving treatment with a quadruple combination therapy consisting of 
frusemide, pimobendan, ACE-I, and spironolactone. This aim was achieved through analysis 
of survival data, identification of comorbidities, and characterisation of repeated exam 
findings in the study population.  
 The median survival time of 419 days (95% confidence interval 184 – 616) in dogs 
with MMVD following initial diagnosis of CHF is comparable to findings of prior retrospective 
studies evaluating survival in dogs treated with this combination of medications. De Madron 
et al. (2011) reported a median survival time of 430 days (75% survival 99 days; 25% 
survival N/A) from time of onset of CHF in 21 dogs with MMVD treated with quadruple 
therapy and amlodipine. More recently, another retrospective study found that the median 
time to development of advanced CHF was 163 days (range 10 – 743 days) in dogs with 
newly diagnosed CHF due to MMVD, with a median survival time of 281 days (range 3 – 885 
days) in advanced CHF (Beaumier et al., 2018). The quadruple combination therapy utilised 
in the present study was employed in 36/54 dogs in the study by Beaumier et al. (2018). 
Although the small number of enrolled dogs is a limitation to all three studies, this agreement 
in central tendency of the data across three studies utilising similar inclusion and exclusion 
criteria strengthens these findings. It can be deduced, then, that combination therapy 
utilising early initiation of pimobendan, comprehensive RAAS inhibition, and frusemide 
results in a median survival time of around 14 – 15 months in these dogs. 
 Interestingly, this figure is ~ 100 days longer than the reported median survival time 
from a recently published retrospective study evaluating the effects of treatment utilising 
frusemide, pimobendan, and ACE-I (M. Mizuno et al., 2017). As the inclusion criteria for this 
study were also similar to that of the aforementioned studies, it is possible that the use of 
comprehensive RAAS inhibition (i.e. spironolactone + ACE-I) may provide survival benefits. 
Unfortunately, these findings are somewhat clouded by the use of spironolactone in ~ 25% 
of the dogs in the study by Mizuno et al. (2017). The results from another prospective study 
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evaluating the benefits of treatment with pimobendan, ACE-I, and frusemide over that of 
pimobendan and frusemide alone are pending (Wess, 2017) but may facilitate further 
comparative assessments of survival. To date, only one study has evaluated long-term 
benefits of adding spironolactone to conventional therapy with ACE-I +/- frusemide +/- 
digoxin in dogs with CHF (Bernay et al., 2010); although therapy including spironolactone 
was associated with ~ 55% reduction in risk of cardiac death, euthanasia, or worsening 
disease, the event rate for the primary endpoint was low (~ 18%), and this study did not 
include pimobendan in the treatment regimen. Despite these suggestions that quadruple 
therapy may provide enhanced survival benefits, further studies are required to confirm this 
suspicion. 
It is also important to note that the studies by Beaumier et al. (2018), De Madron et al. 
(2011), and the present study represent the only studies to date which have examined 
survival outcomes utilising early institution of quadruple therapy in dogs diagnosed with CHF 
based on the ACVIM heart failure classification scheme. A key aspect which differentiates 
this classification scheme from others (such as the ISACHC and modified NYHA) is the 
requirement of pulmonary oedema demonstrated on thoracic radiography in order to 
diagnose CHF; thus, it may be considered a more stringent system for providing a diagnosis, 
with associated implications on survival outcomes. With this being the predominant 
classification scheme utilised to guide diagnosis and treatment of CHF in Australia, reports 
of survival outcomes using this scheme are most relevant to the population of dogs treated 
in this country. Perhaps the single largest survival study in dogs with CHF diagnosed utilising 
this classification scheme is the QUEST study, in which treatment with frusemide + 
benazepril or frusemide + pimobendan was evaluated (Häggström et al., 2008). However, 
“double therapy” is seldom used today; in addition, the primary endpoint of this study was a 
composite of cardiac death, euthanasia, and treatment failure, and dogs were not enrolled 
within a specified period following diagnosis of CHF. Thus, it would appear that despite the 
small numbers, the findings of the present study and those by De Madron et al. (2011) and 
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Beaumier et al. (2018) represent important survival information in dogs with CHF due to 
MMVD when treated with such combination therapy. 
 Recurrent CHF was, by far, the largest contributor towards increased morbidity and 
mortality and accounted for 78% of deaths observed in this study. This is in line with findings 
of existing survival studies, in which cardiac causes comprised the majority (54 – 86%) of 
deaths and euthanasias in dogs with CHF due to MMVD (Beaumier et al., 2018; De Madron 
et al., 2011; Häggström et al., 2008; The BENCH Study Group, 1999). Thus, across a variety 
of treatment methods, it appears death due to CHF or other cardiac causes remains the 
most likely outcome in dogs with CHF due to MMVD. In addition, a majority of dogs (six out 
of nine dogs that died) in this study experienced at least one episode of recurrent CHF prior 
to death or euthanasia, starting from 2 – 6.5 months prior to death. This may be a negative 
prognostic indicator but requires further studies to evaluate its significance. 
 Pulmonary hypertension and arrhythmias are important comorbidities which may 
develop in cases of severe MMVD. Both have been associated with increased morbidity and 
risk of death (Borgarelli et al., 2015; Borgarelli et al., 2008). The estimated prevalence of 
pulmonary hypertension is 14 – 53% across all stages of MMVD, with higher prevalence in 
advanced stages of the disease (Kellihan & Stepien, 2012). In line with this, five dogs (or 
around 45% of dogs) had moderate to severe pulmonary hypertension at enrolment in this 
study; in all of these dogs, clinical symptoms warranting treatment emerged. Ultimately, four 
of these five dogs died or were euthanized because of confirmed or suspected CHF. Of 
known arrhythmias, atrial fibrillation and paroxysmal supraventricular tachycardia were most 
common in dogs with MMVD in one report (Borgarelli et al., 2008), and indeed, these were 
the two significant arrhythmias observed in our study population. Both dogs were euthanized 
due to recurrent CHF. These findings reinforced reports of previous studies regarding 
pulmonary hypertension and arrhythmias in dogs with CHF due to MMVD. 
 Throughout the course of the study, only a few clinical variables showed discernible 
trends in relation to survival. Dogs with larger LA:Ao, wnLVIDs, and wnLVIDd tended to die 
earlier, and the LA:Ao appeared to increase prior to onset of death (Figure 3). This is in line 
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with previous reports which identified these factors as being negative prognostic indicators in 
those treated with other combinations of medications (Borgarelli et al., 2008; Häggström et 
al., 2008; Hezzell, Boswood, Moonarmart, et al., 2012). Body condition, VHS, and the clinical 
score have also been identified as potential risk factors in previous studies, but this was not 
obvious in our study cohort (Borgarelli et al., 2008; Häggström et al., 2008; Slupe et al., 
2008). This is likely owing to the small number of enrolled dogs and vastly heterogeneous 
nature of the disease. Additionally, bias towards monitoring variables relating to the 
cardiorespiratory systems (e.g. respiratory rate, murmur grade) with few items representative 
of systemic well-being (e.g. body condition score) and inability to document clinical changes 
leading up to and at the time of death in every case are also thought to have contributed. 
Despite this, the emergence of trends in LA:Ao, wnLVIDs, and wnLVIDd in the present study 
would suggest that these may be more robust prognostic variables with greater utility in 
clinical practice. 
 Interestingly, the two dogs that were alive at the end of the study period were both 
suspected to have had an acute chordal rupture which led to manifestation of CHF. They 
had stable heart disease and even displayed a reducing trend in LA:Ao, wnLVIDd, and VHS 
(Figure 3). One of these dogs subsequently developed syncope and was diagnosed with 
pulmonary hypertension and decompensated CHF 287 days following completion of the 
study. A large increase in LA:Ao and wnLVIDd was also noted at this time. Despite 
escalation of therapy and addition of further medications, this dog died suddenly 37 days 
later, 805 days from the time of first onset of CHF. The other dog was alive without 
significant cardiac complications 333 days following completion of the study and 1106 days 
from the time of first onset of CHF (as at 25 May 2018). The reported prognosis of dogs 
suffering rupture of chordae tendinae are variable, with some reporting generally poor 
outcomes (Borgarelli & Buchanan, 2012) and others observing better outcomes (median 
survival time of 394 days in dogs with symptomatic CHF) (Serres, Chetboul, Tissier, et al., 
2007). However, to date, there are no studies that have evaluated the effect of combined 
pimobendan and RAAS antagonism on the prognosis of dogs with CHF due to chordal 
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rupture. Both dogs in the present study survived for an extremely long time and 
demonstrated beneficial cardiac remodelling following initial onset of CHF. Whilst it is 
possible that this particular combination of treatments facilitated positive cardiac remodelling 
following chordal rupture and prolonged survival, additional studies are required to 
investigate this theory.  
 There are several ways in which this study could have been modified to strengthen 
the findings and contribute further data. As previously mentioned, greater numbers of 
enrolled animals would have strengthened the observations made in the study. Though the 
initial goal was to enrol up to 50 dogs over the course of the first year, this goal was not 
achieved due to the stringent inclusion criteria, single-centre study design, and small number 
of personnel available for case recruitment and data collection (three veterinarians 
consisting of a specialist cardiologist, cardiology resident, and PhD candidate). Unfortunately, 
extension of the recruitment period was deemed unfeasible due to the longitudinal nature of 
the study and the time constraints to complete data collection within the duration of this PhD 
candidature. A larger number of dogs may have facilitated more accurate extrapolations of 
these findings to the population level or identification of specific risk factors for the primary 
endpoint of death.  
 This study was designed as an observational study of dogs receiving quadruple 
therapy, and therefore, did not include a control group to compare findings. Including a 
positive control group could have provided additional information on the efficacy of 
quadruple therapy in comparison to double or triple therapy. This is an important 
consideration as increasing the number of medications can result in greater financial and 
practical burdens on owners and reduced treatment compliance. However, such a study 
would require very large numbers of dogs to be recruited, and the resources of this research 
team did not allow for this type of study design.  
 Another limitation of this study was the lack of assessment of biomarkers. Natriuretic 
peptides, and in particular, plasma concentrations of NT-proBNP, increase with disease 
severity, and concentrations before and following therapy for CHF have been identified as 
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significant predictors of mortality (Oyama et al., 2008; Serres et al., 2009; Wolf et al., 2012). 
Other biomarkers which may provide information on disease severity and prognosis include 
cardiac troponins, endothelin-1, and various markers of inflammation and endothelial 
function (Boswood, 2009); however, many of these are not specific to the disease process, 
and their clinical utility remains ill-defined at large. The combination of NT-proBNP and 
serum high-sensitivity cardiac troponin I has been suggested to provide superior prognostic 
information than either one alone (Hezzell, Boswood, Chang, Moonarmart, Souttar, et al., 
2012), and such a method of using multiple biomarkers has been advocated by some 
experts in veterinary cardiology (Boswood, 2009; Oyama, 2014). Unfortunately, biomarker 
assessment was limited through the lack of commercially available validated assays and 
concerns over sample stability, given the long duration of storage throughout this study. 
 The method of data collection was yet another limitation. Some of the measured 
items were subjective (e.g. degree of nocturnal discomfort, pulmonary oedema score, etc.); 
where objective data was collected, some (such as sleeping respiratory rate) relied on owner 
observations whereas others (such as echocardiographic measurements) were performed 
by operators with varying levels of experience. The resultant inter-observer variability was 
not quantified or monitored, thus making it possible that some inaccuracies existed in our 
dataset. Nevertheless, it is interesting to note that some trends such as those in LA:Ao, 
wnLVIDs, and wnLVIDd were still apparent. This appears to provide affirmation of the 
robustness of these variables and provides support for their use by those less experienced 
in the skill of echocardiography, such as general practitioners. 
 
Conclusions 
Eleven dogs with CHF due to MMVD were treated with combination medical therapy 
consisting of frusemide, pimobendan, benazepril, and frusemide, and the natural course of 
disease was prospectively evaluated. Nine dogs reached the endpoint of death, with death 
or euthanasia due to confirmed or suspected cardiac causes comprising the majority of 
these deaths. The median survival time from the time of CHF diagnosis was 419 days. 
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Clinically significant pulmonary hypertension and recurrent decompensated CHF were 
commonly encountered in this study cohort. Larger LA:Ao, wnLVIDs, and wnLVIDd 
appeared to be associated with shorter survival times. These findings are in line with 
previous studies evaluating survival outcomes in dogs with MMVD receiving treatment with a 
variety of medications but suggest the potential for prolonged survival using this combination 
of medications; ultimately, however, the benefit of quadruple therapy over other 
combinations remains unproven. Further studies are required to shed light on this matter. 
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Chapter 5: 
Brain natriuretic peptide assay development and evaluation  
in dogs undergoing acute intravascular volume expansion 
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Introduction 
Brain natriuretic peptide (BNP) is a peptide in the natriuretic peptide system (NPS) which 
has been used as a biomarker for congestive heart failure (CHF) in humans and veterinary 
patients (Oyama et al., 2013; Ponikowski et al., 2016). The predominant effects of BNP 
include natriuresis, diuresis, vasodilation, and inhibition of the renin-angiotensin-aldosterone 
system (RAAS); yet CHF occurs in the face of high circulating concentrations of BNP 
(DeFrancesco et al., 2007; Häggström et al., 2000). This paradox has prompted further 
research into the role of BNP and the NPS in CHF in humans (Colucci et al., 2000; 
McMurray, 2015; Publication Committee for the VMAC Investigators, 2002; Vanderheyden et 
al., 2010). 
 One of the reasons for this BNP paradox could be attributed to the many forms of this 
peptide and the relatively non-specific nature of immunoassays, which are the primary 
diagnostic tools used to detect circulating concentrations of BNP. BNP is primarily stored in 
an inactive proform (proBNP1-108), which, upon activation, undergoes enzymatic cleavage 
into a biologically active c-terminal component (BNP1-32) and a biologically inactive 
N-terminal component (NT-proBNP) (Vanderheyden et al., 2010). BNP1-32 is further broken 
down into less active or inactive fragments by a variety of circulating proteases 
(Vanderheyden et al., 2010). Immunoassays designed for quantification of plasma BNP1-32 
and NT-proBNP in humans display cross-reactivity with the inactive proBNP1-108 and less 
active or inactive fragments of BNP1-32 (Heublein et al., 2007; Luckenbill et al., 2008; 
Yandle et al., 1993). The problems associated with this lack of specificity prompted research 
efforts into other techniques for detection and quantification of BNP1-32, the primary active 
molecule, in humans (Vanderheyden et al., 2010). 
 A candidate for such a specific technique of peptide detection is mass spectrometry. 
Mass spectrometers (MS) operate by ionising molecules and measuring the resultant mass-
to-charge ratios – a unique physicochemical footprint that can be used to identify the 
substance of interest. There are numerous methods of ionising molecules, of which 
electrospray (ESI) and matrix-assisted laser desorption/ionisation (MALDI) are most 
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commonly used for peptides and proteins (D. Liebler, 2001). This is coupled with a mass 
analyser and detector to sort and identify the various charged particles. One of the simpler 
MS is a time-of-flight MS, which, when coupled with a MALDI source, uses a laser to ionise 
the analyte and measures the time taken for each ion to reach the detector to determine the 
mass. This method generally yields low numbers of fragmentation ions and can be used to 
measure the mass of a broad range of peptides and proteins (D. Liebler, 2001).  
In certain circumstances, the intact peptide mass alone can be diagnostic of a 
particular peptide sequence; more commonly, however, peptide fragments are monitored. 
With many MS, it is possible to isolate a particular ion (the parent ion) within the instrument, 
fragment it, and analyse the fragment (or product) ions that are produced (D. Liebler, 2001). 
This process is known as tandem mass spectrometry (MS/MS). Triple quadrupole MS are 
particularly adept at monitoring certain parent ion – product ion combinations (or 
“transitions”), which are unique to the analyte of interest due to its specific physicochemical 
properties (D. Liebler, 2001). This makes mass spectrometry an extremely specific method 
of detection and overcomes the issue of cross-reactivity encountered in immunoassays (D. 
Liebler, 2001; D. C. Liebler & Zimmerman, 2013).  
 Though the real forte of mass spectrometry is in peptide detection, it can also be 
used as a tool for peptide quantification, and therefore, as a bioanalytical tool. Aside from the 
specificity, this technique also offers the ability to detect peptide modifications and quantify 
multiple peptides simultaneously (Hoofnagle et al., 2012). Advancements in instrument 
technology, analytical software, and development of standardised techniques have also 
aided in overcoming some of its limitations, which have traditionally included a relatively low 
sensitivity compared to immunoassays, the need for more extensive sample preparation 
prior to analysis, and dependence on operator skills (Addona et al., 2009; Kingsmore, 2006; 
D. C. Liebler & Zimmerman, 2013).  
The successful application of mass spectrometry to quantifying levels of BNP1-32 in 
human plasma has been demonstrated in a small number of published studies (Hawkridge 
et al., 2005; Miller et al., 2011; Niederkofler et al., 2008). When the results of mass 
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spectrometry and immunoassays were compared, the former showed far lower 
concentrations of circulating BNP1-32 in people with heart failure (Hawkridge et al., 2005; 
Miller et al., 2011; Niederkofler et al., 2008). This discovery reinforced the possibility of a 
relative natriuretic peptide deficiency in individuals with CHF and highlighted the importance 
of immunoreactivity between active and inactive forms of natriuretic peptides.  
In veterinary medicine, immunoassays are offered by commercial diagnostic 
laboratories to detect plasma concentrations of immunoreactive BNP-32 (Antech® Cardio-
BNP test; Antech Diagnostics) and NT-proBNP (Cardiopet® proBNP and SNAP Feline 
Cardiopet proBNP tests; IDEXX Laboratories Inc.). A handful of species-specific commercial 
immunoassay kits are also available for research purposes (Phoenix Pharmaceuticals, Inc., 
Peninsula Laboratories International, Inc., Cloud-Clone Corporation, and other internet-
based distributors); yet the vast majority of these have not been validated. Development of a 
mass spectrometry assay for veterinary patients may therefore enable further clarification of 
the role of the BNP system in the pathophysiology of CHF in dogs and cats. Moreover, it 
may contribute towards identification of a new therapeutic target for this disease.  
In order to evaluate the clinical utility of such an assay, testing it on clinical samples 
containing a wide range of concentrations of BNP1-32 and evaluating the results against 
corresponding measures of cardiorenal function would be ideal. To facilitate this, a study 
was designed in which the NPS in healthy dogs was experimentally challenged. Though 
numerous experimental methods of NPS stimulation are available, some of these (such as 
submersion in water or use of a hyperbaric chamber (Anderson et al., 1986; Rico et al., 
1989), strenuous exercise (Ohba et al., 2001), or balloon inflation of the atrium (Dietz, 2005) 
were deemed to be impractical, while others (such as induction of heart failure or 
ischemic/hypoxic damage (Dietz, 2005)) were deemed to be overly invasive. An alternative 
method was the rapid administration of high volumes of intravenous fluids. This technique 
causes a relatively non-invasive, acute, and reversible physiological challenge to the NPS 
through preload augmentation (Borgeson et al., 1998; Hori et al., 2010; Kamp-Jensen et al., 
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1990; Lobo et al., 2010; Watenpaugh et al., 1992; Weil et al., 1985) and appeared to be an 
ideal method for the purposes of this study.  
The aims of this chapter, therefore, were to: 
1. Develop a mass spectrometry method for identification and quantification of endogenous 
concentrations of active BNP1-32 in canine plasma. 
2. Evaluate the BNP system and its effects in normal dogs experiencing an acute expansion 
of intravascular volume and cardiac preload via fluid therapy. 
 
Part 1: Development of a mass spectrometry method for identification of canine 
BNP1-32 
 
Materials and Methods 
Canine synthetic BNP1-32 and canine BNP1-32 IgG antibody (Catalogue no 011-22 and  
G-011-22; Phoenix Pharmaceuticals Inc., Burlingame, CA, USA) were used as a standard 
for assay development and immunoprecipitation. All solvents and protease inhibitors were 
obtained from Sigma Aldrich (Castle Hill, NSW, Australia) unless otherwise specified. The 
following abbreviations were employed: formic acid (FA), trifluoroacetic acid (TFA), sodium 
bicarbonate (NaHCO3), trichloroacetic acid (TCA), phosphate-buffered saline (PBS), 
Acetonitrile (ACN), Ethylenediaminetetraacetic acid (EDTA), 4-(2-aminoethyl) 
benzenesulfonyl fluoride hydrochloride (AEBSF). ACN was obtained from Life Technologies 
Australia Pty Ltd. (Scoresby, VIC Australia). 
Canine serum and plasma anticoagulated with EDTA, with or without protease 
inhibitors (final concentration 5 mM AEBSF + 10 mM Benzamidine), were used during 
development of sample preparation methods. Blood samples were obtained from client-
owned, healthy, adult dogs presenting to the University Veterinary Teaching Hospital, 
Sydney during routine examinations (University of Sydney Animal Ethics Committee 
approved protocol number 2014/727).  
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  The assay development involved three stages: 1. Identification of BNP1-32 standard 
using matrix-associated laser desorption/ionization time-of-flight spectrometry (MALDI-TOF); 
2. Identification of BNP1-32 standard by online liquid chromatography coupled with 
electrospray ionisation tandem mass spectrometry (LC-ESI-MS/MS) using multiple reaction 
monitoring (MRM); and 3. Sample preparation.  
 
1. Identification of BNP1-32 standard using MALDI-TOF: 
Serial dilutions of BNP1-32 standard in 0.1% (v/v) FA and 1 x PBS were made (final 
concentrations ranging from 0.001 – 2 pM/μl). Various concentrations of MALDI matrix 
(700 μl ACN; 40 μl 2.5% (v/v) TFA; 260 μl MilliQ water; and either 2, 5, or 10 mg of α-cyano-
4-hydroxycinnamic acid per ml of matrix solution) were made. 1 μl of each dilution was 
mixed with 1 μl of the MALDI matrix on a MALDI plate and air-dried. MALDI-TOF analysis 
was performed using positive ionisation mode with a laser power of 50% with pulse rate of 
20 Hz as per standard operating procedures within the laboratory. The QSTAR Elite 
spectrometer and the Analyst QS software 2.0 (Applied Biosystems/MDS Sciex Instruments) 
were used for MS and data analysis.  
 
2. Identification of BNP1-32 standard by LC-ESI-MS/MS (MRM): 
Prior to MRM method development, 5+ and 6+ precursor ions were identified as being most 
abundant in unmodified BNP1-32 using information dependent acquisition (IDA) on a Triple 
TOF 6600 spectrometer (AB Sciex).  
Skyline v3.5 (MacCross Lab, Department of Genome Sciences, University of 
Washington) was used for MRM method development and optimisation, as well as for data 
analysis. Peptide settings were initially set to include peptide lengths of 2-35 peptides with 
no digestion or modifications. The transition settings were set to monitor the monoisotopic 
mass of both precursor and product ions. 5+ and 6+ precursor ions and product ions in the 
Y- and B- ion series with charge states of 1+, 2+, and 3+ were monitored. The collision 
energy and declustering potential were automatically selected to start. 
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 The Sciex Eksigent ekspert nano LC 415 system (AB Sciex) was coupled with the 
Sciex QTRAP 6500 mass spectrometer (AB Sciex). Serial dilutions of BNP1-32 standard in 
0.1% (v/v) FA were made (ranging from 0.0001 – 1 pM/μl). 5 μl were injected into a nano-
flow reverse-phase liquid chromatography column containing 5 μm diameter C18 matrix (Dr 
Maisch, Ammerbuch-Entringen, Germany) which was packed in-house. The mobile phase 
consisted of 0.1% (v/v) FA (Buffer A) and 80% ACN plus 0.1% (v/v) FA (Buffer B), and a  
30-minute gradient elution method (from 2 – 95% Buffer B) was used with a flow rate of 
300 nl/min as per standard operating procedures in the laboratory. Nanospray ionisation was 
performed using the negative ion mode with ion spray voltage 2700 V, Curtain gas 25 units, 
collision gas set to high, and interface heater temperature set to 200°C. The entrance 
potential was set to 10, with collision cell exit potential set to 24.  
 Method optimisation (D. C. Liebler & Zimmerman, 2013) was performed through the 
selection of the top three transitions from each precursor-product charge states to monitor, 
followed by collision energy optimisation. Scheduling was not performed as only one peptide 
was being monitored. Further optimisation was performed through inclusion of methionine 
oxidation and deamination modifications.  
 
3. Sample preparation 
A variety of sample preparation methods were explored for the identification of BNP1-32 in 
plasma:  
a) Bulk purification using C4, C8, C18, or HLB sorbent material 
b) Reduction, alkylation, and digestion with Endoproteinase Asp-N (Product P3303; Sigma 
Aldrich, Saint Louis, MO, USA) followed by bulk purification using C18 sorbent material. 
c) Solvent precipitation using TCA, Acetone (L. Jiang et al., 2004), ACN, or ACN/TFA 
(Chertov et al., 2004; Merrell et al., 2004) followed by bulk purification using C8 or C18 
sorbent material. 
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d) Immunoprecipitation using protein A beads (MSIA D.A.R.T.’S ™ Tips, Thermo Fisher; 
Dynabeads ™ Protein A, Thermo Fisher Scientific) cross-linked to canine BNP1-32 antibody, 
with or without final purification using C8 material. 
Method optimisation for immunoprecipitation involved adjustments to the number of 
wash steps; quantities of protein A beads, antigen, and antibody used; incubation 
periods for both antibody loading and antigen loading; amount of detergent in the 
wash solution; and inclusion of cross-linking of the antibody. 
 For the final method, 50 μl (1.5 mg) of Dynabeads™ were washed with wash solution 
(PBS with 0.01% Tween-20), followed by a 30-minute incubation on a rotating 
platform with 200 μl of PBS containing 10 μg of BNP1-32 IgG antibody. Beads were 
washed once with wash solution, once with 0.2 M triethanolamine (pH 8.0), and then 
antibodies were cross-linked with 200 μl of 10 mM Dimethyl pimelimidate (DMP; Life 
Technologies Australia Pty Ltd., Scoresby, VIC Australia) using an incubation time of 
30 minutes on a rotating platform. After removing excess solution, 200 μl of 50 mM 
Tris (pH 7.6) was added to the beads and mixed on a rotating platform for 15 minutes. 
The tris solution was removed, and the beads were washed twice with wash solution. 
300 μl of PBS containing 100 pM BNP1-32 was added to the beads and incubated at 
4°C overnight (~ 12 hours) on a rotating platform. This was followed by a wash with 
PBS, then three washes in water before elution with 50% (v/v) ACN and 0.1% (v/v) 
FA, and MALDI-TOF analysis.   
e) Nonspecific albumin and IgG depletion (ProteoPrep® Blue Albumin and IgG Depletion Kit; 
Sigma Aldrich, Saint Louis, MO, USA).  
Nonspecific albumin and IgG depletion was attempted using the ProteoPrep® Blue 
Albumin and IgG Depletion Kit using the manufacturer’s guidelines. Frozen canine 
plasma and serum samples were defrosted, vortexed, and centrifuged. Briefly, 0.4 ml 
of suspended albumin and IgG medium was added to a spin column and washed 
twice with 0.4 ml of the equilibration buffer. The column was centrifuged at 10,000 
rpm for 20 – 40 seconds between each step. A 20 μl aliquot of plasma or serum was 
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added to the washed and dried medium and incubated at room temperature for 10 
minutes. Following centrifugation for 60 seconds, the flow-through was reapplied, 
and a second incubation and centrifugation step was performed. 100 μl of 
equilibration buffer was used to wash the medium, and the flow through from 
centrifugation was added to the twice depleted sample.  
Elution of bound proteins was performed with 150 μl of 4x sample buffer consisting of 
125 mM Tris (pH 6.8), 30% (v/v) glycerol, 2% (w/v) SDS, 10% (v/v) β-
Mercaptoethanol, and bromophenol blue. After centrifuging for 60 seconds, a further 
150 μl of 4x sample buffer were applied to the medium and centrifuged. The eluates 
were pooled.  
Samples were loaded onto a 12% 1D SDS PAGE gel, and electrophoresis was 
performed using 125 V for 80 minutes. The gel was stained with Coomassie Blue and 
imaged using the ChemiDoc™ MP Imaging System (Bio-Rad Laboratories Pty Ltd., 
Gladesville, NSW Australia). 
 
Results 
The predicted molecular weight for the singly-charged BNP1-32 was 3564.84 Daltons and 
1782.42 for the double-charged ion. In 0.1% FA (v/v), the lowest limit of detection (LLOD) for 
BNP1-32 standard using MALDI-TOF was 0.1 pM/μl (Figure 1). When BNP1-32 standard 
was reconstituted in 1 x PBS, the LLOD increased to 1 pM/μl. Adjusting the concentrations 
of the α-cyano-4-hydroxycinnamic acid improved appearance of the spectrum slightly 
(Figure 2); however, sensitivity (as measured by LLOD) could not be improved any further. 
In contrast, the sensitivity for detection of the BNP1-32 standard in 0.1% FA (v/v) was higher 
using LC-ESI-MS/MS. Following optimisation of the method, the LLOD was 0.0001 pM/μl 
(Figure 3). The final list of transitions, including the declustering potential and collision 
energy, is listed in Table 1. 
 A variety of sample preparation methods were attempted for purification of BNP1-32 
from plasma. Preliminary testing using BNP1-32 standard dissolved in 1 x PBS showed 
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reliable capture of BNP1-32 using C8 sorbent material, some capture of BNP1-32 with C18 
material, but no capture with C4 or HLB material (Figure 4). Subsequently, solvent 
precipitation of BNP1-32 spiked plasma samples, followed by purification using C8 or C18 
material, was trialled. However, none of these methods provided reliable recovery of  
BNP1-32 from plasma. An attempt at digesting BNP1-32 using Endoproteinase Asp-N was 
made; however, digestion was not successful.  
 A targeted approach of purification was also performed through immunoprecipitation 
methods using a commercially available canine BNP1-32 antibody cross-linked to beads 
coated with Protein A. However, these methods failed to recover both synthetic and 
endogenous BNP1-32. This was due to a lack of adequate antigen-antibody interaction. As 
an alternative, sample enrichment using a commercially available kit (ProteoPrep® Blue 
Albumin and IgG Depletion Kit; Sigma Aldrich, Saint Louis, MO, USA) for selective removal 
of albumin and immunoglobulins was attempted. Unfortunately, this kit did not provide 
adequate removal of albumin and immunoglobulins from canine plasma samples (Figure 5).  
Thus, a mass spectrometry assay for detection of clinically significant concentrations 
of canine BNP1-32 in plasma could not be made. 
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Figure 1: MALDI-TOF spectra of a 1 μl spot of BNP1-32 equivalent to 1 pM/μl (A), 0.1 
pM/μl (B), 0.01 pM/μl (C), and 0.001 pM/μl (D) BNP1-32 standard in 0.1% FA. Arrows 
point to BNP1-32 spectra (single and double charged ions). 
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Figure 2: MALDI-TOF spectra of a 1 μl spot of 2 pM/μl BNP-32 standard in PBS using 
MALDI-matrix containing different concentrations of α-cyano-4-hydroxycinnamic acid 
(2mg, 5mg, and 10mg per ml of matrix – A, B, and C respectively). Arrows point to 
BNP1-32 spectra (single and double charged ions).  
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Figure 3: Transition list, chromatogram, and peak areas for the top 42 transitions for 
BNP1-32 using the 5+ and 6+ precursor ions on a sample containing 0.0001 pM/μl 
BNP1-32 standard in 0.1% FA (v/v). Data analysis was performed using Skyline 
software (v3.5).  
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Table 1: Top 42 transitions for BNP1-32 following collision energy optimisation and 
addition of metoxidation and deamination modifications. 
Precursor m/z Product m/z Dwell time Declustering Potential Collision Energy 
714.174614 952.503297 30 83.2 37.4 
714.174614 895.481833 30 83.2 41.4 
714.174614 792.472649 30 83.2 41.4 
714.174614 868.48543 30 83.2 35.4 
714.174614 790.434875 30 83.2 40.4 
714.174614 802.391964 30 83.2 38.4 
714.174614 952.512961 30 83.2 37.4 
714.174614 909.81464 30 83.2 37.4 
714.174614 749.046959 30 83.2 39.4 
595.313391 792.472649 30 74.5 35 
595.313391 678.429721 30 74.5 34 
595.313391 712.326913 30 74.5 35 
595.313391 705.382111 30 74.5 35 
595.313391 661.866097 30 74.5 33 
595.313391 646.290853 30 74.5 31 
595.313391 707.396752 30 74.5 34 
595.313391 655.363048 30 74.5 33 
595.313391 749.046959 30 74.5 33 
720.57258 790.434875 30 83.6 41.8 
720.57258 909.81464 30 83.6 39.8 
720.57258 818.386879 30 83.6 41.8 
600.64503 678.429721 30 74.9 34.3 
600.64503 744.316743 30 74.9 35.3 
600.64503 680.318458 30 74.9 32.3 
714.371418 952.840966 30 83.2 36.5 
714.371418 910.142645 30 83.2 37.5 
714.371418 749.046959 30 83.2 41.5 
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Table 1 (Continued) 
Precursor m/z Product m/z Dwell time Declustering Potential Collision Energy 
595.477394 678.429721 30 74.5 34 
595.477394 705.874119 30 74.5 32 
595.477394 749.046959 30 74.5 30 
717.570401 793.456665 30 83.4 39.6 
717.570401 952.840966 30 83.4 38.6 
717.570401 910.142645 30 83.4 38.6 
598.143213 678.429721 30 74.7 35.1 
598.143213 664.323543 30 74.7 33.1 
598.143213 654.28831 30 74.7 34.1 
720.769384 790.926883 30 83.7 40.8 
720.769384 818.386879 30 83.7 41.8 
720.769384 786.387737 30 83.7 41.8 
600.809032 678.429721 30 74.9 34.3 
600.809032 744.316743 30 74.9 35.3 
600.809032 680.318458 30 74.9 31.3 
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 Figure 4: MALDI-TOF spectra of a 1 μl spot of BNP1-32 eluate following C18 (A, 1 
pM/μl), C8 (B, 1 pM/μl), C4 (C, 2 pM/μl) and HLB (D, 2 pM/μl) preparation. Arrows point 
to BNP1-32 spectra (single and double charged ions). 
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Figure 5: 1D-SDS-PAGE of untreated plasma (P1 – P4; 90, 45, 30, and 15 μg protein 
loading respectively), as well as the “depleted” flow-through (P5 – P6; 50 and 25 μg 
protein loading respectively), and the eluate containing bound proteins (P7 – P8; 20 
and 10 μg protein loading respectively) following treatment of plasma with 
ProteoPrep® Blue Albumin and IgG Depletion Kit. There were no appreciable 
differences between the untreated plasma, flow-through, and eluates. 
 
Discussion 
The aim of this part of the chapter was to create a novel assay for detection of specific 
BNP1-32 in canine plasma. Unfortunately, this aim was not achieved, with several 
unanticipated challenges and limitations being encountered throughout the course of assay 
development.  
 Intact BNP1-32 could be identified with both MALDI-TOF and LC-ESI-MS/MS, with 
the latter showing greater sensitivity towards its detection than the former. High sensitivity of 
the assay was essential due to the extremely low concentrations of circulating peptide 
expected in normal canine plasma. Reported physiological concentrations of 
immunoreactive BNP-32 range from 200 – 300 pg/ml (or 0.0007 – 0.084 fM/μl) 
(DeFrancesco et al., 2007; Forfia et al., 2007; Grantham et al., 1997), dictating the 
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requirement for at least 1 ml of plasma being concentrated 2 – 1,000 times before biological 
concentrations of BNP1-32 would be detectable using LC-ESI-MS/MS using the existing 
techniques. Yet simply concentrating the samples would be inadequate due to the presence 
of substances in plasma which may interfere with the mass spectrometry through signal 
suppression or by reducing the concentration of the analyte captured by the in-line liquid 
chromatography (e.g. salts, proteins); some of these can also degrade or modify BNP1-32 
(e.g. enzymes). As such, methods to improve both the mass spectrometry sensitivity and 
sample preparation were investigated.  
 Of the two mass spectrometry methods used (MALDI-TOF and LC-ESI-MS/MS), 
method refinement was mostly performed on the latter due to its higher sensitivity. This 
involved selecting transitions with highest peak areas, collision energy optimisation, and 
inclusion of methionine oxidation and deamination modifications as these were observed in 
older BNP1-32 standards. From here, trimming of this transition list, increasing the dwell 
time for each transition, and altering some of the mass spectrometer settings such as the ion 
spray voltage, curtain gas, and entrance/exit potentials could have also been attempted. In 
addition, the liquid chromatography conditions such as the gradient and column material 
could have been altered. However, it was deemed that these would be best performed 
following optimisation of sample preparation techniques.  
 Sample preparation plays a large role in peptide mass spectrometry using plasma 
samples due to the extreme dynamic range of proteins, which span over eleven orders of 
magnitude (R. Cunningham et al., 2012). Furthermore, the top fourteen proteins, including 
albumin and immunoglobulins, comprise over 95% of the plasma proteins and are present in 
concentrations of 55 – 75 mg/ml; in contrast, proteins and peptides of interest can often be 
present at the far lower end of the spectrum, in concentrations closer to pg/ml. In order to 
overcome this, several techniques for plasma preparation including non-specific enrichment 
or depletion techniques, separation techniques (such as gel electrophoresis or liquid 
chromatography), and specific immunoprecipitation techniques (Luque-Garcia & Neubert, 
2007) were explored.  
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 Non-specific enrichment or depletion techniques offered the advantage of being easy, 
inexpensive, and readily accessible. The simplest form of this was the use of solid-phase 
extraction (SPE) cartridges for de-salting, extracting smaller peptides, and concentrating the 
sample. BNP1-32 is basic, with mild to moderate hydrophilic properties as suggested by the 
gravy index of -0.39 (Gasteiger et al., 2003; Kyte & Doolittle, 1982). At around 3566 Daltons, 
it is also a small- to medium-sized peptide. These properties suggested that reverse-phase 
SPE using materials such as C18, C8, or HLB would be ideal. Of these, C8 provided less 
retention of non-polar compounds, and as such, appeared most appropriate. This was 
confirmed through the finding that C8 material provided the most consistent capture of 
BNP1-32. However, this non-specific approach was likely to result in inadequate depletion of 
impurities and interfering substances; therefore, this technique was deemed most 
appropriate to use in combination with other techniques of sample preparation (for example, 
as a final de-salting step, or using C8 material with reversed-phase chromatography for the 
in-line LC prior to mass spectrometry). 
 Options for non-specific depletion included solvent precipitation and use of 
substances that bind albumin and non-specific immunoglobulins. Solvent precipitation 
involves addition of organic solvents to precipitate larger plasma proteins whilst leaving 
smaller peptides in the solution. In this process, smaller peptides bound to larger proteins 
can also be dissociated and retrieved. Although this method was appealing, the recovery of 
BNP1-32 using this technique was inconsistent or poor. Potential reasons for this include 
loss of the peptide via precipitation or loss in the recovery, drying, reconstitution, or final 
purification of the solution. Binding and depletion of albumin and non-specific 
immunoglobulins was also attempted with a commercially available kit that utilised a blue 
dye-based technology for albumin and protein G agarose for immunoglobulins. Unfortunately, 
this kit did not work on canine plasma samples, and a canine-specific kit was not available.  
 With these simple techniques proving to be ineffective, and because prior 
publications utilised immunoprecipitation techniques for sample preparation (Hawkridge et 
al., 2005; Miller et al., 2011; Niederkofler et al., 2008), the latter avenue was explored. 
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Immunoprecipitation offers the unique advantage of targeted peptide purification.  
For BNP1-32, this technique would result in capture of both the active BNP1-32 and its 
less/inactive fragments and proform; however, coupled with a mass spectrometer for 
detection, only the specific BNP1-32 would be identified. This technique was also 
unsuccessful due to the lack of adequate antibody-antigen interaction. There are numerous 
potential factors contributing towards this result, including the temperature, pH, and choice of 
antibody (He, 2013). In addition, non-specific binding to the antibodies can reduce capture of 
the desired analyte. In one publication, this was overcome through the use of another 
immunoprecipitation step to remove non-specific immunoglobulins prior to targeting  
BNP1-32 (Niederkofler et al., 2008). It is important to note that antibodies used in these 
publications were raised in-house, as opposed to the commercially available antibodies used 
in the present study. The degree of trial and error involved in the development of this 
technique necessitated time and budgets that were not within the scope of this project. Yet 
given the low concentrations of peptide present and the high degree of complexity of plasma, 
this is likely the most promising technique for achieving adequate sample preparation for 
detection of BNP1-32 using mass spectrometry. 
 Other forms of sample preparation may or may not provide successful recovery of 
BNP1-32. With the low concentrations of endogenous BNP1-32 and its low molecular weight, 
gel electrophoresis was deemed to be an inaccurate and unreliable method of separation of 
peptides of interest. Various techniques of liquid chromatography could have been applied, 
with some of these likely to facilitate a reasonable degree of fractionation or purification of 
BNP1-32; however, the lack of readily available resources and expertise, as well as the 
anticipated time and costs involved in developing this technique, ruled out this option. One 
option that could have been explored further was the use of a centrifugal filter. Some 
problems with this technique include filter failure or clogging and the possibility of peptide 
loss if they become entrapped in the captured protein pellet or are bound to larger proteins 
that are captured. Nevertheless, centrifugal filters or chromatography techniques may be 
another step in the workflow which could be explored in future projects. 
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 Had adequate sample preparation and optimisation of mass spectrometry been 
achieved, absolute quantitation of BNP1-32 would have been performed through the use of 
a heavy isotope-labelled BNP1-32 as an internal standard. Validation of the final assay 
would have involved an assessment of accuracy, precision, quantification limits, linearity, 
and range within our laboratory. Yet ultimately, the utility and practicality of such an assay 
are important factors to weigh against the time and resources required for ongoing assay 
development. With the degree of sample preparation involved, the duration of time required 
to run each sample (~ 1 – 1.5 hours for the LC-ESI-MS/MS method), and the maintenance 
involved in the smooth operation of the LC and MS, it is likely that this type of assay would 
not be practical for large-scale commercial or diagnostic purposes. Despite this, there is 
growing interest in mass spectrometry as a diagnostic tool in veterinary research and 
medicine. Though assay development was not completed during the course of this project, it 
is hoped that the information acquired through this project may contribute towards any future 
attempts.  
 
Part 2: Evaluation of the BNP system and its effects in healthy dogs receiving short-
term intravenous fluids 
 
Materials and Methods 
Animals 
This study was conducted over two weeks in November, 2015 on eight healthy adult dogs, 
which were sourced from a contract research organisation. Prior to enrolment, each dog 
underwent a physical examination, standard echocardiography, three-view chest 
radiographs, and clinical pathology (PCV, TP, electrolytes, BUN, Creatinine, and USG) to 
ensure no significant physical, cardiorespiratory, or renal abnormalities were present. Six 
Beagles and two Kelpie cross breeds were enrolled. There was an even distribution of sexes, 
with three entire males and females and one desexed male and female. The median age 
was 6.5 years (range 2 – 7 years), and the median weight was 13.9 kg (range 12.6 –
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 21.7 kg). The protocol for this study was approved by the University of Sydney Animal 
Ethics Committee (project number 2015/873).  
 
Schedule of events 
On each day of sampling, two dogs (one male and one female) underwent procedures. All 
dogs were fasted for a minimum of 10 hours prior to sampling.  
 Dogs were sedated with 0.2 mg/kg of methadone subcutaneously. Anaesthesia was 
induced with propofol intravenously to effect and maintained with isoflurane and 100% 
oxygen delivered through a cuffed endotracheal tube. Continuous manual ventilation using a 
ventilator (Merlin Small Animal Ventilator, Vetronics Services Ltd, Abbotskerwell, Devon, 
TQ12 5NF, UK) set at a respiratory rate of 15 breaths per minute, tidal volume of  
10 – 15 ml/kg, and peak inspiratory pressure of ~ 10 mmHg was performed throughout 
anaesthesia in all dogs. Dogs were placed in right lateral recumbency and catheterised with 
two 18 g 32 mm intravenous catheters placed in the cephalic veins, a double-lumen jugular 
catheter (B.Braun Certofix Duo; B. Braun Australia Pty Ltd, Bella Vista, NSW Australia) 
placed in the left jugular vein, a 24 g 19 mm arterial catheter placed in an auricular artery, 
and an 8 Fr 55 cm indwelling urinary catheter (Surgivet Premium Foley Catheter; Smiths 
Medical, St Paul, MN USA). The arterial catheter was connected to a pressure transducer 
(Datex-Ohmeda S/5 Monitor, Helsinki, Finland) via an extension line filled with saline for 
evaluation of direct arterial blood pressure measurement. The distal (open) lumen of the 
jugular catheter was connected to a manometer via an extension line. This was filled with 
saline, and the zero mark on the manometer was placed at the level of the right atrium for 
evaluation of the central venous pressure (CVP). The urinary catheter was connected to an 
extension line with a 60 mL syringe attached to the end for collection of urine.  
The timeline of study events is depicted in Figure 6. Following acquisition of baseline 
values, Hartmann's solution was administered at 90 ml/kg/h for 40 minutes via the two 
peripheral intravenous catheters. Blood (8 – 10 ml) and urine (5 – 10 ml) samples were 
collected for evaluation of plasma NT-proBNP, specific BNP1-32, immunoreactive BNP-32, 
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and cyclic guanosine monophosphate (PcGMP) concentrations; biochemistry (PCV, TP, 
BUN, creatinine, electrolytes), and urinary cGMP (UcGMP) and specific gravity (USG). Upon 
completion of sampling, all catheters were removed, and dogs were recovered from 
anaesthesia.  
 
 
 
Figure 6: Timeline of events. Abbreviations: Premed – premedication; GA – general 
anaesthesia; CVP – central venous pressure; HR – heart rate; BP – blood pressure; 
Echo – echocardiogram; UOP – urine output; biochem – biochemistry including PCV, 
TP, BUN, creatinine, electrolytes; USG – urine specific gravity. 
 
Echocardiography, blood pressure, heart rate, and CVP 
Echocardiography was performed as previously described in Chapter 2. The left atrial (LA) 
and aortic (Ao) diameters were measured, and the left ventricular indices consisting of the 
thickness of the interventricular septum in systole and diastole (IVSs, IVSd), left ventricular 
internal diameter in systole and diastole (LVIDs, LVIDd), and thickness of the left ventricular 
posterior wall in systole and diastole (LVPWs, LVPWd) were obtained and normalised to the 
body weight (Cornell et al., 2004). The left atrium to aorta ratio was calculated through 
dividing LA by Ao (LA:Ao), and fractional shortening (FS) was calculated using the formula: 
(LVIDd – LVIDs) / LVIDd. End systolic (ESV) and end diastolic (EDV) volumes were 
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calculated using the Teichholz formula (Teichholz et al., 1976). Stroke volume (SV) was 
calculated as EDV – ESV, and cardiac output (CO) was calculated as (SV * Heart rate) / 
body weight. 
 Blood pressure (systolic – SBP; mean – MBP; diastolic – DBP) and heart rate (HR) 
were recorded off the pressure transducer and pulse oximetry monitor respectively. Three 
consecutive or near-consecutive readings were recorded and averaged at each time point. 
For CVP, the catheter was flushed and the manometer was primed with saline each time a 
reading was taken. The lowest measurement, which was stable for at least 5 seconds, was 
recorded at each time point.  
 
Sample handling and storage 
All blood samples were obtained via the proximal (side) lumen of the jugular catheter. 
Following acquisition, they were placed into chilled plastic blood tubes containing EDTA and 
centrifuged immediately in a cooled centrifuge (at or below 4°C) at 5000 RCF for 5 minutes. 
For NT-proBNP analysis, the plasma was transferred into another blood tube containing 
EDTA; for immunoreactive BNP-32 analysis, it was mixed with a pre-prepared mixture of  
4-(2-Aminoethyl) Benzenesulfonyl Fluoride (AEBSF) and Benzamidine (Sigma Aldrich, 
Castle Hill, NSW Australia) using a previously reported protocol (Niederkofler et al., 2008) for 
protease inhibition (final concentration of 5 mM AEBSF and 10 mM Benzamidine). All 
samples were placed into a freezer without delay and stored at or below -30°C until the time 
of analysis.  
 Blood samples used for biochemistry were placed into plastic blood tubes containing 
lithium heparin and centrifuged for analysis, which occurred within four hours of collection. 
PCV and biochemistry were performed using the in-house laboratory (ABL800 Basic blood 
gas analyser; Radiometer Pacific Pty. Ltd., Mt Waverley, VIC Australia. Catalyst One® 
Chemistry Analyser; IDEXX Laboratories Inc., Rydalmere, NSW Australia) at the University 
Veterinary Teaching Hospital, Sydney. 
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 Urine samples were obtained from the urinary collection system after quantification of 
urine production. The samples were aliquoted and stored frozen at or below -30°C until the 
time of analysis. 
 
NT-proBNP, BNP-32, and cGMP immunoassays 
Plasma NT-proBNP concentrations were measured at a commercial laboratory using a 
validated (Cahill et al., 2015) enzyme-linked immunosorbent assay (Cardiopet® proBNP 
test; IDEXX Laboratories Inc., Brisbane, QLD Australia). Plasma immunoreactive BNP-32 
concentrations were measured at a commercial laboratory using a validated (Schellenberg 
et al., 2008) radioimmunoassay kit made by the company (Canine BNP-32 
Radioimmunoassay RK-011-22; Phoenix Pharmaceuticals Inc., Burlingame, CA, USA). The 
samples were transported frozen to the laboratory, and each sample was assayed in 
duplicate. The analysis was completed over two days. Specific BNP1-32 concentrations 
could not be quantified as assay development using mass spectrometry was unsuccessful. 
 Plasma and urine cGMP concentrations were assayed in triplicate using a 
commercially available competitive enzyme-linked immunosorbent assay kit using the 
manufacturer’s guidelines (ParameterTM cGMP Assay SKGE003; R&D Systems Inc., 
Minneapolis, MN, USA). Briefly, urine and plasma samples were thawed at room 
temperature, and 25 μl of each sample was mixed with 475 μl of the provided diluent. In 
some samples, final concentrations exceeded the range of the assay. These were further 
diluted 1:4 using the diluent provided. 100 μl of each standard and sample were mixed with 
50 μl of the cGMP conjugate, followed by 50 μl of the primary antibody solution. After 
incubating for three hours on a microplate shaker at 450 rpm at room temperature, wells 
were washed four times, and 200 μl of substrate solution were added to each well. This was 
incubated for 30 minutes in the dark, and 50 μl of stop solution were added. The plate was 
read using a TECAN Infinite® M1000 PRO microplate reader set at 450 and 540 nm once 
uniform colour change was achieved.  
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 Readings made at 540 nm were subtracted from those at 450 nm. A standard curve 
was generated using a 4-parameter logistic curve fit using Graphpad Prism V7.02 
(GraphPad Software Inc., La Jolla, CA, USA). Measured concentrations were derived using 
this standard curve and multiplied by the dilution factor. The results of each triplicate were 
averaged to obtain the final result. All standard curves had R2 > 0.99. The %CV of triplicate 
standards and samples were < 10%, and the %CV of standards between plates was < 10% 
for all but the highest concentration of standard (16%). The accuracy of standards ranged 
from 90 – 115% at concentrations in the relevant range of the samples.  
 
Statistical analysis  
Analysis of data was performed using GraphPad Prism and GenStat 16th Edition (VSN 
International Ltd., Hemel Hempstead,UK). 
Descriptive analysis of cardiorenal, endocrine, and biochemical variables was 
performed through visual inspection of graphs displaying the median and interquartile range 
of effects over time.  
Prior to statistical testing, normality of all measured variables was assessed through 
evaluation of the Q-Q plot. Correlations between measured variables were assessed through 
visual inspection of correlation plots. Where a monotonic relationship appeared to exist, 
Spearman’s rank-order correlation was performed. For items which were only measured at 
baseline and 60 minutes (PCV, USG, Na, K, Cl, BUN, Crea), paired t-tests were performed 
to evaluate observed changes.  
Where the data were not normally distributed, log (Ao, BNP-32, DBP, MBP,  
NT-proBNP, TP, UOP, urinary cGMP, urinary excretion of cGMP, CO, weight-normalised 
IVSd and LVIDd) and power (LA:Ao) transformations were performed to resemble normality. 
A linear mixed model with restricted maximal likelihood estimation (REML) was performed to 
assess for significant deviations of the variables from baseline for all those in which > 2 
readings were taken during the study period. For this purpose, the following model was 
used: 
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Ŷ = Time (fixed effect) + Dog ID (random effect) + ε 
Where the overall effect of time was significant (p < 0.05), least square differences (LSD) 
were further evaluated. The significance level was set to 5% for the LSD. Assumptions of the 
model were assessed through visual inspection of residual plots.  
 
Results 
Cardiorenal effects of fluid administration 
Measures of preload and intravascular volume included CVP, LA size (absolute and ratio 
between LA:Ao), and LVIDd. IVF loading caused an immediate and significant rise in CVP 
which gradually increased over the 40-minute duration of fluid loading (Figure 7). The CVP 
reduced upon cessation of fluid administration but remained significantly elevated compared 
to baseline. This was mirrored by the sequential TP concentrations, which decreased 
precipitously during the 40-minute duration of fluid loading, then partially recovered upon 
cessation of fluid loading (Figure 7). There was a strong and significant negative correlation 
between the CVP and serial TP values (Spearman’s r = -0.78, 95% CI -0.86 to -0.66; 
p < 0.0001).  
There was a small but significant increase in LVIDd which persisted for 20 minutes 
after discontinuation of fluid administration (Figure 7). The LA:Ao ratio did not increase 
significantly, despite a moderate and positive correlation between the CVP and LA:Ao values 
(Spearman’s r = 0.52, 95% CI 0.32 – 0.67; p < 0.0001). A monotonic relationship did not 
exist between the CVP and wnLVIDd or between the LA:Ao and wnLVIDd. 
Changes in intravascular volume were also expected to influence plasma 
concentrations of PCV, BUN, and Crea. These reduced between baseline and 60 minutes; in 
contrast, plasma electrolytes (Na, K, Cl) remained static (Figure 8). 
Measures of left ventricular systolic function included LVIDs and FS. Neither these, 
nor other measures of left ventricular function (LVPW and IVS), were observed to change 
from baseline (Figure 8). 
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Figure 7: Change in CVP, TP, LVIDd, and LA:Ao ratio over time. The median and 
interquartile range were plotted. * denotes significant deviations from baseline 
(p < 0.05). Abbreviations: CVP = central venous pressure; TP = total plasma protein; 
LVIDd = left ventricular internal diameter in diastole; LA:Ao = left atrial to aorta ratio.  
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Figure 8: Change in LVIDs, FS, LVPWs, LVPWd, IVSs, IVSd, PCV, BUN, Crea, Na, K, 
and Cl over time. The median and interquartile range were plotted. * denotes 
significant deviations from baseline (p < 0.05). Abbreviations: LVIDs = left ventricular 
internal diameter in systole; FS = fractional shortening; LVPWs/d = left ventricular 
posterior wall thickness in systole/diastole; IVSs/d = interventricular septum 
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thickness in systole/diastole; PCV = packed cell volume; BUN = blood urea nitrogen; 
Crea = creatinine; Na = sodium; K = potassium; Cl = chloride.  
 
 There was a small drop in SBP that was noted when fluid loading was commenced 
(Figure 9). However, overall, BP and HR were not significantly affected by fluid loading.  
 CO was also calculated as a measure of overall cardiovascular performance. This 
was observed to increase significantly from baseline between 20 – 60 minutes, after which it 
declined back to baseline levels (Figure 9). Although statistical significance was reached, 
there was a large degree of inter-dog variability in this measurement.  
Measures of urinary effects included urine output (UOP) and USG. UOP increased 
throughout the duration of fluid administration, reaching maximal production at 60 minutes 
(Figure 9). UOP remained significantly elevated at the end of the study period. A drop in 
USG was observed between baseline and 60 minutes (Figure 9).  
There was no obvious linear correlation between UOP and CVP, MBP, FS, or CO.  
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Figure 9: Change in BP, HR, CO, UOP, and USG over time. The median and 
interquartile range were plotted. * denotes significant deviations from baseline. 
Abbreviations: SBP, MBP, DBP = systolic, mean, and diastolic blood pressure;  
HR = heart rate; CO = cardiac output; UOP = urine output; USG = urine specific gravity. 
 
Immunoassays of NT-proBNP, BNP-32, and cGMP  
Plasma NT-proBNP concentrations were below the lowest limit of detection throughout the 
entire sampling period in one dog (Dog F). However, levels of plasma immunoreactive  
BNP-32, plasma cGMP, and urinary cGMP were similar to concentrations detected in other 
dogs in the study. In one dog (Dog C), plasma concentrations of cGMP were around 10-fold 
higher than in others. Plasma concentrations of immunoreactive BNP-32 were marginally 
higher than those observed in other individuals, but concentrations of NT-proBNP and 
urinary cGMP were similar to concentrations detected in other dogs in the study. PCV, TP, 
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USG, BUN, electrolytes, and Crea, physical exam, and haemodynamic measurements in 
these two individuals were not different to those observed in other dogs in the study.  As 
such, only the NT-proBNP concentrations for Dog F and plasma cGMP concentrations for 
Dog C were removed from general analysis.  
In plasma, concentrations of NT-proBNP were around 10-fold greater than that of 
BNP-32. NT-proBNP decreased significantly from baseline during the period of fluid 
administration (Figure 10). In contrast, concentrations of BNP-32 did not change during or 
after fluid administration (Figure 10). There was a weak, positive correlation between 
concentrations of NT-proBNP and BNP-32 (Spearman’s r = 0.35, 95% CI 0.11 – 0.56; 
p = 0.0049).  
Urinary concentrations of cGMP (UcGMP) were 10 to 20-fold greater than that of 
plasma cGMP (PcGMP). Concentrations were highest in the first 30 minutes of fluid loading 
and reduced from around 40 minutes (Figure 10).  Urinary excretion of cGMP (UEcGMP - 
taking into account urine output and body weight) was higher than baseline levels between 
20 – 80 minutes, with peak levels reached at 30 minutes, followed by a gradual reduction 
back to baseline levels over the remainder of the study period (Figure 10). PcGMP reduced 
from baseline, reaching lowest concentrations at 30 minutes (Figure 10). Significantly lower 
concentrations remained at the end of the study period. The PcGMP and UEcGMP showed 
no correlation. 
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Figure 10: Change in NT-proBNP, BNP-32, UcGMP, UEcGMP, and PcGMP over time. 
The median and interquartile range were plotted. * denotes significant deviations from 
baseline (p < 0.05). Abbreviations: NT-proBNP = plasma N-terminal proBNP 
concentrations; BNP-32 = plasma immunoreactive BNP-32 concentrations;  
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UcGMP = urinary cGMP concentrations; UEcGMP = urinary excretion of cGMP; 
PcGMP = plasma cGMP concentrations. 
 
Measures of cardiovascular effects (CVP, FS, and CO) and measured urinary 
variables (UOP, PcGMP, UEcGMP) were not obviously correlated with NT-proBNP and 
BNP-32. A moderately strong, non-linear association between UEcGMP and CVP was 
present (Spearman’s r = 0.53, 95% CI 0.33 – 0.68; p < 0.0001); in contrast, UEcGMP 
showed negligible correlations with FS, CO, and MBP. There was a moderate, negative 
correlation between PcGMP and CVP (Spearman’s r = -0.41, 95% CI -0.60 to -0.17, 
p = 0.0009), but no obvious correlations were appreciable between PcGMP and MBP, FS, or 
CO. 
 
Discussion 
The aim of this part of the chapter was to utilise a novel mass spectrometry assay to 
evaluate the BNP system in normal dogs receiving short-term, high-rate, intravenous fluids. 
In the absence of this specific BNP1-32 assay, a complete evaluation of the BNP system 
was not possible. Immunoassays of BNP-32 and NT-proBNP were performed; however, it 
was not possible to test for cross-reactivity with inactive or less active fragments of BNP-32 
or the precursor molecule, proBNP1-108. Nevertheless, interesting observations were made 
regarding the cardiorenal and endocrine effects of rapid fluid administration.  
Administration of intravenous fluids caused measurable changes to the 
cardiovascular system as anticipated. Following initiation of therapy, an increase in CVP, 
and therefore, an increase in right atrial and ventricular preload, was detected. The resulting 
rise in intravascular volume and ensuing haemodilution were well-represented by the strong, 
negative correlation between CVP and TP. There was also an increase in wnLVIDd, which 
supports the presence of increased preload to the left ventricle; however, this was not 
proportional to CVP, as evidenced by the lack of an obvious correlation. In contrast, the 
LA:Ao showed a moderate and positive monotonic relationship to CVP; however, it did not 
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significantly increase from baseline. These echocardiogram-derived factors are prone to 
higher degrees of error and variability than direct measurements such as CVP; nevertheless, 
the overall combination of rise in CVP and wnLVIDd, as well as the trend seen in LA:Ao, 
would suggest that a global increase in preload was achieved with intravenous fluids in this 
study.  
The increase in intravascular volume was expected to cause a temporary rise in BP 
and reduction in HR due to activation of the baroreceptor reflex. Surprisingly, the BP 
appeared to reduce slightly in the first 10 minutes of fluid loading, and the HR appeared to 
increase throughout the duration of loading. These effects may have been related to 
anaesthesia or the use of positive pressure ventilation. In addition, the rise in preload was 
expected to increase systolic function due to Starling’s law; unfortunately, this was difficult to 
assess as measures of systolic function in this study (FS, LVIDs) were highly preload-
dependent.  Even so, the overall cardiac performance, as measured by CO, increased – 
likely due to the combination of nonsignificant trends observed in HR, BP, and FS.  
Despite evidence of appropriate increases in preload, the reductions in NT-proBNP 
and BNP-32 concentrations observed during the study were unexpected and raise the 
question as to whether the BNP system was adequately stimulated in the present study. This 
was in contrast to findings of previous reports using a similar model of challenging the BNP 
system (Hori et al., 2010; Lobo et al., 2010), in which increases in NT-proBNP and BNP-32 
concentrations were observed. A potential cause for the initial reduction seen in this study is 
haemodilution due to the administration of intravenous fluids. Indeed, the period of decline in 
NT-proBNP concentrations coincided with the period of fluid administration (the first 40 
minutes of the study), and a reduction in concentrations of other substances in plasma such 
as the total protein, PCV, BUN, Creatinine, and PcGMP concentrations were also observed. 
However, an increase in NT-proBNP and BNP-32 concentrations were seen despite the 
effect of haemodilution in the aforementioned studies. This discrepancy prompts a review of 
the various aspects of this study design. 
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For example, it is possible that the difference in duration and amount of fluid 
administered between studies contributed towards divergent results. In this study, a 40-
minute fluid loading period was used as opposed to a 60 minute protocol in the other two 
studies. The basis for the decision to use 40 instead of 60 minutes was the finding of a 
significant rise in NT-proBNP concentrations from 40 minutes into fluid administration in the 
study by Hori et al., (2010). In addition, as little as 12.5 ml/kg/h of isotonic saline 
administered over an hour was shown to cause an increase in plasma immunoreactive 
BNP-32 concentrations in healthy people (Lobo et al., 2010). At the other end of the 
spectrum, however, dogs receiving 100 ml/kg/h of intravenous fluids for 1.5 h experienced 
no observable changes to plasma BNP-32 concentrations in another study (Borgeson et al., 
1998). Put together, the amount of fluid and duration of administration required for adequate 
stimulation of the BNP system remain somewhat of a mystery.  
In contrast, it is interesting to note that studies have consistently observed stimulation 
of the ANP system following acute intravenous fluid administration (Borgeson et al., 1998; 
Hori et al., 2010; Kamp-Jensen et al., 1990; Watenpaugh et al., 1992; Weil et al., 1985). In 
the absence of obvious rises in BNP-32 and NT-proBNP, quantification of atrial natriuretic 
peptides (ANP) would have provided a more complete understanding of the NPS, and this is 
a limitation of the present study.  
Although ANP was not measured, concentrations of its effector molecules were 
quantified as an intermediate marker of biological effects of the NPS in this study. Binding of 
active ANP and BNP to their receptor (NPR-A) results in synthesis of particulate guanylate 
cyclase-mediated cGMP, which facilitates their downstream effects. As such, augmentation 
of the NPS (both ANP and BNP production) would be expected to result in an increase in 
PcGMP and UEcGMP (Brenner et al., 1990), and numerous studies have documented 
higher concentrations of plasma and urinary cGMP in response to administration of synthetic 
natriuretic peptides (Cataliotti et al., 2004; H. H. Chen et al., 2000; H. H. Chen et al., 2004; 
Forfia et al., 2007; Ichiki et al., 2015; Ishikawa et al., 2005). In prior studies where high rates 
of intravenous fluids were administered, an increase in PcGMP accompanied the stimulation 
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of the NPS (Borgeson et al., 1998; Weil et al., 1985). However, an increase in UEcGMP was 
not observed despite presence of higher PcGMP in one of these studies (Borgeson et al., 
1998). In the present study, PcGMP did not increase, but rather, decreased – likely due to 
haemodilution. The UEcGMP initially increased; however, this peaked at 30 minutes into 
fluid therapy and declined thereafter despite persistent increases in UOP. This raises the 
suspicion that a true increase in cGMP production was not experienced, as UEcGMP would 
have been expected to follow the course of the increase in UOP. Together with trends in 
measured natriuretic peptide concentrations, these findings support the overt lack of 
stimulation of the NPS in the present study. 
Is it possible, then, to conclude that the amount of fluid administered here was 
inadequate to stimulate the BNP system? Though the majority of findings were in favour of 
this conclusion, it is important to note that the initial hydration state of the dogs was not 
regulated. Some objective measures of hydration such as the PCV, TP, and Creatinine at 
baseline did not suggest overt dehydration, but three of the dogs had USG > 1.040 at 
baseline. If the dogs in this study were also relatively dehydrated at baseline compared to 
subjects in other studies, the BNP system may not have been similarly activated by the 
administration of this volume of intravenous fluids.  
It is interesting to note that despite the lack of overt cardiovascular or BNP 
stimulation in this study, a substantial increase in UOP and a corresponding decrease in 
USG were experienced in the dogs. This is likely a consequence of increased renal blood 
flow and reduced plasma osmolarity and the ensuing pressure diuresis, inhibition of RAAS 
activity, and reduction in tubular reabsorption of sodium and water (Hall, 2016). Thus, the 
multiple mechanisms involved in fluid homeostasis were highlighted here. 
The vast majority of endocrine, cardiovascular, and urinary variables measured in 
this study did not display a simple, linear correlation. This was expected, given the complex 
nature of the relationships between these systems. With advancements in computer 
technology and statistical methods, the creation of mathematical models to describe 
physiological effects has become more accessible. Such a model could have been 
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developed to describe the effect of fluid administration on the NPS and cardiorenal systems 
in this study. However, this avenue was not pursued, primarily due to limitations relating to 
time and resources. Had the study been designed with this type of analysis in mind, data 
collection would likely have incorporated other variables used in prior models evaluating 
cardiorenal systems (Hallow & Gebremichael, 2017; Karaaslan et al., 2005; Moss & Thomas, 
2014) to facilitate model building.  
That the timing of analysis for NT-proBNP, BNP-32, and cGMP was not standardised 
due to the challenges encountered during mass spectrometry assay development was 
another limitation of this study. This resulted in a prolonged duration of storage (around 1.5 
years prior to analysis) for the samples used in BNP-32 and cGMP analysis. The protease 
inhibitors used in the protocol have been shown to provide stability of BNP1-32 for 6 months 
at -70°C (Niederkofler et al., 2008), and cGMP has been noted to be stable in EDTA 
anticoagulated plasma at -20°C for 6 months (Vorderwinkler et al., 1991); however, the 
effects of longer storage on these and urine samples is unknown. In spite of this, the lack of 
a rising trend in NT-proBNP (which was assayed promptly) provided support for the 
conclusions drawn from the data. 
 
Overall Conclusions 
We sought to develop a canine specific BNP1-32 mass spectrometry assay and utilise this 
for evaluation of the BNP system in healthy, anaesthetised dogs receiving a short-term, 
high-volume, intravenous fluid bolus. Assay development was unsuccessful, primarily due to 
challenges encountered with sample preparation. For future attempts, an 
immunoprecipitation technique is recommended for sample concentration, followed by use of 
an LC-ESI-MS/MS set up for further purification and detection of the peptide. The fluid 
loading protocol in this study did not produce measurable simulation of the BNP system; 
furthermore, the resultant increase in intravascular volume, haemodilution, and diuresis 
posed an additional challenge to the interpretation of plasma and urinary concentrations of 
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endocrine markers. Alternate methods of ventricular loading would therefore be 
recommended for future studies.   
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Chapter 6:  
Cardiorenal and endocrine effects of synthetic canine BNP1-32  
in dogs with compensated congestive heart failure  
due to myxomatous mitral valve disease: A pilot study 
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Introduction 
Congestive heart failure (CHF) due to myxomatous mitral valve disease (MMVD) is the 
leading cause of cardiac death in older, small-breed dogs (Borgarelli & Buchanan, 2012). 
Medical therapy of CHF remains the predominant form of treatment in veterinary medicine, 
with current guidelines recommending a combination therapy consisting of a diuretic, 
angiotensin converting enzyme inhibitor (ACE-I), and inodilator (Atkins et al., 2009). Though 
survival times using this treatment regimen have not yet been published, an estimation of 
around one year is considered standard amongst experts, based on extrapolations from 
clinical trials and retrospective studies evaluating survival outcomes on components of this 
treatment regimen (Borgarelli et al., 2008; De Madron et al., 2011; Häggström et al., 2008; 
Lombard et al., 2006). The reasonably poor prognosis associated with this condition has 
prompted ongoing efforts in the discovery of additional or alternative therapeutics, including 
various inhibitors of the renin-angiotensin-aldosterone system (RAAS) (Bernay et al., 2010; 
Ovaert et al., 2010), newer diuretics (Chetboul et al., 2017; Peddle et al., 2012), and surgical 
repair (T. Mizuno et al., 2013; Uechi, 2012; Uechi et al., 2012).  
In these research efforts, a somewhat neglected therapeutic target is the natriuretic 
peptide system (NPS). Brain natriuretic peptide (BNP1-32) is an active component of this 
system. Binding to the A-type natriuretic peptide receptor (NPR-A) causes activation of 
guanylyl cyclase, which converts the cytosolic nucleotide, GTP, into cGMP. From there, 
cGMP acts as an intracellular secondary messenger and causes diuresis, natriuresis, 
vasodilation, and RAAS antagonism. These are desirable properties to combat the 
progression of CHF, and indeed, experimental animal studies (Cataliotti et al., 2004; H. H. 
Chen et al., 2000; H. H. Chen, Schirger, et al., 2006; Forfia et al., 2007; Grantham et al., 
1997; Thireau et al., 2014; Yamamoto et al., 1997) and early clinical trials in humans (H. H. 
Chen et al., 2012; H. H. Chen et al., 2004; Colucci et al., 2000; Publication Committee for 
the VMAC Investigators, 2002) have shown benefits of BNP1-32 in the treatment of CHF. 
This led to the registration in the United States of Nesiritide (Natrecor, Scios Inc., Mountain 
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View, CA, USA), a recombinant human BNP1-32 product, for intravenous use in people with 
decompensated CHF displaying symptoms of dyspnea at rest.  
Despite its initial success, an ultimate reduction in the rate of mortality or re-
hospitalization was not observed in humans with CHF (O'Connor et al., 2011). This caused 
Nesiritide to fall out of favor in human medicine and likely contributed towards reduced 
interest for use in veterinary patients. Another limiting factor is its formulation – an injectable 
preparation, which has traditionally resulted in use as an intravenous drug. Yet there is 
growing evidence of its safety and efficacy when administered subcutaneously (H. H. Chen 
et al., 2012; H. H. Chen et al., 2000; H. H. Chen, Huntley, et al., 2006; H. H. Chen et al., 
2004; H. H. Chen, Schirger, et al., 2006; Oyama et al., 2017). Subcutaneous administration 
facilitates its use in chronic therapy, and its potential role in treatment of subclinical heart 
disease (McKie et al., 2016) and in humans with diastolic dysfunction and right-sided CHF 
(H. H. Chen et al., 2012; Clarkson et al., 1995; Kwon et al., 2003; Tong et al., 2004; 
Yamamoto et al., 1997; Zakir et al., 2005) have also been explored. Although no solid 
conclusions to support its benefits in these contexts have been reported to date, there is 
enough theoretical and experimental data to support further investigation into its use in dogs 
with naturally occurring CHF due to MMVD.  
 In this pilot study, the cardiorenal and endocrine effects of subcutaneous doses of 
synthetic canine BNP1-32, given with or without frusemide, were evaluated in dogs with 
compensated CHF due to MMVD.  
 
Materials and Methods 
Animals 
Seven client-owned geriatric (10.5 to 17 years old) male dogs with compensated ACVIM 
class C (chronic) CHF due to MMVD were recruited into this study. Ethics approval was 
obtained from the University of Sydney Animal Ethics Committee prior to commencement of 
the study (approval number 2016/1113). 
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Study design 
This study was a single dose, cross-over, pilot study evaluating the efficacy of synthetic 
canine BNP1-32, given with or without frusemide, in the target population. It was conducted 
at the University Veterinary Teaching Hospital, Sydney between May – September, 2017.  
 
Enrolment Criteria 
Prior to enrolment, each dog had a screening examination which consisted of a review of the 
history, physical examination, and oscillometric blood pressure (BP) measurements 
(VetHDO, Memo Diagnostic, Darmstadt, Germany). Thoracic radiographs, an 
echocardiogram, electrocardiography (ECG), and select blood tests (alanine 
aminotransferase, alkaline phosphatase, blood urea nitrogen, creatinine, glucose, albumin, 
globulin, total protein, PCV, electrolytes) were also performed.  
 The inclusion criteria consisted of a diagnosis of CHF due to MMVD and good control 
of clinical signs with pimobendan (Vetmedin®, Boehringer Ingelheim Pty Ltd, North Ryde, 
NSW, Australia), benazepril (Fortekor; Elanco Australasia Pty Ltd, West Ryde, NSW, 
Australia), and frusemide (APO Frusemide; Apotex Pty Ltd, Macquarie Park, NSW, 
Australia). The exclusion criteria included previously diagnosed or suspected renal disease, 
adrenal disease, diabetes mellitus, systemic hyper/hypotension, primary or concurrent right-
sided CHF, and hemodynamically significant arrhythmias. In addition, dogs were not enrolled 
if concurrent treatments with sildenafil, spironolactone, amlodipine, thiazide diuretics, or 
other medications which may interfere significantly with cGMP metabolism, blood pressure 
regulation, or renal function were required.  
The diagnosis of CHF due to MMVD was made on characteristic history and physical 
examination findings (dyspnea and/or tachypnea responsive to treatment with frusemide; 
presence of abnormal lung sounds, at least a grade 4/6 systolic heart murmur loudest at the 
left apical region, and tachycardia on examination); echocardiographic evidence of severe 
MMVD and cardiac remodeling due to volume overload (i.e. characteristic lesions of the 
mitral valves, severe mitral valve regurgitation, significant left atrial and ventricular 
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enlargement) on an echocardiogram performed by a board-certified veterinary cardiologist 
(Niek Beijerink); and radiographic evidence of cardiomegaly with left atrial enlargement, 
pulmonary edema, and pulmonary vasodilation. Two dogs did not have radiographs 
performed prior to commencement of treatment for CHF. However, serial radiographs 
depicting pulmonary edema which resolved with commencement of therapy were available 
for the remainder of dogs enrolled.  
 
Study outline 
Following enrolment, dogs presented to the University Veterinary Teaching Hospital, Sydney 
on three days, each two weeks apart, for this study. Benazepril was dosed once daily at 
night, including on the night prior to each visit. The morning doses of pimobendan and 
frusemide were withheld on each study day. On the morning of each visit, history and 
physical examinations were performed to ensure well-being of the dogs, and peripheral IV 
and indwelling urinary catheters were placed. At the end of a one hour control period, heart 
rate (HR), BP, and urine output (UOP) were measured; blood and urine samples were 
collected for endocrine, electrolyte, biochemistry, and cGMP testing. The amount of blood 
collected was replaced with 7 ml saline. One of the following treatments was given: 
• BNP: 5 μg/kg synthetic canine BNP1-32 (Canine BNP1-32 (011-22), Phoenix 
Pharmaceuticals Inc, Burlingame, California, USA) subcutaneously (visit one) 
• FRUS: 2 mg/kg frusemide (Ileum Frusemide, Troy Laboratory Ltd., Glendenning, 
NSW, Australia) subcutaneously (visit two) 
• BNP/FRUS: 5 μg/kg synthetic canine BNP1-32 and 2 mg/kg frusemide 
subcutaneously (visit three) 
Treatment order was not randomized, and all dogs received all three treatments in the order 
listed above. 
 Measurement of HR and BP; collection of 7 ml blood; and IV administration of 7 ml 
saline were repeated at one and three hours following treatment. Measurement of UOP and 
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collection of 5 ml urine were performed at one, two, and three hours following treatment. 
PCV and total protein (TP) were monitored for safety purposes throughout. At the completion 
of this sampling period, IV and urinary catheters were removed, and dogs were treated with 
their usual morning medications (pimobendan and frusemide, if frusemide had not been 
given as a part of the treatment), then fed. Dogs were then discharged home to continue 
routine medical therapy with pimobendan, benazepril, and frusemide, and owners were 
advised to monitor for any abnormalities to the injection site, changes in behavior, or 
development of signs of decompensated CHF until the next scheduled visit.  
HR and systolic, diastolic, and mean BP (SBP, DBP, MBP) were measured in 
triplicate and averaged prior to statistical analysis. 
 
Sample processing and storage 
Blood samples were obtained via jugular venipuncture and immediately placed into plastic 
blood tubes containing EDTA or lithium heparin. Urine samples were collected into sterile 
plastic urine tubes. EDTA anticoagulated blood samples and urine samples were 
immediately centrifuged at or below 4°C at 5500 RCF for 10 minutes for collection of plasma 
and sediment-free urine. After obtaining a sample for PCV and TP, the lithium heparin 
anticoagulated blood samples were centrifuged at 4000 RCF for 4 minutes at room 
temperature for collection of plasma. For BNP1-32 testing, additional protease  
inhibition was achieved by adding 1 mL EDTA plasma to a pre-prepared mixture of  
4-(2-Aminoethyl)benzenesulfonyl fluoride hydrochloride (AEBSF) and Benazmidine (Sigma 
Aldrich, Castle Hill, NSW Australia) to give a final concentration of 5 mM AEBSF and 10 mM 
Benzamidine (Niederkofler et al., 2008). The remaining plasma and urine samples were also 
transferred into sterile, plain tubes and frozen for later analysis. Prior to analysis, samples 
were stored at -80°C for up to 136 days for BNP-32; at or below -30°C for up to 144 days for 
cGMP; at -80°C for up to 125 days for sodium, potassium, and creatinine; and at or below  
-40°C for up to 270 days for aldosterone assays.  Stability testing was not performed in this 
study; however, samples treated and held under similar conditions were reportedly stable in 
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human plasma samples for six months for BNP-32 (Niederkofler et al., 2008) and plasma 
and urinary cGMP (W.-c. Liao et al., 2003; Vorderwinkler et al., 1991; Yanhua Zhang et al., 
2009). Furthermore, aldosterone concentrations in human serum control samples stored at  
-30°C at the particular laboratory consulted for aldosterone assays were noted to be stable 
for at least 9 months, with no drift observed at 0.12 nM/L and 0.68 nM/L (n = 78). 
 
Blood and urine analysis 
Plasma immunoreactive BNP-32 concentrations were measured at a commercial laboratory 
(Phoenix Pharmaceuticals, Inc., Burlingame, CA, USA) using a validated (Schellenberg et al., 
2008) radioimmunoassay kit made by the company (BNP-32 Canine RIA kit, RK-011-22, 
Phoenix Pharmaceuticals Inc., Burlingame, CA, USA). The samples were transported frozen 
to the laboratory, and each sample was assayed in duplicate and averaged for analysis. 
 Plasma and urine cGMP concentrations were assayed using a commercially 
available competitive enzyme-linked immunosorbent assay kit using the manufacturer’s 
guidelines (ParameterTM cGMP Assay, KGE003, R&D Systems Inc., Minneapolis, MN, USA). 
Low, medium, and high controls (QC54 cGMP controls, R&D Systems Inc., Minneapolis, MN, 
USA) were added to each plate. Briefly, urine and plasma samples were thawed at room 
temperature, and 25 μl of each sample was mixed with 475 μl of diluent. Samples were 
further diluted 1:2 using the diluent provided if final concentrations exceeded the range of 
the assay. 100 μl of each standard, sample, and control were mixed with 50 μl of the cGMP 
conjugate, followed by 50 μl of the primary antibody solution. After incubating for three hours 
on a microplate shaker at 450 rpm at room temperature, wells were washed four times, and 
200 μl of substrate solution were added. This was incubated for 30 minutes in the dark, and 
50 μl of stop solution were added. The plate was read using a microplate reader (TECAN 
Infinite® M1000 PRO, Männedorf, Switzerland) set at 450 and 540 nm.  
Readings made at 540 nm were subtracted from those at 450 nm. A standard curve 
was generated using a 4-parameter logistic curve fit using Graphpad Prism V7.02 (La Jolla, 
CA, USA). Measured concentrations were derived using this standard curve and multiplied 
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by the dilution factor. All samples and standards were assayed in triplicate, all controls in 
duplicate, and results were averaged for analysis. All standard curves had R^2 > 0.987. 
The %CV of standard, sample, and control replicates were <10%, and the %CV of standards 
between plates were <10%. Each control fell within the expected concentration range. 
Plasma concentrations of cGMP were reported as pM/ml. In order to account for differences 
in concentration due to rate of urine production, urinary excretion of cGMP (UEcGMP; 
pM/kg/min) was also calculated by multiplying the UOP by the urinary concentration of 
cGMP. 
 Plasma and urine sodium (Na), potassium (K), and creatinine concentrations were 
measured at a commercial veterinary diagnostic laboratory (Veterinary Pathology Diagnostic 
Service, Camperdown, NSW, Australia). Fractional excretion of sodium (FENa) and 
potassium (FEK) were calculated using the formula: 
FEx = 100 * (Urinary x * Plasma creatinine) / (Plasma x * Urinary creatinine) 
Where X = sodium or potassium 
 Plasma concentrations of aldosterone were determined at the Radboud University 
Medical Centre laboratory (Nijmegen, Netherlands) using a validated aldosterone assay 
involving ultra-high performance liquid chromatography (UHPLC) coupled with tandem mass 
spectrometry (MS/MS) (Rotteveel-de Groot et al., 2018 manuscript in preparation). Briefly, 
500 μl of plasma was prepared with protein precipitation, supported liquid extraction 
(Isolute® SLE+, Biotage, Uppsala, Sweden) and solid phase extraction (Oasis HLB, Waters, 
Etten-Leur, Netherlands). Eluates were injected on an Agilent Technologies 1290 Infinity VL 
UHPLC system (Agilent Technologies, Santa Clara, California, USA) equipped with a CSH 
Phenyl Hexyl (1.7 μm, 2.1 X 100mm) analytical column (Waters, Etten-Leur, Netherlands) 
and coupled to an Agilent 6490 tandem mass spectrometer (Agilent Technologies, Santa 
Clara, California, USA). Settings included a capillary voltage of 3.0 kV, fragmentor voltage of 
380 V, sheath gas temperature of 350°C, and gas temperature of 200°C. N2 was used as the 
collision gas. Aldosterone was quantified using both aldosterone-d4 and aldosterone-d7 
internal standards (IsoSciences, Pennsylvania, USA). Two transitions (qualitative and 
141
 
 
quantitative) were measured for each analyte. The transitions (Q1 > Q3) were m/z 366.1 > 
338.2 (15 kEV) and m/z 366.1 > 194.1 (15 kEV) for aldosterone-d7; m/z 363.1 > 335.2 (15 
kEV) and m/z 363.1 > 190.1 (15 kEV) for aldosterone-d4; m/z 359.1 > 331.2 (15 kEV) and 
m/z 359.1 > 189.1 (15 kEV) for aldosterone. The dwell time was 60 milliseconds. Sample 
concentrations were derived using a 7-point calibration curve generated from aldosterone 
reference standards (Batch H158, Steraloids, Rhode Island, USA) using Microsoft Excel and 
MassHunter (Agilent Technologies, Santa Clara, California, USA). All samples and 
standards were assayed in duplicate and averaged. The lowest limit of quantification (LLOQ) 
was estimated at 0.070 nM/L, with total %CV of 9.0 and 6.9 at 0.12 nM/L and 0.68 nM/L, 
respectively (n = 78).  
 
Statistical analysis 
Descriptive analysis consisted of visual inspection of trends over time and summary 
statistics. The median and range were reported. Genstat 16th Edition (VSN International Ltd, 
Hemel) was used for statistical analysis. Data were evaluated for normality via inspection of 
Q-Q plots. Where the data were not normally distributed, transformations (loge for UOP, 
plasma immunoreactive BNP-32 concentrations, FEK, urinary cGMP concentrations, urinary 
excretion of cGMP; Logit transformation for FENa) were performed to approximate normality 
prior to statistical analysis.  
Between- and within-treatment effects were evaluated via linear mixed modelling with 
restricted maximum likelihood estimation using the following equation: 
Ŷ = Treatment + Time + Treatment*Time + Dog ID (random effect) + ε 
 Significance was set at α of 0.05. If the interaction term was significant, significant 
interactions were identified using the least square difference method post hoc. If this term 
was not significant, it was dropped from the model. Model assumptions were assessed 
through visual inspection of residual plots.  
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Results  
Breeds represented in the study cohort included the Cavalier King Charles Spaniel (n = 2), 
Kelpie, Maltese cross, Jack Russel Terrier cross, and Miniature Poodle cross (n = 2). 
Baseline characteristics and doses of medications have been summarized in Table 1. At the 
time of the first study day (visit one), dogs had been on treatment with frusemide for a 
median of 59 days (range 18 - 133), pimobendan for 63 days (range 26 - 252), and 
benazepril for 33 days (range 16 - 62). The median number of days between diagnosis of 
CHF and the first study day was 59 days (range 18 - 133). 
A deviation from the protocol occurred during visit one (BNP treatment) in one dog 
when urine samples were erroneously collected from the end of an extension line holding 
10 ml of volume which was attached to the urinary catheter instead of emptying the contents 
of the line each time. As the line was filled with urine prior to collection of data, the 
measurement of urine output was not affected. However, the volume held in this line 
exceeded the amount of urine production in each hour; thus, urinary analyte concentrations 
did not accurately reflect expected concentrations for the period in which the sample was 
taken. As such, urinary endocrine, cGMP, and fractional excretions at visit one for this dog 
were not calculated, and these data were excluded from the overall analysis. 
Synthetic canine BNP1-32 was well-tolerated by all dogs in the study. There were no 
systemic or local adverse effects encountered during the study.  
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Table 1: Baseline characteristics at the time of screening in seven dogs enrolled in 
the study. Abbreviations: LA:Ao = left atrium to aorta ratio; wnLVIDd/s = weight-
normalised left ventricular internal diameter in diastole/systole; FS = fractional 
shortening; HR =  heart rate; SBP/DBP/MBP = systolic/diastolic/mean blood pressure; 
BG = blood glucose; BUN = blood urea nitrogen; Crea = creatinine; TP = total protein; 
ALT = alanine aminotransferase; ALKP = alkaline phosphatase; Na = sodium; 
K = potassium; Cl = chloride; PCV = packed cell volume. 
 
 
Median Range 
Weight at screening (kg) 8.9 5.2 - 14.4 
Age (years) 12 10.5 - 17 
Daily pimobendan dose (mg/kg/d) 0.45 0.32 - 0.56 
Daily frusemide dose (mg/kg/d) 3.85 1.94 - 5.06 
Daily benazepril dose (mg/kg/d) 0.32 0.17 - 0.56 
LA:Ao 2.3 1.8 - 2.5 
wnLVIDd 2.16 1.84 - 2.44 
wnLVIDs 0.95 0.83 - 1.45 
FS (%) 53 35.3 - 56.9 
HR (bpm) 120 114 - 150 
SBP (mmHg) 138 120 - 148 
DBP (mmHg) 80 66 - 85 
MBP (mmHg) 100 92 - 105 
BG (mg/dL) 104.5  82.88 - 120.72 
BUN (mg/dL) 33.33 24.65 - 48.74 
Crea (mg/dL) 1.14 0.74 - 1.67 
TP (g/dL) 7.3 5.1 - 7.8 
Albumin (g/dL) 3.2 2.5 - 4.2 
Globulin (g/dL) 3.6 2.7 - 4.5 
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Table 1 (Continued). 
Parameters Median Range 
ALT (U/L) 95 24 - 293 
ALKP (U/L) 101 12 - 341 
Na (mEq/L) 149 145 - 153 
K (mEq/L) 3.6 2.7 - 4.2 
Cl (mEq/L) 112 106 - 120 
PCV (%) 47 37 - 54 
 
 
Effect of treatments on endocrine variables, cGMP, and fractional excretions 
The effect of each treatment on endocrine, cGMP, and FENa/K are depicted in Figures 1, 2, 
and 3.  
Plasma concentrations of immunoreactive BNP-32 rose significantly within an hour of 
BNP and FRUS/BNP treatments, but not with FRUS (Figure 1). Immunoreactive BNP-32 
levels returned to baseline by three hours following treatment.  
Significant between-treatment or within-treatment effects were not observed with 
regard to plasma concentrations of cGMP, as indicated by the lack of a significant 
treatment*time interaction (Figure 1). In contrast to plasma concentrations of cGMP, a 
significant rise in UEcGMP occurred following BNP and FRUS/BNP treatments, with 
observable differences arising between these treatments and FRUS (Figure 2). Maximal 
effects were reached one hour post treatment and decreased to baseline levels by three 
hours post treatment. In contrast, UEcGMP reduced following FRUS treatment. 
Both FENa and FEK increased when dogs were given any treatment containing 
frusemide (Figure 2). However, administration of BNP did not cause a significant change in 
these variables, and the addition of BNP did not result in significant changes in the excretion 
of these electrolytes when compared to treatment with frusemide alone.  
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Around 60% of plasma samples had aldosterone concentrations < LLOQ. Due to this 
large number, only a descriptive analysis was performed. Traditional approaches for 
handling such data in bioanalytics include reporting values as missing, “rounding down” 
values to zero, or estimating these values to be half the LLOQ (Keizer et al., 2015). As the 
data was not missing, and as aldosterone concentrations would not be expected to be zero 
from a biological perspective, the value of half the LLOQ was assigned where concentrations 
< LLOQ were obtained, and plasma aldosterone concentrations were graphically depicted 
(Figure 3). 
 
Effect of treatments on cardiorenal variables 
The UOP increased significantly from baseline following FRUS and FRUS/BNP and 
remained elevated at the end of the study; in contrast, BNP alone did not result in changes 
to UOP (Figure 4). Maximal effects were reached at 1 hour post treatment in the FRUS and 
FRUS/BNP groups, with a 1246% and 887% increase in median UOP compared to baseline, 
respectively. Though these treatments resulted in significantly higher UOP compared to BNP, 
there were no differences between the two frusemide containing treatments. None of the 
treatments resulted in significant changes in HR or BP (Figure 5).  
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Figure 1: Plasma concentrations of immunoreactive BNP-32 (pg/ml) and cGMP 
(pM/ml) following administration of BNP1-32 (5 μg/kg, solid black line), Frusemide 
(2 mg/kg, solid grey line), or BNP1-32 + Frusemide (5 μg/kg + 2 mg/kg, dashed black 
line) subcutaneously in seven dogs with chronic congestive heart failure due to 
myxomatous mitral valve disease. The median and range were plotted.  
Asterisks denote significant (p < 0.05) differences between BNP1-32 and Frusemide 
(*); and BNP1-32 + Frusemide and Frusemide (***). 
Hats denote significant (p < 0.05) differences from baseline for BNP1-32 (^) and  
BNP1-32 + Frusemide (^^^).  
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Figure 2: Urinary excretion of cGMP (pM/kg/min) and fractional excretions of sodium 
(FENa, %) and potassium (FEK, %) following administration of BNP1-32 (5 μg/kg, solid 
black line), Frusemide (2 mg/kg, solid grey line), or BNP1-32 + Frusemide (5 μg/kg + 
2 mg/kg, dashed black line) subcutaneously in seven dogs with chronic congestive 
heart failure due to myxomatous mitral valve disease. The median and range were 
plotted.  
Asterisks denote significant (p < 0.05) differences between BNP1-32 and Frusemide 
(*); BNP1-32 and BNP1-32 + Frusemide (**); and BNP1-32 + Frusemide and Frusemide 
(***). 
Hats denote significant (p < 0.05) differences from baseline for BNP1-32 (^); 
Frusemide (^^); and BNP1-32 + Frusemide (^^^).  
148
 
 
 
Figure 3: Plasma concentrations of aldosterone (nM/L) following administration of 
BNP1-32 (5 μg/kg, solid black line), Frusemide (2 mg/kg, solid grey line), or BNP1-32 + 
Frusemide (5 μg/kg + 2 mg/kg, dashed black line) subcutaneously in seven dogs with 
chronic congestive heart failure due to myxomatous mitral valve disease. The LLOQ 
of the assay was 0.070 nM/L. All concentrations < LLOQ were estimated to be half the 
LLOQ.  
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Figure 4: Urine output (UOP) following administration of BNP1-32 (5 μg/kg, solid black 
line), Frusemide (2 mg/kg, solid grey line), or BNP1-32 + Frusemide (5 μg/kg + 2 mg/kg, 
dashed black line) subcutaneously in seven dogs with chronic congestive heart 
failure due to myxomatous mitral valve disease. The median and range were plotted.  
Asterisks denote significant (p < 0.05) differences between BNP1-32 and Frusemide 
(*); and BNP1-32 and BNP1-32 + Frusemide (**). 
Hats denote significant (p < 0.05) differences from baseline for Frusemide (^^) and 
BNP1-32 + Frusemide (^^^).   
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Figure 5: Blood pressure (BP) and heart rate (HR) following administration of BNP1-32 
(5 μg/kg, solid black line), Frusemide (2 mg/kg, solid grey line), or BNP1-32 + 
Frusemide (5 μg/kg + 2 mg/kg, dashed black line) subcutaneously in seven dogs with 
chronic congestive heart failure due to myxomatous mitral valve disease. The median 
and range were plotted.  
 
Discussion 
This is a report of the first prospective study evaluating the cardiorenal and endocrine effects 
and tolerability of single doses of synthetic canine BNP1-32 given subcutaneously to dogs 
with compensated ACVIM stage C CHF due to MMVD. BNP1-32 was well-tolerated, and 
following subcutaneous dosing, it was well-absorbed and resulted in an increase in 
UEcGMP; however, there were no measurable effects on biological outcomes (UOP, BP, HR, 
FENa/K, and plasma aldosterone concentration) in this study. These findings are in contrast to 
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results from dogs with experimentally induced CHF, and thus, raise questions regarding the 
potential for natriuretic peptide resistance in dogs with naturally occurring CHF. 
 In particular, derangements of intracellular pathways via which cGMP mediates 
natriuresis and diuresis may exist in dogs with CHF due to MMVD. The rise in plasma 
concentrations of immunoreactive BNP1-32 following its administration confirms successful 
absorption from the site of administration. Appropriate binding to NPR-A is demonstrated 
through the rise in UEcGMP accompanying any treatment containing BNP1-32 but not 
frusemide alone. This is also supported by the trends in plasma concentrations of cGMP 
albeit not reaching significance, likely owing to the high degree of variability across all time 
points and small number of dogs in the study. The validity of urinary and plasma 
concentrations of cGMP in demonstrating this interaction is evidenced by observations from 
numerous previous studies relating to this matter (Boerrigter et al., 2007; Cataliotti et al., 
2004; H. H. Chen et al., 2012; H. H. Chen et al., 2000; H. H. Chen, Huntley, et al., 2006; H. 
H. Chen et al., 2004; H. H. Chen, Schirger, et al., 2006; Forfia et al., 2007; Grantham et al., 
1997; Jensen et al., 1999; McKie et al., 2016; Nakamura et al., 1998; Stasch et al., 1989; 
Wong et al., 1988). These changes in cGMP also make NPR-A receptor downregulation less 
likely. The process of elimination thus renders downstream intracellular mechanisms a 
potential source of natriuretic peptide resistance in these dogs. Although the entirety of the 
pathways by which cGMP mediates cellular effects has yet to be discovered, there is 
evidence to support involvement of cGMP-dependent protein kinases (PKG) (Martel et al., 
2010; Potter et al., 2006; Theilig & Wu, 2015) and amiloride-sensitive cation channels 
(Martel et al., 2010) in the generation of natriuretic peptide-induced vasodilation, natriuresis, 
and diuresis. In addition, phosphodiesterase 5 inhibition to reduce cGMP hydrolysis appears 
to be of benefit in the face of CHF and augments effects of exogenous BNP1-32 (H. H. Chen, 
Huntley, et al., 2006; Forfia et al., 2007; Guazzi et al., 2011; Katz et al., 2000; Takimoto et al., 
2005). These intracellular mechanisms remain an interesting area for future investigation 
from both a pathophysiological and therapeutic perspective, and the findings arising from 
this study justify the need for such a scientific quest. 
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 Notwithstanding this theory, it remains possible that biological effects of BNP1-32 
may have been obscured in the present study due to aspects relating to its study design. 
The labelled use of Nesiritide in people is for acutely decompensated CHF, to be given as an 
intravenous bolus followed by a continuous rate infusion. In contrast, this study utilized a 
subcutaneous mode of delivery in dogs with compensated chronic CHF in order to minimize 
variability in clinical presentation and investigate the potential for its use in chronic therapy. 
Despite experimental studies showing effects of BNP1-32 in chronic CHF (H. H. Chen et al., 
2012; H. H. Chen et al., 2004; H. H. Chen, Schirger, et al., 2006), it is possible that the lack 
of an overt state of volume overload may have resulted in lack of diuresis and natriuresis in 
this study, or that longer exposure to BNP1-32 (either as a constant rate infusion or via 
multiple doses of subcutaneous BNP1-32) may have been required to produce detectable 
changes to cardiorenal variables. The non-invasive techniques of measuring BP and HR 
may have lacked the sensitivity to detect BNP1-32 effects in such a small group of dogs, and 
only a limited number of cardiovascular variables were evaluated. Renal blood flow and 
measures of renal function other than UOP and FENa/K were not measured. The small 
number of sampling points may have also resulted in a failure to detect short-lived effects. A 
cross-over treatment design was used so that each dog acted as its own “control”, thereby 
reducing variability and increasing chances of detecting treatment effects in this small cohort 
of dogs; however, the inclusion of a placebo treatment stream in which no frusemide or 
BNP1-32 was given could have helped to highlight smaller treatment effects. Finally, a group 
of healthy dogs undergoing the same study procedures would have strengthened the 
conclusions drawn from this study and enabled direct comparisons to be made between 
healthy and diseased dogs. These limitations highlight the need for further research efforts 
into the role of BNP1-32 in dogs with CHF. 
 The effect of BNP1-32 on the spontaneous and frusemide-activated RAAS in this 
population remains ill-defined due to the majority of samples containing aldosterone 
concentrations below the LLOQ. With the reported range of plasma aldosterone 
concentrations being anywhere from around 20 - 800 pM/L in dogs with naturally occurring 
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CHF (Häggström et al., 1997; Häggström, Lord, et al., 2013), a LLOQ of 70 pM/L (equiv. to 
0.07 nM/L) would appear to be adequate. Although in-house stability testing showed 
prolonged stability of serum aldosterone, sample degradation in plasma remains a possible 
cause of these low concentrations. Alternative explanations include the chronicity of 
benazepril therapy (16 - 62 days, with median 33 days) and the possibility for reduced RAAS 
activation in the chronic, stable phase of CHF (Hezzell, Boswood, Chang, Moonarmart, & 
Elliott, 2012). Despite this, it is interesting to note that both treatments containing BNP1-32 
appeared to demonstrate an initial suppression of aldosterone concentrations followed by an 
rise in concentrations by three hours post treatment where trends could be appreciated on 
Figure 3. This observation is weak but is in contrast to previous reports of aldosterone 
suppression following BNP1-32 administration in people with CHF (H. H. Chen et al., 2004) 
and in dogs with frusemide-induced RAAS activation (Cataliotti et al., 2004). This 
unexpected effect therefore requires further investigations to elucidate. 
  As a final note, the cGMP and aldosterone assays employed in this study 
should ideally have been fully validated for use in canine plasma and urine. Instead, formal 
validation was performed by the manufacturers of the assays utilising samples from other 
species (humans and rodents), and partial validation and quality control monitoring of canine 
samples were employed during the course of this study. Yet with the molecular structure of 
both cGMP and aldosterone being conserved between species, it is expected that the 
assays will perform similarly in samples from different species. These tests were thus 
deemed fit for use for the purposes of this study.  
 
Conclusions 
The cardiorenal and endocrine effects of a single dose of synthetic BNP1-32, given 
subcutaneously with or without frusemide, were evaluated in dogs with compensated CHF 
due to MMVD receiving chronic therapy with pimobendan, frusemide, and benazepril. 
Subcutaneous BNP1-32 was well-absorbed and increased UEcGMP. However, there were 
no biological effects on HR, BP, UOP, or FENa/K, and BNP1-32 did not augment effects of 
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frusemide on UOP or FENa/K. These findings raise further questions regarding the role of 
BNP1-32 in both the pathophysiology and treatment of CHF in dogs with MMVD. Areas of 
potential future research were highlighted. 
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Chapter 7:  
Discussion and conclusions 
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7.1) Discussion 
The five chapters encompassing the body of this work served two overarching purposes – to 
provide justification for current off-label practices and to provide novel insights for guidance 
of future advancements in the treatment of canine and feline CHF. Each chapter set out to 
fulfil the following aims: 
• To evaluate the pharmacokinetics and pharmacodynamics of pimobendan and its 
active metabolite of a novel nonaqueous oral solution of pimobendan in healthy dogs 
(Chapter 2). 
• To evaluate the pharmacokinetics and pharmacodynamics of pimobendan in healthy 
cats (Chapter 3). 
• To prospectively evaluate the natural course of disease in dogs with newly diagnosed 
CHF due to MMVD when treated with a combination therapy of frusemide, 
pimobendan, an ACE-I, and spironolactone (Chapter 4). 
• To develop a mass spectrometry assay for identification and quantification of active 
BNP1-32 in canine plasma (Chapter 5).  
• To evaluate the BNP system and its effects in normal dogs experiencing an acute 
expansion of intravascular volume via fluid therapy (Chapter 5). 
• To investigate the efficacy of synthetic canine BNP1-32 given subcutaneously, with 
or without frusemide, in dogs with CHF due to MMVD (Chapter 6). 
Most of these aims were met, with numerous subsidiary discoveries made along the way.  
The pharmacokinetics of the liquid formulation of pimobendan in healthy dogs 
(Chapter 2) revealed similar overall kinetics to that of other published reports of pimobendan 
in dogs. At the standard dose of 0.25 mg/kg, the solution was rapidly absorbed (Tmax 1.1 h 
with Cmax 18.6 ng/ml) and converted to its active metabolite, ODMP (ODMP Tmax 1.3 h with 
Cmax 16.2 ng/ml), widely distributed (V/F 15.5 L/kg), and rapidly cleared 
(CL/F 176.5 ml/min/kg with t1/2 0.9 h). Pimobendan was deemed unlikely to accumulate 
when given twice daily using the investigated dose. However, the magnitudes of these 
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measures of kinetics have been somewhat variable across existing reports. For example, the 
reported mean plasma Cmax of pimobendan following oral dosing of ~ 0.25 mg/kg ranged 
from ~ 3 ng/ml (Boehringer Ingelheim Ltd., 2012b) to ~ 40 ng/ml (Bell et al., 2016), with a 
Tmax of 40 min to 2 h (Bell et al., 2016; Boehringer Ingelheim Ltd., 2012b). Following 
intravenous pimobendan at ~ 0.12 mg/kg, a mean volume of distribution and clearance of 
~ 0.25 L/kg and ~ 0.4 L*h/kg were calculated using concentrations of the drug in whole blood 
(Bell et al., 2016); in contrast, the mean values reported on the product insert for various oral 
solid dose forms and injectable formulation of pimobendan were ~ 2.6 L/kg and 
~ 90 ml/kg/min (Boehringer Ingelheim Ltd., 2008, 2012a, 2012b). The t1/2, however, 
remained similar between all studies, indicating the presence of similarities across studies in 
the slope of the terminal portion of the concentration-time curve. The metabolite displayed a 
similar Cmax to that of pimobendan and had a prolonged t1/2 in the product insert of a 
registered formulation (Boehringer Ingelheim Ltd., 2012b), and the findings in Chapter 2 of 
this thesis were in line with this. As the metabolite was not directly administered, the 
clearance and volume of distribution of ODMP were not described and remains a mystery 
due to the lack of published information regarding this in dogs. Aside from these, there are 
no other published reports of metabolite kinetics in dogs; however, plasma concentrations of 
ODMP following high doses of intravenous pimobendan (0.25 – 2.25 mg/kg) have been 
reported (Schneider et al., 1997). Unfortunately, the scarcity of published pharmacokinetic 
reports; differences in methodology including number of dogs utilised, sampling points, and 
analytical methods; use of various formulations; and the lack of data regarding bioavailability 
from the present study make it extremely difficult to directly compare the results of these 
studies. Nevertheless, the work in Chapter 2 contributed valuable pharmacokinetic data on 
this novel pimobendan solution. 
The study in Chapter 2 described the pharmacokinetics and pharmacodynamics of a 
novel formulation of pimobendan but did not compare these against the registered 
formulations of pimobendan. The reasons for this particular study design were 
circumstantial; yet such a comparative study would have enabled a more accurate 
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assessment of its performance in relation to existing formulations. In this case, bioavailability 
would have been an essential fraction to clarify. Moreover, demonstration of bioequivalence 
is often necessary for registration of alternate formulations and generic products (Australian 
Pesticides and Veterinary Medicines Authority 2017). Although this study was conducted 
and reported independently, the data obtained from this study, together with additional 
pharmacokinetic, safety, and stability work, ultimately contributed towards successful 
registration of the product through the Australian Pesticides and Veterinary Medicines 
Authority in 2016 (Product No. 81552).  
One of the key findings arising from the studies on pimobendan in healthy dogs and 
cats (Chapters 2 and 3) was the discovery of reduced metabolism of pimobendan in cats 
compared to dogs. In dogs, the AUC0-∞ of its active metabolite, ODMP, exceeded that of 
pimobendan; in contrast, the AUC0-∞ of pimobendan far exceeded that of ODMP in cats. This 
finding supports and extends upon the pharmacokinetic work of Hanzlicek et al. (2012) in 
which reduced metabolism of pimobendan was suspected in cats, and it provides the first 
published description of metabolite kinetics in cats. Although the metabolic pathways of 
pimobendan in dogs and cats have yet to be characterised and remains an area for future 
research efforts, this difference in its metabolism could contribute towards inter-species 
variation in drug effects. 
Indeed, a discrepancy in the pharmacodynamics of pimobendan was detected 
between dogs and cats, with increases in echocardiographic measures of systolic function 
being readily apparent in the former but not in the latter (Chapters 2 and 3). This was 
surprising as the higher concentration of pimobendan in cats was expected to produce 
greater cardiovascular effects (Böhm et al., 1991; Endoh et al., 1991; Verdouw et al., 1987). 
As discussed previously, it is possible that the non-invasive methods of detection utilised in 
Chapter 3 lacked the sensitivity required for identification of the magnitude and duration of its 
effects in cats. The combination of an inherently small size of the heart, influence of patient 
anxiety on the outcome parameters, and lack of effects beyond the published normal 
reference ranges could have obscured treatment effects. Furthermore, measures of its 
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effects on the left ventricular diastolic and left atrial systolic indices were not quantified, 
therefore limiting assessment of its impact on global cardiac function. Alternatively, true 
inter-species differences in the magnitude of its effects might also exist. Comparison of the 
pharmacokinetics of pimobendan between dogs and cats (Chapters 2 and 3) revealed that 
the Cmax appeared higher in cats than in dogs at comparable mg/kg doses; in addition, this 
tended to be reached earlier than in dogs. Although the lack of absolute bioavailability and 
the difference in formulations utilised were limitations of these studies, a higher 
bioavailability in cats would be suggested by these two variables. The elimination rate 
constants were similar, as evidenced by the similarities in t1/2. In contrast, a lower CL/F and 
Vz/F of pimobendan was found in cats compared to dogs. Though somewhat speculative in 
the absence of bioavailability, plasma protein, and blood or cell binding data, both the lower 
CL/F and Vz/F in cats could be explained through reduced uptake of pimobendan by its 
effector organs. The vasodilatory effect of pimobendan differs between species and types of 
vessels (Fujimoto, 1994); as such, it is possible that an inter-species variation in 
pimobendan uptake by the myocardium may also exist. This, in turn, may have resulted in 
diminished cardiovascular effects in cats. In addition to being the first published work 
describing the acute cardiovascular responses to oral doses of pimobendan in conscious 
cats, Chapter 3 therefore served the important function of questioning the true utility of 
pimobendan in this species and emphasising the need for further prospective evaluations.  
The magnitude and duration of effects following oral dosing of pimobendan in cats 
remain ill-defined, but the discovery of measurable echocardiographic treatment effects in 
healthy dogs (Chapter 2) provides support for commonly employed off-label dosing regimen 
in this species and a method by which therapeutic monitoring may be pursued in the future. 
The onset of peak activity at 2 – 4 h following dosing and return to baseline by 8 h would 
mean that a thrice daily dosing regimen as suggested in the ACVIM consensus report 
(Atkins et al., 2009) would cause a longer duration of enhanced systolic activity. Further 
increases in frequency or dose would result in accumulation of effects which, due to 
physiological limits, would be mainly characterised by a higher trough systolic function. The 
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impact of such alterations to standard treatment regimen, as well as any differences arising 
from use of various formulations or administration methods (e.g. with food or with other 
medications) can now be monitored in clinical practice using echocardiography.  
Although beyond the scope of this thesis, longer-term outcomes of such alternate 
dosing regimens can also be predicted through simultaneous pharmacokinetic-
pharmacodynamic modelling. Based on the findings from Chapter 2, modelling work is 
currently being undertaken using an enriched pool of data from additional healthy dogs. In 
order to assess its applicability to diseased dogs, further data is also being collected from 
dogs with ACVIM stage B MMVD to test the utility of this model in target animals. This model 
could be used to guide the design of survival studies to clarify ideal dosing regimen and 
therapeutic monitoring in clinical practice. The use of multiple pharmacokinetic-
pharmacodynamic models, in combination with parametric time to event modelling, have 
been advocated in the field of oncology to individualise treatment regimen in the face of 
multiple drug interactions and variable courses of disease (Bender et al., 2015; Buil-Bruna et 
al., 2016). However, it remains an unexplored area in the field of CHF therapeutics. For 
veterinary patients, the work completed in Chapter 2 may therefore provide a foundation for 
such future developments into individualisation and improvement of CHF therapeutics. 
It is common knowledge amongst veterinary professionals that pimobendan is 
seldom used alone for the treatment of CHF. Most often, it is given in combination with 
frusemide and an ACE-I; other concomitant treatments include MRAs and afterload reducers 
such as amlodipine or hydralazine (Atkins et al., 2009). Yet the benefits, if any, of such 
combination therapy, as well as the expected natural course of disease utilising different 
treatment regimen, remain ill-defined. This, together with the lack of available information 
defining the role of the RAAS in development and propagation of CHF in MMVD, formed the 
basis for the longitudinal observational study outlined in Chapter 4. 
The data gathered during the course of this study led to an interesting observation 
regarding survival in the cohort of enrolled dogs. When treated with combination therapy 
consisting of frusemide, pimobendan, spironolactone, and benazepril, the MST in dogs with 
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CHF due to MMVD was 419 days (Chapter 4). As previously identified, this finding supports 
and strengthens the observations made by two retrospective studies investigating survival 
outcomes in a similar population of dogs receiving similar medical therapy (430 days in 21 
dogs (De Madron et al., 2011); 163 to advanced CHF + 281 days in advanced CHF in 54 
dogs (Beaumier et al., 2018)). Furthermore, these values are ~ 100 days greater than the 
MST (334 days) reported in 64 dogs receiving treatment with standard doses of pimobendan, 
frusemide, and ACE-I in another recent retrospective study (M. Mizuno et al., 2017). The 
retrospective nature of many of these studies, various global locations from which the 
participants were selected, inclusion of cases from a range of years (2003 – 2016), and the 
small numbers of individuals enrolled place some constraints on the interpretation of this 
discrepancy. However, some credibility is redeemed as matching inclusion criteria were 
used across these studies, thereby reducing clinical variability between populations. It is 
therefore possible that the use of spironolactone and ACE-I to provide comprehensive RAAS 
inhibition, together with pimobendan and frusemide, may offer survival benefits in dogs with 
CHF due to MMVD. Evidence is provided to support larger clinical trials investigating this 
matter. 
In contrast, the MST observed in Chapter 4 cannot be compared to those reported in 
numerous other survival studies due to critical differences in study designs. For example, 
some previous survival studies included both dogs with MMVD and DCM (Ettinger et al., 
1998; Slupe et al., 2008; The BENCH Study Group, 1999), with the latter being associated 
with poorer survival (M. W. S. Martin et al., 2010; O'Grady et al., 2008). In addition, there 
were discrepancies in the classification schemes utilised to diagnose CHF. In the absence of 
documented radiographic evidence of CHF, symptoms such as coughing or exercise 
intolerance could be attributable to non-cardiac comorbidities such as airway disease or 
degenerative joint disease; thus, the use of ISACHC classification (Bernay et al., 2010; 
Borgarelli et al., 2008; Serres, Chetboul, Tissier, et al., 2007; The BENCH Study Group, 
1999) without documented evidence of volume overload could result in over-estimation of 
survival. Conversely, under-estimation of survival may have resulted in studies which did not 
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strictly enrol dogs at first onset of CHF (Bernay et al., 2010; Ettinger et al., 1998; Häggström 
et al., 2008; Lombard et al., 2006; The BENCH Study Group, 1999). Numerous 
combinations of treatments have been utilised across these studies, with pimobendan not 
being employed or only being provided to a small portion of enrolled dogs in many studies 
despite its widespread use today (Bernay et al., 2010; Borgarelli et al., 2008; Ettinger et al., 
1998; Serres, Chetboul, Tissier, et al., 2007; Slupe et al., 2008; The BENCH Study Group, 
1999). The criteria for diagnosis of CHF and the treatment utilised in the present study are 
commonly employed in Australia; as such, the results presented in Chapter 4 contribute 
important information regarding survival in this population of dogs despite the small number 
of enrolled animals. In examining the context in which this study lies, the need for better 
global standardisation of heart failure classification and a more systematic method of 
undertaking survival studies in veterinary medicine is also highlighted. 
In theory, counteracting the deleterious effects of the RAAS and providing 
vasodilation and inotropic support could contribute towards positive cardiac remodelling and 
haemodynamics and alter the course of disease in dogs treated with quadruple therapy; 
however, this was not apparent in the study comprising Chapter 4. The most common cause 
of death and euthanasia was recurrent CHF (78% of deaths), with clinically relevant 
pulmonary hypertension experienced in five dogs (45%, but a sixth dog developed this 
following conclusion of the study) and haemodynamically significant arrhythmias (atrial 
fibrillation and supraventricular tachycardia) developing in two dogs (18%). Dogs with larger 
left atrial and ventricular sizes tended to die earlier, and left atrial size appeared to increase 
prior to the onset of death. These figures and trends are all consistent with existing reports of 
dogs with MMVD on a variety of treatment regimens (Beaumier et al., 2018; Borgarelli et al., 
2008; De Madron et al., 2011; Häggström et al., 2008; Hezzell, Boswood, Moonarmart, et al., 
2012; Kellihan & Stepien, 2012; The BENCH Study Group, 1999). It would seem, then, that 
while some treatment combinations may lengthen survival, the overall course of disease 
remains largely unaffected on a population level.  
163
 
 
To shed further light upon this observation, the study design should have ideally 
incorporated assessments of short-term treatment effects of pimobendan and RAAS 
inhibitors. Such assessments could act as intermediate markers of treatment benefits which 
could be directly evaluated against survival outcomes or development of certain 
complications as described above. Although far larger numbers of enrolled animals would be 
required for formal assessment of such relationships, Chapter 4 was, in some ways, a 
missed opportunity to explore the utility and practicality of these methods.  
Based on findings from Chapter 2, the original study design called for 
echocardiographic assessment of systolic function at 2 – 4 h following treatment with 
pimobendan. However, it did not include assessment of trough cardiac function (i.e. prior to 
administration of pimobendan). Although this design was chosen to minimise handling and 
time spent in hospital at each follow-up visit, it also meant the need to coordinate timing of 
study visits with that of treatments administered by each owner. This, combined with the 
need to dose on an empty stomach without food, various daily commitments of each owner, 
and the demands of an otherwise busy clinical service, made for an impossible combination 
of elements to facilitate long-term pharmacodynamic monitoring. Retrospectively, a study 
design in which each dog was required to stay the day of the recheck and allocating a 
dedicated investigator to perform procedures each day may have improved data collection. 
Noting the exact timing of dosing and echocardiography, as well as identifying plasma 
concentrations of pimobendan and ODMP, may have also enabled retrospective analysis of 
treatment effects with the use of the aforementioned pharmacokinetic-pharmacodynamic 
model. This experience (Chapter 4) thus highlighted some of the practical concerns that 
would need to be addressed in future use of echocardiography to monitor treatment effects 
of pimobendan (Chapter 2). 
Contrary to the relative ease of therapeutic monitoring for pimobendan, the 
assessment of short-term anti-RAAS therapy is far more challenging. The presence of both 
circulating and local tissue RAAS, which may act independently, makes global RAAS 
assessments through non-invasive methods difficult (Atlas, 2007). To date, plasma and urine 
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concentrations of RAAS hormones have been used most commonly in the assessment of 
treatment effects. However, there are disparate findings across studies. For example, a 
recent pharmacokinetic-pharmacodynamic model identified an increase in plasma renin 
activity, along with a reduction in plasma angiotensin II and aldosterone concentrations 
following benazepril therapy in healthy dogs undergoing RAAS stimulation via a low sodium 
diet (Mochel et al., 2015). Yet in dogs with CHF due to MMVD on frusemide therapy, no 
significant effects of benazepril were observed in these measures or urinary aldosterone to 
creatinine ratio (UAldo:C), urinary angiotensin to creatinine ratio, or urinary vasopressin to 
creatinine ratio (Häggström, Lord, et al., 2013). Similarly, other studies in healthy dogs with 
frusemide-induced RAAS activation saw little or no effects of ACE-I therapy on the urinary 
aldosterone to creatinine ratio (UAldo:C) despite a decrease in serum and plasma ACE 
activity (M. K.  Ames et al., 2016; M. K. Ames et al., 2015; Lantis, Ames, Atkins, et al., 2015; 
Lantis, Ames, Werre, et al., 2015). Further complicating these traditional approaches to 
monitoring anti-RAAS therapy in dogs with CHF treated with MRAs (Chapter 4) is the fact 
that MRAs invariably cause an increase in circulating and urinary aldosterone concentrations 
due to receptor antagonism, rendering these measures useless for this purpose. In order to 
overcome such issues, research into the effects of anti-RAAS therapy on novel biomarkers 
such as those reflecting myocardial fibrosis (e.g. procollagens), extracellular matrix 
degradation (e.g. matrix metalloproteases), and renal anti-RAAS activity (e.g. aquaporin 2, 
epithelial sodium channels) is required. Indeed, a reduction in markers of fibrosis has been 
associated with survival benefits in people with CHF treated with spironolactone and ACE-I 
(Zannad et al., 2000); in addition, administration of ACE-I have reduced matrix 
metalloproteases in experimental models of heart failure (Brower et al., 2007; Li et al., 2000). 
However, the effects of anti-RAAS therapy on such measures have not been evaluated in 
dogs with naturally occurring CHF. As can be appreciated, further research efforts are 
required to identify the optimal method of detecting short-term effects of anti-RAAS therapy 
in the face of multi-drug use.  
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An alternative approach to identify treatment success might involve the use of 
natriuretic peptides as a biomarker of reduced preload, afterload, and enhanced cardiac 
output produced through the combined use of frusemide, pimobendan, and RAAS inhibition. 
Plasma concentrations of NT-proBNP and BNP have been observed to reduce following 
various treatments in people with acutely decompensated CHF (Antoni et al., 2004; Knebel 
et al., 2005; Marco et al., 2007; Michtalik et al., 2011; Paterna et al., 2005) and in chronic 
therapy (Anand et al., 2003; Hartmann et al., 2004; Jourdain et al., 2007; McMurray et al., 
2008; Troughton et al., 2000; Tsutamoto et al., 2001) due to various aetiologies leading to 
CHF; yet despite the findings of greater morbidity and mortality in those experiencing less 
reduction in these peptides in many of the aforementioned studies, larger meta-analysis 
have found some conflicting evidence regarding this matter (De Vecchis et al., 2014; Felker 
et al., 2009; Porapakkham et al., 2010; Savarese et al., 2013), and clear guidelines for its 
use to guide therapy have not been established (Yancy et al., 2017). Similarly, reductions in 
circulating NT-proBNP concentrations have been observed in dogs following initiation of 
CHF therapeutics (Häggström, Lord, et al., 2013; Schober et al., 2011); in addition, a post-
treatment NT-proBNP concentration of < 965 pM/L, but not the percentage of reduction in 
NT-proBNP in response to therapy, has been associated with longer survival in dogs with 
MMVD in a recent study (Wolf et al., 2012). As in human medicine, however, optimal 
methods of employing this measure to guide treatment regimen have yet to be developed. 
Nevertheless, the inclusion of serial assessments of circulating natriuretic peptide 
concentrations over time could have provided interesting longitudinal information about the 
NPS and global treatment response in the cohort of dogs evaluated in Chapter 4.  
Yet some concerns exist regarding the specificity of existing NT-proBNP and BNP 
assays, and these formed the basis of the specific BNP1-32 assay development which took 
place in Chapter 5. The primary drawback of using immunoassays to detect components of 
the NPS is related to cross-reactivity with inactive or less active pro-forms and fragments. 
This has been demonstrated in commonly used immunoassays for detection of both  
NT-proBNP and BNP in human medicine using plasma samples spiked with ProBNP1-108, 
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BNP fragments, and NT-proBNP (Heublein et al., 2007; Liang et al., 2007; Luckenbill et al., 
2008; Shimizu et al., 2002). Using western blotting and specific immunoassays for ProBNP1-
108, studies have also identified a large presence of high-molecular-weight BNP 
components consistent with ProBNP1-108 in plasma samples of people with CHF (Giuliani 
et al., 2006; Liang et al., 2007). Because ProBNP1-108 and fragments of BNP1-32 appear to 
have reduced or no biological activity (Boerrigter et al., 2009; Boerrigter et al., 2007; 
Heublein et al., 2007; Huntley et al., 2015; Liang et al., 2007), and given the presence of 
some evidence to suggest altered ProBNP1-108, ProANP, and BNP processing in the face 
of CHF (Gomez et al., 2012; Huntley et al., 2015; Ibebuogu et al., 2011), there is a clear 
need for better detection methods of the various components of the BNP system in order to 
facilitate a deeper understanding of how this counter-regulatory system of the RAAS may be 
involved in the syndrome of CHF. 
The finding that canine BNP1-32, the biologically active component of the BNP 
system, could be detected using mass spectrometry (Chapter 5) was promising in that it 
highlighted a method of detection which could be utilised in veterinary medicine to facilitate 
further understanding of BNP processing in the face of CHF. In accordance with existing 
studies in human medicine evaluating this technique for the detection of BNP1-32 
(Hawkridge et al., 2005; Miller et al., 2011; Niederkofler et al., 2008), both MALDI-TOF and 
LC-ESI-MS/MS methods were observed to reliably detect canine BNP1-32 in standard 
preparations. The latter was associated with a higher sensitivity (0.0001 pM/μl vs 0.1 pM/μl 
with MALDI-TOF), making it a more suitable method of BNP1-32 detection in plasma.  
Unfortunately, application of this method to quantify canine BNP1-32 concentrations 
in plasma was not successful, owing to the large dynamic range of protein concentrations in 
plasma and the extremely low concentrations of circulating immunoreactive BNP species. 
Notably, the aforementioned articles utilising mass spectrometry for the quantification of 
plasma BNP1-32 levels employed immunoprecipitation techniques during sample 
preparation to remove abundant protein and peptide species and concentrate each sample. 
The work in Chapter 5 demonstrated that inexpensive and less time-consuming methods of 
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sample preparation such as routine solid-phase extraction, solvent precipitation, and 
commercially available kits for depletion of albumin and nonspecific immunoglobulins did not 
provide adequate refinement of plasma samples to aid in mass spectrometry-based 
detection of canine BNP1-32 in plasma. Although the potential utility of sophisticated 
chromatography with or without centrifugal filters remains an unexplored avenue of sample 
preparation, the available evidence to date would suggest that immunoprecipitation steps 
remain a vital component of such an assay.  
In a curious coincidence of events, the fluid administration protocol employed in the 
second part of Chapter 5 was also unsuccessful in that it failed to demonstrate adequate 
stimulation of the endogenous BNP system. It was particularly difficult to interpret the results 
due to the haemodilution and pressure diuresis caused by the fluid, and this formed the 
basis of the recommendations against this method of stimulating the NPS in future studies 
where plasma and urinary markers are to be evaluated. This may be one of the reasons why 
it has been employed infrequently for this purpose in the existing literature. Nevertheless, a 
coherent relationship between the fluid administered and measures of preload was 
demonstrated, and trends in both the urinary and plasma endocrine variables showed 
consistency in their lack of a convincing BNP response. Even in the absence of a specific 
BNP1-32 assay, the complexity of the interactions between the cardiovascular, renal and 
endocrine systems in maintaining fluid balance was accentuated through this study. 
In the absence of a specific BNP1-32 assay to investigate whether a BNP1-32 
deficiency might be associated with the development of CHF in dogs, an alternative 
approach was taken in Chapter 6 whereby the effects of augmenting the NPS through 
administration of exogenous BNP1-32 was evaluated in dogs with CHF due to MMVD.  
In doing so, this work described, for the first time, the use of exogenous BNP1-32 in dogs 
with naturally occurring CHF due to MMVD. Based on its use in experimental models of CHF 
and people with CHF, it was hypothesised that exogenous BNP1-32 would result in 
additional diuresis, natriuresis, and RAAS antagonism in dogs with naturally occurring CHF.  
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Subcutaneously administered BNP1-32 was readily absorbed from its administration 
site and displayed evidence of successful receptor-ligand interaction (Chapter 6). These 
were demonstrated through a rise in plasma immunoreactive BNP-32 and urinary cGMP 
production following administration of any treatment containing BNP1-32. Although the 
plasma cGMP concentrations also appeared to reflect this trend, significance was not 
reached due to the larger variability observed at baseline. The reason for this baseline 
variability remains unclear as there were no apparent influences of animal factors such as 
hydration status, medications, BNP-32 concentrations, and blood pressure; sample 
abnormalities such as haemolysis/lipaemia or processing anomalies; or assay effects such 
as location of wells (i.e. no potential carry-over effects), inter-assay variability (i.e. not 
associated with a particular batch of samples showing higher concentrations), or erroneous 
pipetting of samples. As cGMP is a product of both membrane-bound and soluble guanylate 
cyclase activation, it is possible that unmeasured processes involving the NPS or nitrous 
oxide pathways may have contributed towards this finding.  
It should be noted that although cGMP is primarily an intracellular messenger 
molecule, there is strong evidence to support the utility of plasma and urinary cGMP 
concentrations as biomarkers of natriuretic peptide effects. Numerous studies have 
observed an increase in urinary and plasma cGMP concentrations, accompanied by 
cardiorenal effects, following administration of ANP1-28 (Eiskjær et al., 1991; Gerzer et al., 
1985; Nakamura et al., 1998; Riegger et al., 1988; Wong et al., 1988) and BNP1-32 
(Boerrigter et al., 2007; Cataliotti et al., 2004; H. H. Chen et al., 2012; H. H. Chen et al., 
2000; H. H. Chen, Huntley, et al., 2006; H. H. Chen et al., 2004; H. H. Chen, Schirger, et al., 
2006; Forfia et al., 2007; Grantham et al., 1997; Jensen et al., 1999; McKie et al., 2016; 
Nakamura et al., 1998; Yamamoto et al., 1997; Yoshimura et al., 1991). These observations 
are supported by in vitro cell and tissue studies in which increasing extracellular 
concentrations of cGMP over time in the medium were documented upon bathing samples in 
medium spiked with ANP (Stasch et al., 1989; Wong et al., 1988). Furthermore, a review of 
various cellular and physiological studies concluded that cGMP efflux into the extracellular 
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space is exhibited by a wide range of cells in the body and appears to be an ATP-dependent, 
active process that is facilitated by transport proteins in cell membranes (Sager, 2004). The 
family of multidrug resistance proteins and the SLC22A7 (also known as the hOAT2) 
member of the solute carrier family are of particular importance, with the latter also providing 
bidirectional movement of cGMP both in and out of cells (Cropp et al., 2008; Sager, 2004; 
van Aubel et al., 2002). The OAT1 isoform, which is abundant in the basolateral membrane 
of proximal tubules, also facilitates intracellular transport of cGMP (Sekine et al., 1997). 
Within the kidneys, there is evidence to support the role of extracellular cGMP in facilitating 
ANP1-28, nitric oxide, and pressure-induced natriuresis (Ahmed et al., 2007; Chevalier et al., 
1996; Jin et al., 2004), and it also mediates learning in the brain (Cabrera-Pastor et al., 
2016; Erceg et al., 2006; Erceg et al., 2005). Together, this body of evidence supports the 
existence of transmembrane transport of cGMP and its role as an extracellular mediator of 
biological effects, and they validate its use as a marker of successful binding of BNP1-32 to 
its receptor in the studies conducted in Chapters 5 and 6. 
Yet in spite of this, no significant biological effects of BNP1-32 were observed in dogs 
with naturally occurring CHF (Chapter 6) – a finding which was contrary to much of the 
available literature describing its use in dogs with induced CHF and people with naturally 
occurring CHF. In particular, its renal effects, such as the increase in urinary sodium 
excretion (Cataliotti et al., 2004; H. H. Chen et al., 2000; H. H. Chen, Huntley, et al., 2006; H. 
H. Chen et al., 2004; H. H. Chen, Schirger, et al., 2006; Grantham et al., 1997; Jensen et al., 
1999) and urine output (Cataliotti et al., 2004; H. H. Chen et al., 2000; H. H. Chen, Huntley, 
et al., 2006; H. H. Chen et al., 2004; H. H. Chen, Schirger, et al., 2006; Grantham et al., 
1997), were not apparent. It is possible that this difference may be partly attributable to the 
different statistical analysis and measures of urinary sodium excretion utilised across the 
studies. For example, the massive diuresis and natriuresis/kaliuresis caused by frusemide 
administration may have obscured smaller changes experienced by BNP1-32 administration 
in the present study. Indeed, even in these prior studies, the magnitude of the increase in 
urine output due to BNP1-32 was low (around 0.2 – 1 ml/min on average in dogs weighing 
170
 
 
an average of ~ 20kgs – equivalent of around 0.01 – 0.05 ml/kg/min). The trends in urine 
output following BNP1-32 administration in the present study showed a mild increase at 1 h 
post treatment in line with the lower end of this range (~ 0.01 ml/kg/min on average). A sub-
analysis using only the urine output data following BNP1-32 administration did show a 
significant overall difference over time (p = 0.022), with it being higher than baseline at 1 h 
post treatment. However, the fact remains that the magnitude of effect was quite small. 
Furthermore, the average urine output was lower with the frusemide + BNP1-32 combination 
compared to frusemide alone in the present study – a finding that refutes that of a previous 
study in dogs with induced CHF (Cataliotti et al., 2004). Trends over time for sodium and 
potassium excretions were underwhelming following BNP1-32 administration, and a similar 
sub-analysis using only the data from this treatment stream showed no significant changes 
over time (p = 0.3 for FENa and p = 0.075 for FEK). Put together, the renal effects of BNP1-32 
were not obvious in dogs with naturally occurring CHF. This lack of convincing effects in the 
face of strong evidence to suggest adequate binding of BNP1-32 to its receptor raises 
concerns for potential abnormalities in intracellular mechanisms which facilitate the biological 
activity of cGMP in dogs with CHF due to MMVD. In this way, Chapter 6 provides grounds 
for future investigations into this novel area of pathophysiology in dogs with naturally 
occurring CHF. 
Simultaneously, this finding prompts contemplation of whether alternate methods of 
NPS augmentation would be effective in dogs with CHF due to MMVD and how study 
designs examining these may be optimised. As discussed in Chapter 1 of this thesis, the 
most recent advancement in CHF therapeutics in humans is the ARNI, with it demonstrating 
convincing survival benefits over the use of an ACE-I (McMurray et al., 2014). It is tempting 
to follow in the footsteps of such a discovery; however, it is possible that neprilysin inhibitors 
may not necessarily be beneficial if the activity of BNP1-32 is being hindered by malfunction 
of intracellular cGMP pathways. Any benefits of ARNI in this population of dogs will therefore 
need to be differentiated from the effects of the ARB alone. This is a limitation that clouds 
the findings of a very recently published pilot study investigating the use of ARNI versus 
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ACE-I in dogs with ACVIM Stage B2 MMVD (Newhard et al.), and larger studies 
investigating the use of ARNI may benefit from the inclusion of an ARB treatment stream to 
clarify the role of the neprilysin inhibitor in these dogs. The use of virtually identical 
intracellular pathways by ANP1-28 would also mean that using this as an alternative to 
BNP1-32 may be similarly disappointing in these dogs. Including evaluations of cGMP-
mediated pathways in the study designs would provide further insight into this matter. 
Findings from Chapter 6 can therefore be used to guide such future investigations into the 
NPS in dogs with CHF due to MMVD. 
The trends in plasma aldosterone concentrations and immunoreactive BNP-32 
(Chapter 6), albeit not being representative of the entirety of the RAAS and NPS respectively, 
provided some interesting insights regarding these systems. In general, the plasma 
aldosterone concentrations were low in the dogs enrolled. The majority of plasma samples 
(~ 60%) contained concentrations below the LLOQ of ~ 70 pM/L; this fit within the low end of 
the reported range of concentrations in dogs with CHF (20 – 800 pM/L) (Häggström et al., 
1997; Häggström, Lord, et al., 2013). These low concentrations may have been due to 
adequate ACE-I activity, sample degradation, or a lack of overt circulating RAAS activity in 
compensated CHF. Conversely, the plasma concentration of immunoreactive BNP-32 was 
higher than previously reported ranges (~ 5 – 250 pg/ml, with the majority being < ~ 80 
pg/ml) (Asano et al., 1999; DeFrancesco et al., 2007; Häggström et al., 2000; MacDonald et 
al., 2003; Prošek et al., 2007), with it averaging ~ 240 pg/ml (range 160 – 407 pg/ml) at 
baseline across all treatment days. It is possible that these prior studies under-estimated 
immunoreactive BNP-32 concentrations as not all studies utilised protease inhibitors or used 
aprotinin, which is inferior to Benzamidine and AEBSF in the preservation of BNP1-32 
(Belenky et al., 2004; Niederkofler et al., 2008). Furthermore, it was noted during BNP1-32 
assay development in Chapter 5 that C18 material could not reliably concentrate BNP1-32; 
thus, assays utilising this material could have produced erroneously low results. There is a 
clear need for standardising these assays and establishing appropriate reference ranges in 
dogs with CHF. The observation of a late rising trend in aldosterone following treatment with 
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BNP1-32 also requires further clarification. In addition to highlighting the need for future 
research into the NPS in dogs with naturally occurring CHF, Chapter 6 also accentuated the 
importance of clarifying the interaction between the NPS and RAAS in these dogs. 
The research presented in the body of this thesis uncovered numerous avenues for 
further investigations in the field of veterinary CHF therapeutics. In particular, the following 
areas are suggested as priorities for further evaluation: 
• The systolic and diastolic effects of pimobendan in cats to clarify whether it provides 
beneficial effects in this species. 
• Large-scale clinical trials investigating the benefits, if any, of quadruple therapy 
(consisting of frusemide, an ACE-I, pimobendan, and an MRA) in dogs with CHF. 
• The role of the NPS in dogs with CHF in order to assess its suitability as a 
therapeutic target. 
• The utility of therapeutic monitoring of pimobendan in dogs with CHF. 
In looking forward to these next steps, some limitations to the overall structure of the current 
project should be considered. To start, addressing the topic of CHF therapeutics within the 
confines of a PhD candidature posed a considerable challenge, primarily due to the breadth 
of the topic. The approach undertaken, in which a selection of issues was explored, yielded 
positive findings in a variety of areas; however, the significance of each may have been 
diluted through the inability to explore deeper grounds. Focusing on a smaller aspect of this 
research topic may have enhanced a limited number of outcomes. This project utilised the 
expertise and resources of several laboratories and departments located within and outside 
of the University of Sydney. Yet extending such collaborations may have facilitated even 
greater success in the works performed in Chapters 4 and 5. Finally, the organisation and 
timing of events both within and across studies could have been better optimised. For 
example, commencing the BNP1-32 assay development (Chapter 5) earlier in the course of 
the project would have allowed for more time to be dedicated to this work, and establishing a 
more precise study protocol for the longitudinal study (Chapter 4) may have facilitated 
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acquisition of data relating to the RAAS and NPS. Such aspects of project design may 
contribute greatly to the outcomes of research attempts made in the face of time and 
financial constraints, and thus, form important considerations for future studies. 
 
7.2) Conclusions 
This thesis reviewed current veterinary practices in CHF therapeutics and explored novel 
avenues for medical therapy in this field. It began with a comprehensive literature review, 
which identified knowledge gaps in the use of pimobendan in veterinary patients and clear 
deficiencies in present understanding of the role and therapeutic potential of the RAAS and 
NPS in canine and feline CHF. An investigation into the pharmacokinetics and 
pharmacodynamics of pimobendan was performed, which uncovered inter-species variation 
in metabolism of the drug and measurable cardiovascular effects. Pimobendan metabolism 
was reduced in cats compared to dogs; although this was expected to produce greater 
cardiovascular effects in cats, changes to echocardiogram-derived measures of systolic 
function were less obvious and resulted in an inability to define the duration and magnitude 
of treatment effects for the two doses investigated. This finding prompts an evaluation of the 
way pimobendan is currently used in this species and highlights the need for further 
prospective studies into its effects, ideal dosing regimen, and whether it truly offers treatment 
benefits in cats with CHF. Conversely, the cardiovascular impacts of pimobendan were 
readily apparent in dogs, with echocardiographic measures of systolic function showing 
maximal treatment effects between 2 – 4 h following oral dosing. Echocardiography 
therefore appears to be a useful tool for monitoring treatment effects in individual dogs. This 
opens up the scope for further work evaluating the benefits of personalising therapy in 
canine patients. When pimobendan was used as a part of multi-modal therapy together with 
an ACE-I, MRA, and a diuretic in dogs with newly diagnosed CHF due to MMVD, the 
treatment was well-tolerated. The natural course of disease was similar to that described 
with other combinations of treatments utilised in the existing literature; recurrent CHF 
remained the leading contributor towards morbidity and mortality, and common 
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complications of clinical relevance included moderate to severe pulmonary hypertension and 
supraventricular arrhythmias. Despite the small number of dogs enrolled and involvement of 
investigators with varying degrees of experience, rising trends in echocardiographic 
measures of cardiac remodelling (LA:Ao and weight-normalised LVIDd) were observed prior 
to death – suggesting the robustness and utility of these variables in providing prognostic 
information in everyday practice. Considered alongside existing literature evaluating 
longitudinal outcomes of other commonly employed treatment regimens, possible survival 
benefits in terms of longevity were observed with this combination of drugs, thereby 
supporting the value of larger clinical trials to pursue this question. The importance of global 
standardisation of heart failure classification and clinical study designs was also stressed. 
  In the final sections of this work, the NPS was investigated as a novel therapeutic 
target for dogs with CHF due to MMVD. Although an attempt was made to develop a specific 
BNP1-32 assay to investigate whether relative deficiencies in this protective mechanism 
existed in dogs with CHF, assay development was unsuccessful. Standard preparations of 
canine BNP1-32 could be detected using various methods of mass spectrometry; yet 
challenges surrounding sample preparation limited its detection in canine plasma. With 
simpler methods proving to be insufficient, immunoprecipitation or sophisticated separation 
techniques such as chromatography are recommended for future attempts. In addition, using 
clinical samples from animals undergoing transient preload augmentation via intravenous 
fluids is not recommended when assessing new assays of the BNP system. This model does 
not reliably stimulate the BNP system, and the direct increase in intravascular volume, 
haemodilution, and ensuing diuresis cloud interpretation of results. Further scrutiny of this 
system in dogs with CHF due to MMVD is, however, recommended, as a lack of identifiable 
biological effects of exogenous BNP1-32 was found in dogs with this disease. In particular, 
the intracellular downstream pathways facilitating cGMP-mediated effects in dogs with CHF 
are areas for novel research.  
 Despite the wealth of advancements made in the understanding of canine and feline 
CHF since its first description around a hundred years ago, much about its pathophysiology, 
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and therefore optimal treatment approaches, remain hidden or unresolved. It is hoped that 
further work building on the discoveries shared in this thesis will be undertaken to attain the 
ultimate goal of providing the best quality of life in our patients. 
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